US11040039B2 - Treatment of inflammatory disorders - Google Patents

Treatment of inflammatory disorders Download PDF

Info

Publication number
US11040039B2
US11040039B2 US16/157,069 US201816157069A US11040039B2 US 11040039 B2 US11040039 B2 US 11040039B2 US 201816157069 A US201816157069 A US 201816157069A US 11040039 B2 US11040039 B2 US 11040039B2
Authority
US
United States
Prior art keywords
compound
optionally substituted
pharmaceutically acceptable
acceptable salt
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US16/157,069
Other languages
English (en)
Other versions
US20190105322A1 (en
Inventor
Susan Macdonald
Adna Halilovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aldeyra Therapeutics Inc
Original Assignee
Aldeyra Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aldeyra Therapeutics Inc filed Critical Aldeyra Therapeutics Inc
Priority to US16/157,069 priority Critical patent/US11040039B2/en
Assigned to ALDEYRA THERAPEUTICS, INC. reassignment ALDEYRA THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HALILOVIC, ADNA, MACDONALD, SUSAN
Publication of US20190105322A1 publication Critical patent/US20190105322A1/en
Priority to US17/328,772 priority patent/US11583529B2/en
Application granted granted Critical
Publication of US11040039B2 publication Critical patent/US11040039B2/en
Priority to US18/092,758 priority patent/US20230248727A1/en
Priority to US18/202,694 priority patent/US20230293527A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to aldehyde-trapping compounds such as I-5, or a pharmaceutically acceptable salt thereof, for treatment of inflammatory disorders and other diseases, disorders, and conditions such as those described herein.
  • Inflammatory disorders include a group of diseases and conditions in which the body's biological response to stimuli results in the immune system attacking the body's own cells or tissues, leading to abnormal inflammation and resulting in chronic pain, redness, swelling, stiffness, and damage to normal tissues. Inflammatory disorders can be acute or chronic.
  • the treatment of inflammatory disorders includes the use of immunosuppressants, such as steroids (e.g., prednisone, budesonide (Entocort EC), and prednisolone), anti-metabolites (e.g., methotrexate), and cytotoxic agents (e.g., cyclophosphamide), to reduce or inhibit the activity of immune system cells that participate in the inflammatory response.
  • immunosuppressants such as steroids (e.g., prednisone, budesonide (Entocort EC), and prednisolone), anti-metabolites (e.g., methotrexate), and cytotoxic agents (e.g., cyclophosphamide), to reduce or inhibit the activity of immune system cells that participate in the inflammatory response.
  • Some treatments are directed to inhibiting cytokine mediators of the inflammatory response, such as TNF- ⁇ and proinflammatory cytokines, including IL-1, IL 6, IL-8, IL-12,
  • ⁇ treatments include therapeutic antibodies, such as abatacept, adalimumab, anakinra (Kineret), certolizumab, etanercept, golimumab, infliximab, ixekizumab, natalizumab, rituximab, secukinumab, tocilizumab, ustekinumab, and vedolizumab.
  • therapeutic antibodies such as abatacept, adalimumab, anakinra (Kineret), certolizumab, etanercept, golimumab, infliximab, ixekizumab, natalizumab, rituximab, secukinumab, tocilizumab, ustekinumab, and vedolizumab.
  • calcineurin inhibitors e.g., cyclosporine and tacrolimus
  • mTOR inhibitors e.g., sirolimus and everolimus
  • IMPDH inhibitors e.g., azathioprine, leflunomide, and mycophenolate
  • the present disclosure provides compounds that are capable of reacting with aldehydes for the treatment of certain inflammatory disorders.
  • the inflammatory disorder can be systemic or localized to a particular tissue or organ.
  • the disease, disorder or disease for treatment with the compounds of the disclosure is non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis, inflammatory bowl disease, Crohn's disease, ulcerative colitis (UC), psoriasis, IBS (irritable bowel syndrome or spastic colon), including spastic colon, ankylosing spondylitis, osteoporosis, rheumatoid arthritis (RA), psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, pulmonary arterial hypertension, pyridoxine-dependent epilepsy, atopic dermatitis, rosacea, multiple sclerosis (MS), systemic lupus erythematosus (SLE), lupus nep
  • the disease, disorder, or condition for treatment with the compounds of the disclosure is light chain deposition disease, IgA nephropathy, end stage renal disease, gout, pseudogout, diabetic nephrophathy, diabetic neuropathy, traumatic brain injury, noise-induced hearing loss, Alzheimer's Disease, Parkinson's Disease, Huntington Malase, amyotrophic lateral sclerosis, primary biliary cirrhosis, primary sclerosing cholangitis, uterine leiomyoma, sarcoidosis, or chronic kidney disease.
  • the disease, disorder, or condition for treatment with the compounds of the disclosure is an ocular inflammatory disorder.
  • the ocular inflammatory disorder is diabetic macular edema (DME), atopic keratoconjunctivitis (AKC), vernal keratoconjunctivitis (VKC), age-related macular degeneration (AMD), dry eye disease (DED), allergic conjunctivitis (AC), dry eye disease with allergic conjunctivitis, noninfectious anterior uveitis, posterior uveitis, pan-uveitis, post-surgical ocular pain and inflammation.
  • DME diabetic macular edema
  • ACD age-related macular degeneration
  • DED dry eye disease
  • AC allergic conjunctivitis
  • dry eye disease with allergic conjunctivitis noninfectious anterior uveitis, posterior uveitis, pan-uveitis, post-surgical ocular pain and inflammation.
  • the compound of the disclosure is administered in an effective amount for the prevention of corneal fibrosis after radial keratotomy, prevention of corneal fibrosis after trauma, or prevention of corneal fibrosis after infection.
  • a method of treating an inflammatory disorder comprises administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I):
  • the compound for use in the treatment of the disease, disorder, or condition is a compound of formula II:
  • each of R 1 , R 7 , and R 8 is independently H, D, halogen, —NH 2 , —CN, —OR, —SR, optionally substituted C 1-6 aliphatic, or
  • R 1 , R 7 and R 8 are —NH 2 and other one of R 1 R 7 and R 8 is
  • R 2 is absent or is selected from —R, halogen, —CN, —OR, —SR, —N(R) 2 , —N(R)C(O)R, —C(O)N(R) 2 , —N(R)C(O)N(R) 2 , —N(R)C(O)OR, —OC(O)N(R) 2 , —N(R)S(O) 2 R, —SO 2 N(R) 2 , —C(O)R, —C(O)OR, —OC(O)R, —S(O)R, and —S(O) 2 R;
  • R 3 is absent or is selected from —R, halogen, —CN, —OR, —SR, —N(R) 2 , —N(R)C(O)R, —C(O)N(R) 2 , —N(R)C(O)N(R) 2 , —N(R)C(O)OR, —OC(O)N(R) 2 , —N(R)S(O) 2 R, —SO 2 N(R) 2 , —C(O)R, —C(O)OR, —OC(O)R, —S(O)R, and —S(O) 2 R;
  • R 4 is absent or is selected from —R, halogen, —CN, —OR, —SR, —N(R) 2 , —N(R)C(O)R, —C(O)N(R) 2 , —N(R)C(O)N(R) 2 , —N(R)C(O)OR, —OC(O)N(R) 2 , —N(R)S(O) 2 R, —SO 2 N(R) 2 , —C(O)R, —C(O)OR, —OC(O)R, —S(O)R, and —S(O) 2 R;
  • R 5 is absent or is selected from —R, halogen, —CN, —OR, —SR, —N(R) 2 , —N(R)C(O)R, —C(O)N(R) 2 , —N(R)C(O)N(R) 2 , —N(R)C(O)OR, —OC(O)N(R) 2 , —N(R)S(O) 2 R, —SO 2 N(R) 2 , —C(O)R, —C(O)OR, —OC(O)R, —S(O)R, and —S(O) 2 R;
  • R a is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium or halogen atoms
  • R b is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium or halogen atoms
  • R a and R b taken together with the carbon atom to which they are attached, form a 3- to 8-membered cycloalkyl or heterocyclyl ring containing 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur;
  • each R is independently selected from hydrogen, deuterium, and an optionally substituted group selected from C 1-6 aliphatic; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; an 8- to 10-membered bicyclic aryl ring; a 3- to 8-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6- to 10-membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • the compound for use in treatment of the disease, disorder, or condition is a compound of formula III:
  • Q, T, and V are independently S, N, O, or —C—R;
  • each of R 1 , R 6 , R 7 , and R 8 is independently H, D, halogen, —NH 2 , —CN, —OR, —SR, optionally substituted C 1-6 aliphatic, or
  • R 1 , R 6 , R 7 , and R 8 are —NH 2 and other one of R 1 , R 6 , R 7 , and R 8 is
  • R a is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium or halogen atoms
  • R b is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium or halogen atoms; or R a and R b , taken together with the carbon atom to which they are attached, form a 3-8 membered cycloalkyl or heterocyclyl ring containing 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur; and
  • each R is independently selected from hydrogen, deuterium, and an optionally substituted group selected from: C 1-6 aliphatic, a 3- to 8-membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8- to 10-membered bicyclic aryl ring, a 3- to 8-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 6- to 10-membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • the compound for use in treating the disease, disorder, or condition is a compound of formula I-22:
  • the compound for use in treating the disease, disorder, or condition is a compound of formula I-5:
  • the compound for use in treating the disease, disorder, or condition is a compound of formula I-6:
  • the compounds can be administered systemically, such as intravenously or parenterally, or locally, such as topically or localized injection, to effect treatment of the disease, disorder or condition.
  • FIG. 1 shows results of administering compound I-22 to the eye of animals with chemically-induced diabetes. Retinas of animal treated with the Compound I-22 show reduced retinal thickness as compared to animals not treated with the compound.
  • FIG. 2 shows results of administering compound I-22 in a rat model of endotoxin-induced uveitis. Retinas of test animals were scored for retinal vasculopathy, and retinal hemorrhage, exudate and detachment.
  • FIG. 3 depicts ocular discomfort & 4-Symptom Questionnaire: Dryness [Intent-To-Treat (ITT) Population with Observed Data Only] for a dry eye disease (DED) clinical trial.
  • FIG. 4 depicts ocular discomfort & 4-Symptom Questionnaire: Overall Ocular Discomfort (ITT Population with Observed Data Only) for a DED clinical trial.
  • FIG. 5 depicts Fluorescein Staining: Conjunctival Sum Score (Nasal and Temporal) (ITT Population with Observed Data Only) for a DED clinical trial.
  • FIG. 6 depicts Fluorescein Staining: Nasal (ITT Population with Observed Data Only) for a DED clinical trial.
  • FIG. 7 depicts Tear Quantity and Quality Improved: Tear Film Break-Up Time (TFBUT), Schirmer's Test and Tear Osmolarity Supports Broad Activity Profile (Endpoint-Specific Worst Eye: ITT Population with Observed Data Only) for a DED clinical trial.
  • CFB change from baseline.
  • FIG. 11 shows body weight change from Study Day ⁇ 3 (g) in female Swiss Webster mice in a model of dextran sulfate sodium (DSS)-induced acute ulcerative colitis (UC).
  • FIG. 12 shows Disease Activity Index Stool Consistency Score data in female Swiss Webster mice in a model of DSS-induced acute UC. *p ⁇ 0.05 Kruskal-Wallis test (Dunn's post hoc) vs. Vehicle (PO); ⁇ p ⁇ 0.05 Student's t-test/Mann-Whitney test vs. Vehicle (IP)
  • FIG. 13 shows Disease Activity Index Occult/Gross Blood Score data in female Swiss Webster mice in a model of DSS-induced acute UC. ⁇ p ⁇ 0.05 Student's t-test/Mann-Whitney test vs. Vehicle (IP)
  • FIG. 14 shows Disease Activity Index Summed Score data in female Swiss Webster mice in a model of DSS-induced acute UC. ⁇ p ⁇ 0.05 Student's t-test/Mann-Whitney test vs. Vehicle (IP); ⁇ p ⁇ 0.05 Student's t-test vs. Vehicle (PO)
  • FIG. 15 shows Colon Length in cm for mice treated with I-5, I-22, or I-6 in a model of DSS-induced acute UC.
  • FIG. 16 shows Colon Weight per length (g/cm) for mice treated with I-5, I-22, or I-6 in a model of DSS-induced acute UC. ⁇ p ⁇ 0.05 Student's t-test vs. Vehicle (IP); ⁇ p ⁇ 0.05 Student's t-test vs. Vehicle PO.
  • FIG. 17 shows Mean Inflammation Score (0-5) for mice treated with I-5, I-22, or I-6 in a model of DSS-induced acute UC. ⁇ p ⁇ 0.05 Student's t-test vs. Vehicle (IP); ⁇ p ⁇ 0.05 Student's t-test vs. Vehicle PO.
  • FIG. 18 shows Mean Gland Loss Score (0-5) for mice treated with I-5, I-22, or I-6 in a model of DSS-induced acute UC. ⁇ p ⁇ 0.05 Student's t-test vs. Vehicle (IP); ⁇ p ⁇ 0.05 Student's t-test vs. Vehicle PO.
  • FIG. 19 shows Erosion Score (0-5) for mice treated with I-5, I-22, or I-6 in a model of DSS-induced acute UC. ⁇ p ⁇ 0.05 Student's t-test vs. Vehicle (IP); ⁇ p ⁇ 0.05 Student's t-test vs. Vehicle PO; *p ⁇ 0.05 ANOVA (Dunnett's post-hoc) vs. Vehicle (PO).
  • FIG. 20 shows Mean Hyperplasia Score (0-5) for mice treated with I-5, I-22, or I-6 in a model of DSS-induced acute UC. ⁇ p ⁇ 0.05 Student's t-test vs. Vehicle (IP); ⁇ p ⁇ 0.05 Student's t-test vs. Vehicle PO; *p ⁇ 0.05 ANOVA (Dunnett's post-hoc) vs. Vehicle (PO).
  • FIG. 21 shows Edema Width ( ⁇ m) for mice treated with I-5, I-22, or I-6 in a model of DSS-induced acute UC. ⁇ p ⁇ 0.05 Student's t-test vs. Vehicle (IP); ⁇ p ⁇ 0.05 Student's t-test vs. Vehicle PO; *p ⁇ 0.05 ANOVA (Dunnett's post-hoc) vs. Vehicle (PO).
  • FIG. 22 shows Neutrophil score for mice treated with I-5, I-22, or I-6 in a model of DSS-induced acute UC. ⁇ p ⁇ 0.05 Student's t-test vs. Vehicle (IP); ⁇ p ⁇ 0.05 Student's t-test vs. Vehicle PO.
  • FIG. 23 shows Mucosal Thickness ( ⁇ m) for mice treated with I-5, I-22, or I-6 in a model of DSS-induced acute UC. ⁇ p ⁇ 0.05 Student's t-test vs. Vehicle (IP); ⁇ p ⁇ 0.05 Student's t-test vs. Vehicle PO; *p ⁇ 0.05 ANOVA (Dunnett's post-hoc) vs. Vehicle (PO).
  • FIG. 24 shows Lymphoid Aggregate Count for mice treated with I-5, I-22, or I-6 in a model of DSS-induced acute UC. ⁇ p ⁇ 0.05 Student's t-test vs. Vehicle (IP); ⁇ p ⁇ 0.05 Student's t-test vs. Vehicle PO.
  • the present disclosure provides compounds capable of reacting with aldehydes for use in methods of treating inflammatory disorders, including systemic inflammatory disorders and ocular inflammatory disorders.
  • the compounds are amino carbinol-containing compounds that are capable of effectively reacting with and “trapping” aldehyde compounds, thus preventing their reaction with biological molecules and interfering with their normal function.
  • the compounds and methods of treating inflammatory disorders with the compounds are described below.
  • aliphatic or “aliphatic group”, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as “carbocycle,” “cycloaliphatic” or “cycloalkyl”), that has a single point of attachment to the rest of the molecule.
  • aliphatic groups contain 1-6 aliphatic carbon atoms.
  • aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms.
  • “cycloaliphatic” (or “carbocycle” or “cycloalkyl”) refers to a monocyclic C 3 -C 6 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule.
  • Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
  • lower alkyl refers to a C 1-4 straight or branched alkyl group.
  • exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.
  • lower haloalkyl refers to a C 1-4 straight or branched alkyl group that is substituted with one or more halogen atoms.
  • heteroatom means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR + (as in N-substituted pyrrolidinyl)).
  • unsaturated means that a moiety has one or more units of unsaturation.
  • bivalent C 1-8 (or C 1-6 ) saturated or unsaturated, straight or branched, hydrocarbon chain refers to bivalent alkylene, alkenylene, and alkynylene chains that are straight or branched as defined herein.
  • alkylene refers to a bivalent alkyl group.
  • An “alkylene chain” is a polymethylene group, i.e., —(CH 2 ) n —, wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3.
  • a substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
  • alkenylene refers to a bivalent alkenyl group.
  • a substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
  • halogen means F, Cl, Br, or I.
  • aryl used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” or “aryloxyalkyl,” refers to monocyclic or bicyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members.
  • aryl may be used interchangeably with the term “aryl ring.”
  • aryl used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” or “aryloxyalkyl,” refers to monocyclic and bicyclic ring systems having a total of five to 10 ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains three to seven ring members.
  • aryl refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents.
  • aryl is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like.
  • heteroaryl and “heteroar-,” used alone or as part of a larger moiety, e.g., “heteroaralkyl,” or “heteroaralkoxy,” refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 ⁇ electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms.
  • heteroatom refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen.
  • Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl.
  • heteroaryl and “heteroar-”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring.
  • Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-1,4-oxazin-3(4H)-one.
  • heteroaryl group may be mono- or bicyclic.
  • heteroaryl may be used interchangeably with the terms “heteroaryl ring,” “heteroaryl group,” or “heteroaromatic,” any of which terms include rings that are optionally substituted.
  • heteroarylkyl refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.
  • heterocycle As used herein, the terms “heterocycle,” “heterocyclyl,” “heterocyclic radical,” and “heterocyclic ring” are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7- to 10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above.
  • nitrogen includes a substituted nitrogen.
  • the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or + NR (as in N-substituted pyrrolidinyl).
  • a heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted.
  • saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothiophenyl pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, di azepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl.
  • heterocycle refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.
  • partially unsaturated refers to a ring moiety that includes at least one double or triple bond.
  • partially unsaturated is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.
  • compounds of the disclosure may contain “optionally substituted” moieties.
  • substituted whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent.
  • an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
  • Combinations of substituents envisioned for the compounds herein are preferably those that result in the formation of stable or chemically feasible compounds.
  • stable refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
  • Suitable monovalent substituents on a substitutable carbon atom of an “optionally substituted” group are independently halogen, —(CH 2 ) 0-4 Ro; —(CH 2 ) 0-4 ORo; —O(CH 2 ) 0-4 Ro, (CH 2 ) 0-4 C(O)ORo); —(CH 2 ) 0-4 CH(ORo) 2 ; —(CH 2 ) 0-4 SRo; —(CH 2 ) 0-4 Ph, which may be substituted with Ro; —(CH 2 ) 0-4 O(CH 2 ) 0-1 Ph which may be substituted with Ro; —CH ⁇ CHPh, which may be substituted with Ro; —(CH 2 ) 0-4 O(CH 2 ) 0-1 Ph-pyridyl which may be substituted with Ro; —NO 2 ; —CN; —N 3 ; —(CH 2 ) 0-4 N(Ro) 2 ; —(CH 2 )
  • Suitable monovalent substituents on Ro are independently halogen, —(CH 2 ) 0-2 R ⁇ , -(haloR ⁇ ), —(CH 2 ) 0-2 OH, —(CH 2 ) 0-2 OR ⁇ , —(CH 2 ) 0-2 CH(OR ⁇ ) 2 ; —O(haloR ⁇ ), —CN, —N 3 , —(CH 2 ) 0-2 C(O)R ⁇ , —(CH 2 ) 0-2 C(O)OH, —(CH 2 ) 0-2 C(O)OR ⁇ , —(CH 2 ) 0-2 SR ⁇ , —(CH 2 ) 0-2 SH, —(CH 2 ) 0-2 NH 2 , —(CH 2 ) 0-2 NHR ⁇ , —(CH 2 ) 0
  • Suitable divalent substituents on a saturated carbon atom of an “optionally substituted” group include the following: ⁇ O, ⁇ S, ⁇ NNR* 2 , ⁇ NNHC(O)R*, ⁇ NNHC(O)OR*, ⁇ NNHS(O) 2 R*, ⁇ NR*, ⁇ NOR*, —O(C(R* 2 )) 2-3 O—, or —S(C(R* 2 )) 2-3 S—, wherein each independent occurrence of R* is selected from hydrogen, C 1-6 aliphatic which may be substituted as defined below, and an unsubstituted 5- to 6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • Suitable divalent substituents that are bound to vicinal substitutable carbons of an “optionally substituted” group include: —O(CR*2) 2-3 O—, wherein each independent occurrence of R* is selected from hydrogen, C 1-6 aliphatic which may be substituted as defined below, and an unsubstituted 5 to 6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • Suitable substituents on the aliphatic group of R* include halogen, —R ⁇ , -(haloR ⁇ ), —OH, —OH ⁇ , —O(haloR ⁇ ), —CN, —C(O)OH, —C(O)OR ⁇ , —NH 2 , —NHR ⁇ , —NR ⁇ 2 , or —NO 2 , wherein each R ⁇ is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently C 1-4 aliphatic, —CH 2 Ph, —O(CH 2 ) 0-1 Ph, or a 5- to 6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • Suitable substituents on a substitutable nitrogen of an “optionally substituted” group include —R ⁇ , —NR ⁇ 2 , —C(O)R ⁇ , —C(O)OR ⁇ , —C(O)C(O)R ⁇ , —C(O)CH 2 C(O)R ⁇ , —S(O) 2 R ⁇ , —S(O) 2 NR ⁇ 2 , —C(S)NR ⁇ 2 , —C(NH)NR ⁇ 2 , or —N(R ⁇ )S(O) 2 R ⁇ ; wherein each R ⁇ is independently hydrogen, C 1-6 aliphatic which may be substituted as defined below, unsubstituted —OPh, or an unsubstituted 5- to 6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or, notwithstanding the definition above, two independent occurrence
  • Suitable substituents on the aliphatic group of R ⁇ are independently halogen, —R ⁇ , -(halo R ⁇ ), —OH, —OR ⁇ , —O(halo R ⁇ ), —CN, —C(O)OH, —C(O)OR R ⁇ , —NH 2 , —NHR ⁇ , —NR ⁇ 2 , or —NO 2 , wherein each R ⁇ is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently C 1-4 aliphatic, —CH 2 Ph, —O(CH 2 ) 0-1 Ph, or a 5- to 6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference.
  • Pharmaceutically acceptable salts of the compounds of the present disclosure include those derived from suitable inorganic and organic acids and bases.
  • Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid
  • organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, besylate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate,
  • Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1-4 alkyl) 4 salts.
  • Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate.
  • structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the present disclosure. Unless otherwise stated, all tautomeric forms of the compounds described herein are within the scope of the the present disclosure.
  • treatment refers to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein.
  • treatment is administered after one or more symptoms have developed.
  • treatment is administered in the absence of symptoms.
  • treatment is administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment is also continued after symptoms have resolved, for example to prevent, delay or lessen the severity of their recurrence.
  • a method of inflammatory disease or disorder in a subject comprises administering to a subject in need thereof a therapeutically effective amount of an aldehyde trapping compound.
  • the compound is selected from the compounds recited in U.S. Pat. No. 7,973,025 and published international patent application nos.
  • the inflammatory disease or disorder is a systemic inflammatory disease or disorder. In some embodiments, the inflammatory disease or disorder is an ocular inflammatory disease or disorder.
  • a method of treating an inflammatory disease or disorder in a subject comprises administering to a subject in need thereof a therapeutically effective amount of a compound of formula I:
  • each W, X, Y, or Z is independently selected from N, O, S, CU, CH and C—NH 2 , wherein one of W, X, Y, or Z is C—NH 2 ;
  • R a is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium or halogen atoms
  • R b is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium or halogen atoms; or R a and R b , taken together with the carbon atom to which they are attached, form a 3- to 8-membered cycloalkyl or heterocyclyl ring containing 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur;
  • k 0, 1, 2, 3, or 4;
  • each U is independently selected from halogen, cyano, —R, —OR, —SR, —N(R) 2 , —N(R)C(O)R, —C(O)N(R) 2 , —N(R)C(O)N(R) 2 , —N(R)C(O)OR, —OC(O)N(R) 2 , —N(R)S(O) 2 R, —SO 2 N(R) 2 , —C(O)R, —C(O)OR, —OC(O)R, —S(O)R, and —S(O) 2 R;
  • U on adjacent carbon atoms can form an optionally substituted fused ring, selected from a fused phenyl ring; a fused 5- to 6-membered saturated or partially unsaturated heterocyclic ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a fused 5- to 6-membered heteroaryl ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and
  • each R is independently selected from hydrogen, deuterium, and an optionally substituted group selected from C 1-6 aliphatic; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; an 8- to 10-membered bicyclic aryl ring; a 3- to 8-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6- to 10-membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • W is independently selected from N, O, S, CU, CH and C—NH 2 .
  • W is N.
  • W is O.
  • W is S.
  • W is CU.
  • W is CH.
  • W is C—NH 2 .
  • X is independently selected from N, O, S, CU, CH and C—NH 2 .
  • X is N.
  • X is O.
  • X is S.
  • X is CU.
  • X is CH.
  • X is C—NH 2 .
  • Y is independently selected from N, O, S, CU, CH and C—NH 2 .
  • Y is N.
  • Y is O.
  • Y is S.
  • Y is CU.
  • Y is CH.
  • Y is C—NH 2 .
  • Z is independently selected from N, O, S, CU, CH and C—NH 2 .
  • Z is N.
  • Z is O.
  • Z is S.
  • Z is CU.
  • Z is CH.
  • Z is C—NH 2 .
  • k is 0, 1, 2, 3, or 4. In some embodiments k is 0. In some embodiments, k is 1. In some embodiments, k is 2. In some embodiments, k is 3. In some embodiments, k is 4.
  • each U is independently selected from halogen, cyano, —R, —OR, —SR, —N(R) 2 , —N(R)C(O)R, —C(O)N(R) 2 , —N(R)C(O)N(R) 2 , —N(R)C(O)OR, —OC(O)N(R) 2 , —N(R)S(O) 2 R, —SO 2 N(R) 2 , —C(O)R, —C(O)OR, —OC(O)R, —S(O)R, and —S(O) 2 R.
  • U is halogen. In some embodiments, U is fluorine. In some embodiments, U is chlorine. In some embodiments, U is bromine.
  • U is —R. In some embodiments, U is hydrogen. In some embodiments, U is deuterium. In some embodiments, U is optionally substituted C 1-6 aliphatic. In some embodiments, U is an optionally substituted 3- to 8-membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, U is an optionally substituted 8- to 10-membered bicyclic aryl ring. In some embodiments, U is an optionally substituted 3- to 8-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • U is an optionally substituted 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • U is an optionally substituted 6- to 10-membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • U is an optionally substituted 7- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • U is —S(O) 2 R. In some embodiments, U is —S(O) 2 CH 3 .
  • U is an optionally substituted phenyl ring. In some embodiments, U is a phenyl ring, optionally substituted with halogen. In some embodiments, U is a phenyl ring, optionally substituted with fluorine. In some embodiments, U is a phenyl ring, optionally substituted with chlorine.
  • two occurrences of U on adjacent carbon atoms can form an optionally substituted fused ring, selected from a fused phenyl ring; a fused 5- to 6-membered saturated or partially unsaturated heterocyclic ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a fused 5- to 6-membered heteroaryl ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • two occurrences of U on adjacent carbon atoms form a fused phenyl ring. In some embodiments, two occurrences of U on adjacent carbon atoms form an optionally substituted fused phenyl ring. In some embodiments, two occurrences of U on adjacent carbon atoms form a fused phenyl ring, optionally substituted with 1 or more halogen atoms. In some embodiments, two occurrences of U on adjacent carbon atoms form a fused phenyl ring, optionally substituted with one halogen atom. In some embodiments, two occurrences of U on adjacent carbon atoms form a fused phenyl ring, optionally substituted with fluorine.
  • two occurrences of U on adjacent carbon atoms form a fused phenyl ring, optionally substituted with chlorine. In some embodiments, two occurrences of U on adjacent carbon atoms form a fused phenyl ring, optionally substituted with 2 halogen atoms. In some embodiments, two occurrences of U on adjacent carbon atoms form a fused phenyl ring, optionally substituted with 2 fluorines. In some embodiments, two occurrences of U on adjacent carbon atoms form a fused phenyl ring, optionally substituted with 2 chlorines. In some embodiments, two occurrences of U on adjacent carbon atoms form a fused phenyl ring, optionally substituted with fluorine and chlorine.
  • two occurrences of U on adjacent carbon atoms form a fused 5- to 6-membered heteroaryl ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • two occurrences of U on adjacent carbon atoms form an optionally substituted fused 5- to 6-membered heteroaryl ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • two occurrences of U on adjacent carbon atoms form a fused 5-membered heteroaryl ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, two occurrences of U on adjacent carbon atoms form an optionally substituted fused 5-membered heteroaryl ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • two occurrences of U on adjacent carbon atoms form a fused 5-membered heteroaryl ring containing one nitrogen and one oxygen heteroatom. In some embodiments, two occurrences of U on adjacent carbon atoms form an optionally substituted fused 5-membered heteroaryl ring containing one nitrogen and one oxygen heteroatom. In some embodiments, two occurrences of U on adjacent carbon atoms form a fused 5-membered heteroaryl ring containing one nitrogen and one oxygen heteroatom, optionally substituted with phenyl. In some embodiments, two occurrences of U on adjacent carbon atoms form a fused 5-membered heteroaryl ring containing one nitrogen and one oxygen heteroatom, optionally substituted with tosyl.
  • two occurrences of U on adjacent carbon atoms form a fused 5-membered heteroaryl ring containing one nitrogen and one oxygen heteroatom, optionally substituted with C 1-6 aliphatic. In some embodiments, two occurrences of U on adjacent carbon atoms form a fused 5-membered heteroaryl ring containing one nitrogen and one oxygen heteroatom, optionally substituted with C 1-6 alkyl. In some embodiments, two occurrences of U on adjacent carbon atoms form a fused 5-membered heteroaryl ring containing one nitrogen and one oxygen heteroatom, optionally substituted with cyclopropyl.
  • two occurrences of U on adjacent carbon atoms form a fused 5-membered heteroaryl ring containing one nitrogen and one sulfur heteroatom. In some embodiments, two occurrences of U on adjacent carbon atoms form an optionally substituted fused 5-membered heteroaryl ring containing one nitrogen and one sulfur heteroatom. In some embodiments, two occurrences of U on adjacent carbon atoms form a fused 5-membered heteroaryl ring containing one nitrogen and one sulfur heteroatom, optionally substituted with phenyl.
  • two occurrences of U on adjacent carbon atoms form a fused 5-membered heteroaryl ring containing two nitrogen heteroatoms. In some embodiments, two occurrences of U on adjacent carbon atoms form an optionally substituted fused 5-membered heteroaryl ring containing two nitrogen heteroatoms. In some embodiments, two occurrences of U on adjacent carbon atoms form a fused 5-membered heteroaryl ring containing two nitrogen heteroatoms, optionally substituted with phenyl.
  • two occurrences of U on adjacent carbon atoms form a fused 6-membered heteroaryl ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • two occurrences of U on adjacent carbon atoms form an optionally substituted fused 6-membered heteroaryl ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • two occurrences of U on adjacent carbon atoms form a fused 6-membered heteroaryl ring containing one nitrogen heteroatom. In some embodiments, two occurrences of U on adjacent carbon atoms form an optionally substituted fused 6-membered heteroaryl ring containing one nitrogen heteroatom. In some embodiments, two occurrences of U on adjacent carbon atoms form a fused 6-membered heteroaryl ring containing two nitrogen heteroatoms. In some embodiments, two occurrences of U on adjacent carbon atoms form an optionally substituted fused 6-membered heteroaryl ring containing two nitrogen heteroatoms.
  • the fused ring system formed by two occurrences of U on adjacent carbon atoms is quinazolinyl. In some embodiments, the fused ring system formed by two occurrences of U on adjacent carbon atoms is an optionally substituted quinazolinyl.
  • the fused ring system formed by two occurrences of U on adjacent carbon atoms is quinolinyl. In some embodiments, the fused ring system formed by two occurrences of U on adjacent carbon atoms is optionally substituted quinolinyl. In some embodiments, the fused ring system formed by two occurrences of U on adjacent carbon atoms is quinolinyl, optionally substituted with 1-2 halogen atoms. In some embodiments, the fused ring system formed by two occurrences of U on adjacent carbon atoms is quinolinyl, optionally substituted with 1 halogen atom.
  • the fused ring system formed by two occurrences of U on adjacent carbon atoms is quinolinyl, optionally substituted with fluorine. In some embodiments, the fused ring system formed by two occurrences of U on adjacent carbon atoms quinolinyl, optionally substituted with chlorine.
  • the fused ring system formed by two occurrences of U on adjacent carbon atoms is benzoxazolyl. In some embodiments, the fused ring system formed by two occurrences of U on adjacent carbon atoms is optionally substituted benzoxazolyl. In some embodiments, the fused ring system formed by two occurrences of U on adjacent carbon atoms is benzoxazolyl, optionally substituted with phenyl. In some embodiments, the fused ring system formed by two occurrences of U on adjacent carbon atoms is benzoxazolyl, optionally substituted with phenyl and a halogen atom.
  • the fused ring system formed by two occurrences of U on adjacent carbon atoms is benzoxazolyl, optionally substituted with phenyl and chlorine. In some embodiments, the fused ring system formed by two occurrences of U on adjacent carbon atoms is benzoxazolyl, optionally substituted with tosyl and chlorine.
  • the fused ring system formed by two occurrences of U on adjacent carbon atoms is benzisoxazolyl. In some embodiments, the fused ring system formed by two occurrences of U on adjacent carbon atoms is optionally substituted benzisoxazolyl. In some embodiments, the fused ring system formed by two occurrences of U on adjacent carbon atoms is benzisoxazolyl, optionally substituted with phenyl. In some embodiments, the fused ring system formed by two occurrences of U on adjacent carbon atoms is benzisoxazolyl, optionally substituted with cyclopropyl and a halogen atom. In some embodiments, the fused ring system formed by two occurrences of U on adjacent carbon atoms is benzisoxazolyl, optionally substituted with cyclopropyl and chlorine.
  • the fused ring system formed by two occurrences of U on adjacent carbon atoms is benzothiazolyl. In some embodiments, the fused ring system formed by two occurrences of U on adjacent carbon atoms is optionally substituted benzothiazolyl. In some embodiments, the fused ring system formed by two occurrences of U on adjacent carbon atoms is benzothiazolyl, optionally substituted with phenyl.
  • the fused ring system formed by two occurrences of U on adjacent carbon atoms is benzisothiazolyl. In some embodiments, the fused ring system formed by two occurrences of U on adjacent carbon atoms is optionally substituted benzisothiazolyl. In some embodiments, the fused ring system formed by two occurrences of U on adjacent carbon atoms is benzisothiazolyl, optionally substituted with phenyl.
  • the fused ring system formed by two occurrences of U on adjacent carbon atoms is benzimidazolyl. In some embodiments, the fused ring system formed by two occurrences of U on adjacent carbon atoms is optionally substituted benzimidazolyl. In some embodiments, the fused ring system formed by two occurrences of U on adjacent carbon atoms is benzimidazolyl, optionally substituted with phenyl.
  • W, X, Y, and Z provide a phenyl ring. In some embodiments, W, X, Y, and Z provide a phenyl ring, substituted with k occurrences of U. In some embodiments where W, X, Y, and Z provide a phenyl ring, one of W, X, Y, and Z is —C—NH 2 .
  • W, X, Y, and Z provide a pyridinyl ring. In some embodiments, W, X, Y, and Z provide a pyridinyl ring, substituted with k occurrences of U. In some embodiments where W, X, Y, and Z provide a pyridinyl ring, one of W, X, Y, and Z is —C—NH 2 .
  • one of W, X, Y, and Z is —C—NH 2 , one or more of the other of W, X, Y, and Z are CH; and k is 0.
  • one of W, X, and Y is —C—NH 2 , one or more of the other of W, X, or Y are CH; Z is N; and k is 0.
  • one of W, X, Y, and Z is —C—NH 2 , one or more of the other of W, X, Y, and Z are CH; k is 1; and U is halogen.
  • one of W, X, Y, and Z is —C—NH 2 , one or more of the other of W, X, Y, and Z are CH; k is 1; and U is fluorine.
  • one of W, X, Y, and Z is —C—NH 2 , one or more of the other of W, X, Y, and Z are CH; k is 1; and U is chlorine.
  • one of W, X, Y, and Z is —C—NH 2 , one or more of the other of W, X, Y, and Z are CH; k is 1; and U is bromine.
  • one of W, X, and Y is —C—NH 2 , one or more of the other of W, X, and Y are CH; Z is N; k is 1; and U optionally substituted phenyl.
  • one of W, X, and Y is —C—NH 2 ; one or more of the other of W, X, and Y are CH; Z is N; k is 1; and U is phenyl, optionally substituted with halogen.
  • one of W, X, and Y is —C—NH 2 , one or more of the other of W, X, and Y are CH; Z is N; k is 1; and U is phenyl, optionally substituted with chlorine.
  • one of W, X, and Y is —C—NH 2 , one or more of the other of W, X, and Y are CH; Z is N; k is 1; and U is phenyl, optionally substituted with fluorine.
  • W is N; one of X, Y, and Z is —C—NH 2 ; the other of X, Y, and Z are CH; k is 1; and U is optionally substituted phenyl.
  • W is N; one of X, Y, and Z is —C—NH 2 ; the other of X, Y, and Z are CH; k is 1; and U is phenyl, optionally substituted with halogen.
  • W is N; one of X, Y, and Z is —C—NH 2 ; the other of X, Y, and Z are CH; k is 1; and U is phenyl, optionally substituted with chlorine.
  • W is N; one of X, Y, and Z is —C—NH 2 ; the other of X, Y, and Z are CH; k is 1; and U is phenyl, optionally substituted with fluorine.
  • one of W, X, and Y is —C—NH 2 ; one or more of the other of W, X, and Y are CH; Z is N; k is 2; and the two occurrences of U on adjacent carbon atoms form a fused phenyl ring.
  • one of W, X, and Y is —C—NH 2 ; one or more of the other of W, X, and Y are CH; Z is N; k is 2; and the two occurrences of U on adjacent carbon atoms form an optionally substituted fused phenyl ring.
  • one of W, X, and Y is —C—NH 2 ; one or more of the other of W, X, and Y are CH; Z is N; k is 2; and the two occurrences of U on adjacent carbon atoms form a fused phenyl ring, optionally substituted with halogen.
  • one of W, X, and Y is —C—NH 2 ; one or more of the other of W, X, and Y are CH; Z is N; k is 2; and the two occurrences of U on adjacent carbon atoms form a fused phenyl ring, optionally substituted with chlorine.
  • one of W, X, and Y is —C—NH 2 ; one or more of the other of W, X, and Y are CH; Z is N; k is 2; and the two occurrences of U on adjacent carbon atoms form a fused phenyl ring, optionally substituted with fluorine.
  • W is N; one of X, Y, and Z is —C—NH 2 ; the other of X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form a fused phenyl ring.
  • W is N; one of X, Y, and Z is —C—NH 2 ; the other of X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form an optionally substituted fused phenyl ring.
  • W is N; one of X, Y, and Z is —C—NH 2 ; the other of X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form a fused phenyl ring, optionally substituted with halogen.
  • W is N; one of X, Y, and Z is —C—NH 2 ; the other of X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form a fused phenyl ring, optionally substituted with fluorine.
  • W is N; one of X, Y, and Z is —C—NH 2 ; the other of X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form a fused phenyl ring, optionally substituted with chlorine.
  • W is N; one of X, Y, and Z is —C—NH 2 ; the other of X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form a fused phenyl ring, optionally substituted with chlorine and fluorine.
  • W is N; one of X, Y, and Z is —C—NH 2 ; the other of X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form a fused phenyl ring, optionally substituted with chlorine at 2 positions.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form a fused 5- to 6-membered heteroaryl ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form an optionally substituted fused 5- to 6-membered heteroaryl ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form an optionally substituted fused 6-membered heteroaryl ring containing one nitrogen heteroatom.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form a fused pyridine ring.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form an optionally substituted fused pyridine ring.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form an optionally substituted fused 6-membered heteroaryl ring containing two nitrogen heteroatoms.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form a fused pyrimidine ring.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form an optionally substituted fused pyrimidine ring.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form fused aryl ring with 2 heteroatoms.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form a 5-membered fused oxazole ring.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form a 5-membered fused oxazole ring, optionally substituted with phenyl.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z is CH; k is 2; and the two occurrences of U on adjacent carbon atoms form an optionally substituted fused 5-membered heteroaryl ring containing one nitrogen and one oxygen heteroatom.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z is CH; k is 2; and the two occurrences of U on adjacent carbon atoms form a fused 5-membered heteroaryl ring containing one nitrogen and one oxygen heteroatoms, optionally substituted with phenyl.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z is CH; k is 2; and the two occurrences of U on adjacent carbon atoms form a fused 5-membered heteroaryl ring containing one nitrogen and one oxygen heteroatoms, optionally substituted with tosyl.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z is CH; k is 2; and the two occurrences of U on adjacent carbon atoms form a fused 5-membered heteroaryl ring containing one nitrogen and one oxygen heteroatoms, optionally substituted with cyclopropyl.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form an optionally substituted fused oxazole ring.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form a fused oxazole ring, optionally substituted with phenyl.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form a fused oxazole ring, optionally substituted with tosyl.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form an optionally substituted fused isoxazole ring.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form a fused isoxazole ring, optionally substituted with phenyl.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form a fused isoxazole ring, optionally substituted with cyclopropyl.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form an optionally substituted fused 5-membered heteroaryl ring containing one nitrogen and one sulfur heteroatom.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z is CH; k is 2; and the two occurrences of U on adjacent carbon atoms form a fused 5-membered heteroaryl ring containing one nitrogen and one sulfur heteroatom, optionally substituted by phenyl.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form an optionally substituted fused thiazole ring.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form a fused thiazole ring, optionally substituted with phenyl.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form an optionally substituted fused 5 membered heteroaryl ring containing two nitrogen heteratoms.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form an optionally substituted fused imidazole ring.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 2; and the two occurrences of U on adjacent carbon atoms form a fused imidazole ring, optionally substituted with phenyl.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 3; U 1 is chlorine and U 2 and U 3 on adjacent carbon atoms form an optionally substituted fused 5-membered heteroaryl ring containing one nitrogen and one oxygen heteroatom.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 3; U 1 is chlorine and U 2 and U 3 on adjacent carbon atoms form a fused 5-membered heteroaryl ring containing one nitrogen and one oxygen heteroatom, optionally substituted with phenyl.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 3; U 1 is chlorine and U 2 and U 3 on adjacent carbon atoms form a fused 5-membered heteroaryl ring containing one nitrogen and one oxygen heteroatom, optionally substituted with tosyl.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 3; U 1 is chlorine and U 2 and U 3 on adjacent carbon atoms form an optionally substituted fused oxazole ring.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 3; U 1 is chlorine and U 2 and U 3 on adjacent carbon atoms form a fused oxazole ring, optionally substituted with phenyl.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 3; U 1 is chlorine and U 2 and U 3 on adjacent carbon atoms form a fused oxazole ring, optionally substituted with tosyl.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 3; U 1 is chlorine and U 2 and U 3 on adjacent carbon atoms form an optionally substituted fused isoxazole ring.
  • one of W, X, Y, and Z is —C—NH 2 ; one or more of the other of W, X, Y, and Z are CH; k is 3; U 1 is chlorine and U 2 and U 3 adjacent carbon atoms form a fused isoxazole ring, optionally substituted with cyclopropyl.
  • each R is independently selected from hydrogen, deuterium, and an optionally substituted group selected from C 1-6 aliphatic; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; an 8- to 10-membered bicyclic aryl ring; a 3- to 8-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6- to 10-membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • R is hydrogen. In some embodiments, R is deuterium. In some embodiments, R is C 1-6 aliphatic. In some embodiments R is methyl. In some embodiments, R is ethyl. In some embodiments, R is optionally substituted C 1-6 aliphatic. In some embodiments, R is optionally substituted methyl. In some embodiments, R is optionally substituted ethyl. In some embodiments, R is phenyl. In some embodiments, R is optionally substituted phenyl. In some embodiments, R is phenyl, optionally substituted with halogen. In some embodiments, R is phenyl, optionally substituted with fluorine.
  • R a is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium or halogen atoms.
  • R a is C 1-4 aliphatic. In some embodiments, R a is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium atoms. In some embodiments, R a is C 1-4 aliphatic optionally substituted with 1, 2, or 3 halogen atoms.
  • R a is C 1-4 alkyl. In some embodiments, R a is C 1-4 alkyl optionally substituted with 1, 2, or 3 deuterium or halogen atoms. In some embodiments, R a is C 1-4 alkyl optionally substituted with 1, 2, or 3 halogen atoms. In some embodiments, R a is methyl or ethyl optionally substituted with 1, 2, or 3 halogen atoms. In some embodiments, R a is methyl.
  • R b is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium or halogen atoms.
  • R b is C 1-4 aliphatic. In some embodiments, R b is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium atoms. In some embodiments, R b is C 1-4 aliphatic optionally substituted with 1, 2, or 3 halogen atoms.
  • R b is C 1-4 alkyl. In some embodiments, R b is C 1-4 alkyl optionally substituted with 1, 2, or 3 deuterium or halogen atoms. In some embodiments, R b is C 1-4 alkyl optionally substituted with 1, 2, or 3 halogen atoms. In some embodiments, R b is methyl or ethyl optionally substituted with 1, 2, or 3 halogen atoms. In some embodiments, R b is methyl.
  • R a and R b taken together with the carbon atom to which they are attached, form a 3- to 8-membered cycloalkyl or heterocyclyl ring containing 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur.
  • R a and R b taken together with the carbon atom to which they are attached, form a 3- to 8-membered cycloalkyl. In some embodiments, R a and R b , taken together with the carbon atom to which they are attached, form a 3- to 8-membered heterocyclyl ring containing 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur.
  • R a and R b taken together with the carbon atom to which they are attached, form a cyclopropyl, cyclobutyl, or cyclopentyl ring. In some embodiments, R a and R b , taken together with the carbon atom to which they are attached, form an oxirane, oxetane, tetrahydrofuran, or aziridine.
  • R a and R b are methyl.
  • the compound for use in the treatment of an inflammatory disorder is a compound of formula II:
  • each of R 1 , R 7 , and R 8 is independently H, D, halogen, —NH 2 , —CN, —OR, —SR, optionally substituted C 1-6 aliphatic, or
  • R 1 , R 7 and R 8 are —NH 2 and other one of R 1 R 7 and R 8 is
  • R 2 is absent or is selected from —R, halogen, —CN, —OR, —SR, —N(R) 2 , —N(R)C(O)R, —C(O)N(R) 2 , —N(R)C(O)N(R) 2 , —N(R)C(O)OR, —OC(O)N(R) 2 , —N(R)S(O) 2 R, —SO 2 N(R) 2 , —C(O)R, —C(O)OR, —OC(O)R, —S(O)R, and —S(O) 2 R;
  • R 3 is absent or is selected from —R, halogen, —CN, —OR, —SR, —N(R) 2 , —N(R)C(O)R, —C(O)N(R) 2 , —N(R)C(O)N(R) 2 , —N(R)C(O)OR, —OC(O)N(R) 2 , —N(R)S(O) 2 R, —SO 2 N(R) 2 , —C(O)R, —C(O)OR, —OC(O)R, —S(O)R, and —S(O) 2 R;
  • R 4 is absent or is selected from —R, halogen, —CN, —OR, —SR, —N(R) 2 , —N(R)C(O)R, —C(O)N(R) 2 , —N(R)C(O)N(R) 2 , —N(R)C(O)OR, —OC(O)N(R) 2 , —N(R)S(O) 2 R, —SO 2 N(R) 2 , —C(O)R, —C(O)OR, —OC(O)R, —S(O)R, and —S(O) 2 R;
  • R 5 is absent or is selected from —R, halogen, —CN, —OR, —SR, —N(R) 2 , —N(R)C(O)R, —C(O)N(R) 2 , —N(R)C(O)N(R) 2 , —N(R)C(O)OR, —OC(O)N(R) 2 , —N(R)S(O) 2 R, —SO 2 N(R) 2 , —C(O)R, —C(O)OR, —OC(O)R, —S(O)R, and —S(O) 2 R;
  • R a is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium or halogen atoms
  • R b is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium or halogen atoms; or R a and R b , taken together with the carbon atom to which they are attached, form a 3- to 8-membered cycloalkyl or heterocyclyl ring containing 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur; and
  • each R is independently selected from hydrogen, deuterium, and an optionally substituted group selected from C 1-6 aliphatic; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; an 8- to 10-membered bicyclic aryl ring; a 3- to 8-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6- to 10-membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • R a is C 1-4 aliphatic. In some embodiments, R a is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium atoms. In some embodiments, R a is C 1-4 aliphatic optionally substituted with 1, 2, or 3 halogen atoms.
  • R a is C 1-4 alkyl. In some embodiments, R a is C 1-4 alkyl optionally substituted with 1, 2, or 3 deuterium or halogen atoms. In some embodiments, R a is C 1-4 alkyl optionally substituted with 1, 2, or 3 halogen atoms. In some embodiments, R a is methyl or ethyl optionally substituted with 1, 2, or 3 halogen atoms. In some embodiments, R a is methyl.
  • R b is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium or halogen atoms.
  • R b is C 1-4 aliphatic. In some embodiments, R b is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium atoms. In some embodiments, R b is C 1-4 aliphatic optionally substituted with 1, 2, or 3 halogen atoms.
  • R b is C 1-4 alkyl. In some embodiments, R b is C 1-4 alkyl optionally substituted with 1, 2, or 3 deuterium or halogen atoms. In some embodiments, R b is C 1-4 alkyl optionally substituted with 1, 2, or 3 halogen atoms. In some embodiments, R b is methyl or ethyl optionally substituted with 1, 2, or 3 halogen atoms. In some embodiments, R b is methyl.
  • R a and R b taken together with the carbon atom to which they are attached, form a 3- to 8-membered cycloalkyl or heterocyclyl ring containing 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur.
  • R a and R b taken together with the carbon atom to which they are attached, form a 3- to 8-membered cycloalkyl. In some embodiments, R a and R b , taken together with the carbon atom to which they are attached, form a 3- to 8-membered heterocyclyl ring containing 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur.
  • R a and R b taken together with the carbon atom to which they are attached, form a cyclopropyl, cyclobutyl, or cyclopentyl ring. In some embodiments, R a and R b , taken together with the carbon atom to which they are attached, form an oxirane, oxetane, tetrahydrofuran, or aziridine.
  • the —NH 2 on one of R 1 , R 7 , and R 8 and the carbinol on the other of R 1 , R 7 , and R 8 are on adjacent carbon atoms of the pyridine moiety.
  • the compound is a compound of formula II-a, II-b, or II-c:
  • each of R 1 , R 7 , and R 8 when present is independently H, D, halogen, —CN, —OR, —SR, optionally substituted C 1-6 aliphatic, or
  • R 2 , R 3 , R 4 , R 5 , R a , R b and R are as defined for formula II.
  • the compound for use in the method is a compound of formula II-d, II-e, II-f or II-g:
  • R 1 and R 7 is independently H, D, halogen, —CN, —OR, —SR, optionally substituted C 1-6 aliphatic;
  • R 2 , R 3 , R 4 , R 5 , R a , R b and R are as defined for formula II.
  • the compound for use in the method is a compound of formula III:
  • Q, T and V are independently S, N, O, or —C—R;
  • each of R 1 , R 6 , R 7 , and R 8 is independently H, D, halogen, —NH 2 , —CN, —OR, —SR, optionally substituted C 1-6 aliphatic, or
  • R 1 , R 6 , R 7 , and R 8 are —NH 2 and other one of R 1 , R 6 , R 7 , and R 8 is
  • R a is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium or halogen atoms
  • R b is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium or halogen atoms; or R a and R b , taken together with the carbon atom to which they are attached, form a 3-8 membered cycloalkyl or heterocyclyl ring containing 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur; and
  • each R is independently selected from hydrogen, deuterium, and an optionally substituted group selected from: C 1-6 aliphatic, a 3- to 8-membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8- to 10-membered bicyclic aryl ring, a 3- to 8-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 6- to 10-membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • the —NH 2 on one of R 1 , R 6 , R 7 , and R 8 and the carbinol on the other of R 1 , R 6 , R 7 , and R 8 are on adjacent carbon atoms of the phenyl moiety.
  • one of Q, T and V is N, and other of Q, T and V is O.
  • Q is O
  • V is N
  • T is C—R.
  • Q is N
  • T is O and V is C—R.
  • the compound is a compound of formula III-a or III-b:
  • each of R 1 , R 6 , R 7 , and R 8 when present is independently H, D, halogen, —CN, —OR, —SR, optionally substituted C 1-6 aliphatic, or
  • R 1 , R 6 , R 7 , and R 8 is
  • the compound is a compound of formula III-c, III-d or III-e:
  • each of R 1 , R 6 , and R 7 when present is independently H, D, halogen, —CN, —OR, —SR, optionally substituted C 1-6 aliphatic;
  • the compound is a compound of formula III-f, III-h or III-i:
  • each of R 1 , R 6 , R 7 , and R 8 when present is independently H, D, halogen, —CN, —OR, —SR, optionally substituted C 1-6 aliphatic or
  • R 1 , R 6 , R 7 , and R 8 is
  • R, R a and R b are as defined in formula III.
  • the compound is a compound of formula III-j, III-k, III-l or III-m:
  • each of R 1 , R 6 , R 7 , and R 8 when present is independently H, D, halogen, —CN, —OR, —SR, optionally substituted C 1-6 aliphatic; and
  • R, R a and R b are as defined in formula III.
  • the compound is a compound of formula III-n:
  • each of R 1 , R 6 , R 7 , and R 8 is independently H, D, halogen, —NH 2 , —CN, —OR, —SR, optionally substituted C 1-6 aliphatic, or
  • R 1 , R 6 , R 7 , and R 8 are —NH 2 and other one of R 1 , R 6 , R 7 , and R 8 is
  • R, R a , and R b are as defined in formula III
  • the compound is a compound of formula III-o, III-p, III-q or III-r:
  • each of R 1 , R 6 , R 7 , and R 8 when present is independently H, D, halogen, —CN, —OR, —SR, optionally substituted C 1-6 aliphatic, or
  • R 1 , R 6 , R 7 , and R 8 is
  • R, R a , and R b are as defined in formula III
  • the compound is a compound of formula III-s, III-t, III-u, III-v, III-w, or III-x:
  • each of R 1 , R 6 , R 7 , and R 8 when present is independently H, D, halogen, —CN, —OR, —SR, optionally substituted C 1-6 aliphatic; and
  • R, R a and R b are as defined in formula III.
  • the compound for use in the method is a compound of formula IV:
  • Ring A is a 5-membered partially unsaturated heterocyclic or heteroaromatic ring containing 1-3 nitrogen atoms, 1 or 2 oxygen atoms, 1 sulfur atom, or 1 nitrogen and 1 sulfur atom; or a 6-membered partially unsaturated heterocyclic or heteroaromatic ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-membered partially unsaturated heterocyclic or heteroaromatic ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • Ring A is a 5-membered partially unsaturated heterocyclic or heteroaromatic ring containing 1-3 nitrogen atoms, 1 or 2 oxygen atoms, 1 sulfur atom, or 1 nitrogen and 1 sulfur atom. In some embodiments, Ring A is a 6-membered partially unsaturated heterocyclic or heteroaromatic ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring A is a 7-membered partially unsaturated heterocyclic or heteroaromatic ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • Ring A is imidazole or triazole. In some embodiments, Ring A is thiazole. In some embodiments, Ring A is thiophene or furan. In some embodiments, Ring A is pyridine, pyrimidine, pyrazine, pyridazine, or 1,2,4-triazine. In some embodiments, Ring A is pyridine.
  • R 1 is H, D, halogen, —CN, —OR, —SR, or optionally substituted C 1-6 aliphatic.
  • R 1 is H. In some embodiments, R 1 is D. In some embodiments, R 1 is halogen. In some embodiments, R 1 is —CN. In some embodiments, R 1 is —OR. In some embodiments, R 1 is —SR. In some embodiments, R 1 is optionally substituted C 1-6 aliphatic.
  • R 2 is absent or is selected from —R, halogen, —CN, —OR, —SR, —N(R) 2 , —N(R)C(O)R, —C(O)N(R) 2 , —N(R)C(O)N(R) 2 , —N(R)C(O)OR, —OC(O)N(R) 2 , —N(R)S(O) 2 R, —SO 2 N(R) 2 , —C(O)R, —C(O)OR, —OC(O)R, —S(O)R, and —S(O) 2 R.
  • R 2 is absent. In some embodiments, R 2 is —R. In some embodiments, R 2 is halogen. In some embodiments, R 2 is —CN. In some embodiments, R 2 is —OR. In some embodiments, R 2 is —SR. In some embodiments, R 2 is —N(R) 2 . In some embodiments, R 2 is —N(R)C(O)R. In some embodiments, R 2 is —C(O)N(R) 2 . In some embodiments, R 2 is —N(R)C(O)N(R) 2 . In some embodiments, R 2 is —N(R)C(O)OR.
  • R 2 is —OC(O)N(R) 2 . In some embodiments, R 2 is —N(R)S(O) 2 R. In some embodiments, R 2 is —SO 2 N(R) 2 . In some embodiments, R 2 is —C(O)R. In some embodiments, R 2 is —C(O)OR. In some embodiments, R 2 is —OC(O)R. In some embodiments, R 2 is —S(O)R. In some embodiments, R 2 is —S(O) 2 R.
  • R 2 is hydrogen. In some embodiments, R 2 is deuterium. In some embodiments, R 2 is an optionally substituted C 1-6 aliphatic. In some embodiments, R 2 is an optionally substituted 3- to 8-membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, R 2 is an optionally substituted phenyl. In some embodiments, R 2 is an optionally substituted 8- to 10-membered bicyclic aryl ring. In some embodiments, R 2 is an optionally substituted 3- to 8-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • R 2 is an optionally substituted 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 2 is an optionally substituted 6- to 10-membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 2 is an optionally substituted 7- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • R 2 is Cl or Br. In some embodiments, R 2 is Cl.
  • R 3 is absent or is selected from —R, halogen, —CN, —OR, —SR, —N(R) 2 , —N(R)C(O)R, —C(O)N(R) 2 , —N(R)C(O)N(R) 2 , —N(R)C(O)OR, —OC(O)N(R) 2 , —N(R)S(O) 2 R, —SO 2 N(R) 2 , —C(O)R, —C(O)OR, —OC(O)R, —S(O)R, and —S(O) 2 R.
  • R 3 is absent. In some embodiments, R 3 is —R. In some embodiments, R 3 is halogen. In some embodiments, R 3 is —CN. In some embodiments, R 3 is —OR. In some embodiments, R 3 is —SR. In some embodiments, R 3 is —N(R) 2 . In some embodiments, R 3 is —N(R)C(O)R. In some embodiments, R 3 is —C(O)N(R) 2 . In some embodiments, R 3 is —N(R)C(O)N(R) 2 . In some embodiments, R 3 is —N(R)C(O)OR.
  • R 3 is —OC(O)N(R) 2 . In some embodiments, R 3 is —N(R)S(O) 2 R. In some embodiments, R 3 is —SO 2 N(R) 2 . In some embodiments, R 3 is —C(O)R. In some embodiments, R 3 is —C(O)OR. In some embodiments, R 3 is —OC(O)R. In some embodiments, R 3 is —S(O)R. In some embodiments, R 3 is —S(O) 2 R.
  • R 3 is hydrogen. In some embodiments, R 3 is deuterium. In some embodiments, R 3 is an optionally substituted C 1-6 aliphatic. In some embodiments, R 3 is an optionally substituted 3- to 8-membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, R 3 is an optionally substituted phenyl. In some embodiments, R 3 is an optionally substituted 8- to 10-membered bicyclic aryl ring. In some embodiments, R 3 is an optionally substituted 3- to 8-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • R 3 is an optionally substituted 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 3 is an optionally substituted 6- to 10-membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 3 is an optionally substituted 7- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • R 3 is Cl or Br. In some embodiments, R 3 is Cl.
  • R 4 is absent or is selected from —R, halogen, —CN, —OR, —SR, —N(R) 2 , —N(R)C(O)R, —C(O)N(R) 2 , —N(R)C(O)N(R) 2 , —N(R)C(O)OR, —OC(O)N(R) 2 , —N(R)S(O) 2 R, —SO 2 N(R) 2 , —C(O)R, —C(O)OR, —OC(O)R, —S(O)R, and —S(O) 2 R.
  • R 4 is absent. In some embodiments, R 4 is —R. In some embodiments, R 4 is halogen. In some embodiments, R 4 is —CN. In some embodiments, R 4 is —OR. In some embodiments, R 4 is —SR. In some embodiments, R 4 is —N(R) 2 . In some embodiments, R 4 is —N(R)C(O)R. In some embodiments, R 4 is —C(O)N(R) 2 . In some embodiments, R 4 is —N(R)C(O)N(R) 2 . In some embodiments, R 4 is —N(R)C(O)OR.
  • R 4 is —OC(O)N(R) 2 . In some embodiments, R 4 is —N(R)S(O) 2 R. In some embodiments, R 4 is —SO 2 N(R) 2 . In some embodiments, R 4 is —C(O)R. In some embodiments, R 4 is —C(O)OR. In some embodiments, R 4 is —OC(O)R. In some embodiments, R 4 is —S(O)R. In some embodiments, R 4 is —S(O) 2 R.
  • R 4 is hydrogen. In some embodiments, R 4 is deuterium. In some embodiments, R 4 is an optionally substituted C 1-6 aliphatic. In some embodiments, R 4 is an optionally substituted 3- to 8-membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, R 4 is an optionally substituted phenyl. In some embodiments, R 4 is an optionally substituted 8- to 10-membered bicyclic aryl ring. In some embodiments, R 4 is an optionally substituted 3- to 8-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • R 4 is an optionally substituted 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 4 is an optionally substituted 6- to 10-membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 4 is an optionally substituted 7- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • R 4 is Cl or Br. In some embodiments, R 4 is Cl.
  • R a is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium or halogen atoms.
  • R a is C 1-4 aliphatic. In some embodiments, R a is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium atoms. In some embodiments, R a is C 1-4 aliphatic optionally substituted with 1, 2, or 3 halogen atoms.
  • R a is C 1-4 alkyl. In some embodiments, R a is C 1-4 alkyl optionally substituted with 1, 2, or 3 deuterium or halogen atoms. In some embodiments, R a is C 1-4 alkyl optionally substituted with 1, 2, or 3 halogen atoms. In some embodiments, R a is methyl or ethyl optionally substituted with 1, 2, or 3 halogen atoms. In some embodiments, R a is methyl.
  • R b is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium or halogen atoms.
  • R b is C 1-4 aliphatic. In some embodiments, R b is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium atoms. In some embodiments, R b is C 1-4 aliphatic optionally substituted with 1, 2, or 3 halogen atoms.
  • R b is C 1-4 alkyl. In some embodiments, R b is C 1-4 alkyl optionally substituted with 1, 2, or 3 deuterium or halogen atoms. In some embodiments, R b is C 1-4 alkyl optionally substituted with 1, 2, or 3 halogen atoms. In some embodiments, R b is methyl or ethyl optionally substituted with 1, 2, or 3 halogen atoms. In some embodiments, R b is methyl.
  • R a and R b taken together with the carbon atom to which they are attached, form a 3- to 8-membered cycloalkyl or heterocyclyl ring containing 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur.
  • R a and R b taken together with the carbon atom to which they are attached, form a 3- to 8-membered cycloalkyl. In some embodiments, R a and R b , taken together with the carbon atom to which they are attached, form a 3- to 8-membered heterocyclyl ring containing 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur.
  • R a and R b taken together with the carbon atom to which they are attached, form a cyclopropyl, cyclobutyl, or cyclopentyl ring. In some embodiments, R a and R b , taken together with the carbon atom to which they are attached, form an oxirane, oxetane, tetrahydrofuran, or aziridine.
  • R a and R b are methyl.
  • the compound for use in the method is a compound of formula V:
  • R 2 is selected from —R, halogen, —CN, —OR, —SR, —N(R) 2 , —N(R)C(O)R, —C(O)N(R) 2 , —N(R)C(O)N(R) 2 , —N(R)C(O)OR, —OC(O)N(R) 2 , —N(R)S(O) 2 R, —SO 2 N(R) 2 , —C(O)R, —C(O)OR, —OC(O)R, —S(O)R, and —S(O) 2 R.
  • R 2 is —R. In some embodiments, R 2 is halogen. In some embodiments, R 2 is —CN. In some embodiments, R 2 is —OR. In some embodiments, R 2 is —SR. In some embodiments, R 2 is —N(R) 2 . In some embodiments, R 2 is —N(R)C(O)R. In some embodiments, R 2 is —C(O)N(R) 2 . In some embodiments, R 2 is —N(R)C(O)N(R) 2 . In some embodiments, R 2 is —N(R)C(O)OR. In some embodiments, R 2 is —OC(O)N(R) 2 .
  • R 2 is —N(R)S(O) 2 R. In some embodiments, R 2 is —SO 2 N(R) 2 . In some embodiments, R 2 is —C(O)R. In some embodiments, R 2 is —C(O)OR. In some embodiments, R 2 is —OC(O)R. In some embodiments, R 2 is —S(O)R. In some embodiments, R 2 is —S(O) 2 R.
  • R 2 is hydrogen. In some embodiments, R 2 is deuterium. In some embodiments, R 2 is an optionally substituted C 1-6 aliphatic. In some embodiments, R 2 is an optionally substituted 3- to 8-membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, R 2 is an optionally substituted phenyl. In some embodiments, R 2 is an optionally substituted 8- to 10-membered bicyclic aryl ring. In some embodiments, R 2 is an optionally substituted 3- to 8-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • R 2 is an optionally substituted 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 2 is an optionally substituted 6- to 10-membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 2 is an optionally substituted 7- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • R 2 is Cl or Br. In some embodiments, R 2 is Cl.
  • R 3 is selected from —R, halogen, —CN, —OR, —SR, —N(R) 2 , —N(R)C(O)R, —C(O)N(R) 2 , —N(R)C(O)N(R) 2 , —N(R)C(O)OR, —OC(O)N(R) 2 , —N(R)S(O) 2 R, —SO 2 N(R) 2 , —C(O)R, —C(O)OR, —OC(O)R, —S(O)R, and —S(O) 2 R.
  • R 3 is —R. In some embodiments, R 3 is halogen. In some embodiments, R 3 is —CN. In some embodiments, R 3 is —OR. In some embodiments, R 3 is —SR. In some embodiments, R 3 is —N(R) 2 . In some embodiments, R 3 is —N(R)C(O)R. In some embodiments, R 3 is —C(O)N(R) 2 . In some embodiments, R 3 is —N(R)C(O)N(R) 2 . In some embodiments, R 3 is —N(R)C(O)OR. In some embodiments, R 3 is —OC(O)N(R) 2 .
  • R 3 is —N(R)S(O) 2 R. In some embodiments, R 3 is —SO 2 N(R) 2 . In some embodiments, R 3 is —C(O)R. In some embodiments, R 3 is —C(O)OR. In some embodiments, R 3 is —OC(O)R. In some embodiments, R 3 is —S(O)R. In some embodiments, R 3 is —S(O) 2 R.
  • R 3 is hydrogen. In some embodiments, R 3 is deuterium. In some embodiments, R 3 is an optionally substituted C 1-6 aliphatic. In some embodiments, R 3 is an optionally substituted 3- to 8-membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, R 3 is an optionally substituted phenyl. In some embodiments, R 3 is an optionally substituted 8- to 10-membered bicyclic aryl ring. In some embodiments, R 3 is an optionally substituted 3- to 8-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • R 3 is an optionally substituted 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 3 is an optionally substituted 6- to 10-membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R 3 is an optionally substituted 7- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • R 3 is Cl or Br. In some embodiments, R 3 is Cl.
  • R 4 is selected from —R, halogen, —CN, —OR, —SR, —N(R) 2 , —N(R)C(O)R, —C(O)N(R) 2 , —N(R)C(O)N(R) 2 , —N(R)C(O)OR, —OC(O)N(R) 2 , —N(R)S(O) 2 R, —SO 2 N(R) 2 , —C(O)R, —C(O)OR, —OC(O)R, —S(O)R, and —S(O) 2 R.
  • R 4 is —R. In some embodiments, R 4 is halogen. In some embodiments, R 4 is —CN. In some embodiments, R 4 is —OR. In some embodiments, R 4 is —SR. In some embodiments, R 4 is —N(R) 2 . In some embodiments, R 4 is —N(R)C(O)R. In some embodiments, R 4 is —C(O)N(R) 2 . In some embodiments, R 4 is —N(R)C(O)N(R) 2 . In some embodiments, R 4 is —N(R)C(O)OR. In some embodiments, R 4 is —OC(O)N(R) 2 .
  • R 4 is —N(R)S(O) 2 R. In some embodiments, R 4 is —SO 2 N(R) 2 . In some embodiments, R 4 is —C(O)R. In some embodiments, R 4 is —C(O)OR. In some embodiments, R 4 is —OC(O)R. In some embodiments, R 4 is —S(O)R. In some embodiments, R 4 is —S(O) 2 R.
  • R 4 is hydrogen. In some embodiments, R 4 is deuterium. In some embodiments, R 4 is an optionally substituted C 1-6 aliphatic. In some embodiments, R 4 is an optionally substituted 3- to 8-membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, R 4 is an optionally substituted phenyl. In some embodiments, R 4 is an optionally substituted 8- to 10-membered bicyclic aryl ring. In some embodiments, R 4 is an optionally substituted 3- to 8-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • R 4 is an optionally substituted 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 4 is an optionally substituted 6- to 10-membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 4 is an optionally substituted 7- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • R 4 is Cl or Br. In some embodiments, R 4 is Cl.
  • R 5 is selected from —R, halogen, —CN, —OR, —SR, —N(R) 2 , —N(R)C(O)R, —C(O)N(R) 2 , —N(R)C(O)N(R) 2 , —N(R)C(O)OR, —OC(O)N(R) 2 , —N(R)S(O) 2 R, —SO 2 N(R) 2 , —C(O)R, —C(O)OR, —OC(O)R, —S(O)R, and —S(O) 2 R.
  • R 5 is —R. In some embodiments, R 5 is halogen. In some embodiments, R 5 is —CN. In some embodiments, R 5 is —OR. In some embodiments, R 5 is —SR. In some embodiments, R 5 is —N(R) 2 . In some embodiments, R 5 is —N(R)C(O)R. In some embodiments, R 5 is —C(O)N(R) 2 . In some embodiments, R 5 is —N(R)C(O)N(R) 2 . In some embodiments, R 5 is —N(R)C(O)OR. In some embodiments, R 5 is —OC(O)N(R) 2 .
  • R 5 is —N(R)S(O) 2 R. In some embodiments, R 5 is —SO 2 N(R) 2 . In some embodiments, R 5 is —C(O)R. In some embodiments, R 5 is —C(O)OR. In some embodiments, R 5 is —OC(O)R. In some embodiments, R 5 is —S(O)R. In some embodiments, R 5 is —S(O) 2 R.
  • R 5 is hydrogen. In some embodiments, R 5 is deuterium. In some embodiments, R 5 is an optionally substituted C 1-6 aliphatic. In some embodiments, R 5 is an optionally substituted 3- to 8-membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, R 5 is an optionally substituted phenyl. In some embodiments, R 5 is an optionally substituted 8- to 10-membered bicyclic aryl ring. In some embodiments, R 5 is an optionally substituted 3- to 8-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • R 5 is an optionally substituted 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 5 is an optionally substituted 6- to 10-membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 5 is an optionally substituted 7- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • R 5 is Cl or Br. In some embodiments, R 5 is Cl.
  • R a is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium or halogen atoms.
  • R a is C 1-4 aliphatic. In some embodiments, R a is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium atoms. In some embodiments, R a is C 1-4 aliphatic optionally substituted with 1, 2, or 3 halogen atoms.
  • R a is C 1-4 alkyl. In some embodiments, R a is C 1-4 alkyl optionally substituted with 1, 2, or 3 deuterium or halogen atoms. In some embodiments, R a is C 1-4 alkyl optionally substituted with 1, 2, or 3 halogen atoms. In some embodiments, R a is methyl or ethyl optionally substituted with 1, 2, or 3 halogen atoms. In some embodiments, R a is methyl.
  • R b is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium or halogen atoms.
  • R b is C 1-4 aliphatic. In some embodiments, R b is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium atoms. In some embodiments, R b is C 1-4 aliphatic optionally substituted with 1, 2, or 3 halogen atoms.
  • R b is C 1-4 alkyl. In some embodiments, R b is C 1-4 alkyl optionally substituted with 1, 2, or 3 deuterium or halogen atoms. In some embodiments, R a is C 1-4 alkyl optionally substituted with 1, 2, or 3 halogen atoms. In some embodiments, R b is methyl or ethyl optionally substituted with 1, 2, or 3 halogen atoms. In some embodiments, R b is methyl.
  • R a and R b taken together with the carbon atom to which they are attached, form a 3- to 8-membered cycloalkyl or heterocyclyl ring containing 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur.
  • R a and R b taken together with the carbon atom to which they are attached, form a 3- to 8-membered cycloalkyl. In some embodiments, R a and R b , taken together with the carbon atom to which they are attached, form a 3- to -membered heterocyclyl ring containing 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur.
  • R a and R b taken together with the carbon atom to which they are attached, form a cyclopropyl, cyclobutyl, or cyclopentyl ring. In some embodiments, R a and R b , taken together with the carbon atom to which they are attached, form an oxirane, oxetane, tetrahydrofuran, or aziridine.
  • R a and R b are methyl.
  • the compound for use in treatment of an inflammatory disorder is a compound of formula VI-a, VI-b, VI-c, or VI-d:
  • each of R, R 1 , R 2 , R 3 , R 4 , R a , and R b is as defined is as defined above and described in embodiments herein, both singly and in combination.
  • the compound is of formula VI-a above.
  • R 1 and R 4 are H.
  • R 2 is H.
  • R a and R b are C 1-4 alkyl optionally substituted with 1, 2, or 3 deuterium or halogen atoms, or R a and R b are taken together with the carbon to which they are attached to form a 3-8 membered cycloalkyl ring.
  • R 3 is H, C 1-4 alkyl, halogen, —NR, —OR, —SR, —CO 2 R, or —C(O)R, wherein R is H, optionally substituted C 1-4 alkyl, or optionally substituted phenyl.
  • the compound for use in the method is a compound of formula VI-e, VI-f, VI-g, or VI-h:
  • the compound for use in the method is a compound of formula VI-i, VI-j, VI-k, VI-l, VI-m, or VI-n:
  • the compound for use in the method is a compound of formula VII-a:
  • each of R, R 3 , R a , and R b is as defined is as defined above and described in embodiments herein, both singly and in combination.
  • the compound for use in the method is a compound of formula I selected from those depicted in Table 1a, below:
  • the compound is selected from:
  • the present invention provides a compound selected from these depicted in Table 1b, below.
  • compound for use in the method is a compound of formula VIII:
  • Each k, U, and R is as defined and described above.
  • Q is selected from N or NH, S, O, CU, and CH. In some embodiments, Q is selected from N or NH, S, O, CU, and CH. In some embodiments, Q is N or NH. In some embodiments, Q is S. In some embodiments, Q is O. In some embodiments, Q is CU. In some embodiments, Q is CH.
  • T is selected from N or NH, S, O, CU, and CH. In some embodiments, T is selected from N or NH, S, O, CU, and CH. In some embodiments, T is N or NH. In some embodiments, T is S. In some embodiments, T is O. In some embodiments, T is CU. In some embodiments, T is CH.
  • V is selected from N or NH, S, O, CU, and CH. In some embodiments, V is selected from N or NH, S, O, CU, and CH. In some embodiments, V is N or NH. In some embodiments, V is S. In some embodiments, V is O. In some embodiments, V is CU. In some embodiments, V is CH.
  • k is 0, 1, 2, 3, or 4. In some embodiments k is 0. In some embodiments, k is 1. In some embodiments, k is 2. In some embodiments, k is 3. In some embodiments, k is 4.
  • the ring formed represents two double bonds within the ring, which comply with the valency requirements of the atoms and heteroatoms present in the ring.
  • the ring formed is thiophene.
  • the ring formed is oxazole.
  • the ring formed is isothiazole.
  • one or more of Q and V are CH; T is S;
  • one or more of Q is CH; T is N or NH; V is O;
  • one or more of Q is S; T and V are CH;
  • Q is S; T and V are CH;
  • the compound of formula VIII is selected from those depicted in Table 2, below:
  • the compound for use in the method is a compound of formula IX-A or IX-B:
  • Each of k, U, and R is as defined and described above.
  • the compound for use in the method is a compound of formulae IX-A or IX-B selected from those depicted in Table 3, below:
  • the compound is a deuterated form of a compound above or a pharmaceutically acceptable salt thereof.
  • the compound for use in the method is a compound of formula X:
  • R 1 is selected from —NH 2 , —NHD, or —ND 2 ;
  • R 2 is selected from hydrogen or deuterium
  • R 3 and R 4 are independently selected from —CH 3 , —CH 2 D, —CHD 2 , or —CD 3 ;
  • R 5 , R 6 , R 7 , and R 8 are each independently selected from hydrogen or deuterium; provided that at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , or R 8 is or contains deuterium.
  • the compound for use in the method is a compound of formula X-A:
  • R 1 is selected from —NH 2 , —NHD, or —ND 2 ;
  • R 2 is selected from hydrogen or deuterium
  • R 3 and R 4 are independently selected from —CH 3 , —CH 2 D, —CHD 2 , or —CD 3 ;
  • R 5 , R 6 , R 7 , and R 8 are each independently selected from hydrogen or deuterium; provided that at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , or R 8 is or contains deuterium.
  • the compound for use in the method is a compound of formulae XI-A or XI-B:
  • R 1 is selected from —NH 2 , —NHD, or —ND 2 ;
  • R 2 is selected from hydrogen or deuterium
  • R 3 and R 4 are independently selected from —CH 3 , —CH 2 D, —CHD 2 , or —CD 3 ;
  • R 5 , R 6 , R 7 , and R 8 are each independently selected from hydrogen or deuterium; provided that at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , or R 8 in formula XI-A is or contains deuterium.
  • the compound for use in the method is a compound of formulae XII-A, XII-B, or XII-C:
  • R 1 is selected from —NH 2 , —NHD, or —ND 2 ;
  • R 2 is selected from hydrogen or deuterium
  • R 3 and R 4 are independently selected from —CH 3 , —CH 2 D, —CHD 2 , or —CD 3 ;
  • R 5 , R 6 , R 7 , and R 8 are each independently selected from hydrogen or deuterium; provided that at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , or R 8 is or contains deuterium.
  • the compound for use in the method is a compound of formula XIII:
  • R 1 is selected from —NH 2 , —NHD, or —ND 2 ;
  • R 2 is selected from hydrogen or deuterium
  • R 3 and R 4 are independently selected from —CH 3 , —CH 2 D, —CHD 2 , or —CD 3 ;
  • R 5 , R 6 , R 7 , and R 8 are each independently selected from hydrogen or deuterium; provided that at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , or R 8 is or contains deuterium.
  • the compound for use in the method is a compound of formula XIV:
  • R 1 is selected from —NH 2 , —NHD, or —ND 2 ;
  • R 2 is selected from hydrogen or deuterium
  • R 3 and R 4 are independently selected from —CH 3 , —CH 2 D, —CHD 2 , or —CD 3 ;
  • R 5 , R 6 , R 7 , and R 8 are each independently selected from hydrogen or deuterium; provided that at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , or R 8 is or contains deuterium.
  • the compound for use in the method is a compound of formulae XV-A or XV-B:
  • each A is independently hydrogen or deuterium
  • R 1 is selected from —NH 2 , —NHD, or —ND 2 ;
  • R 2 is selected from hydrogen or deuterium
  • R 5 , R 6 , R 7 , and R 8 are each independently selected from hydrogen or deuterium; provided that at least one of A, R 1 , R 2 , R 5 , R 6 , R 7 , or R 8 is or contains deuterium.
  • the compound for use in the method is a compound of formulae XVI-A or XVI-B:
  • each A is independently hydrogen or deuterium
  • R 1 is selected from —NH 2 , —NHD, or —ND 2 ;
  • R 2 is selected from hydrogen or deuterium
  • R 3 and R 4 are independently selected from —CH 3 , —CH 2 D, —CHD 2 , or —CD 3 ;
  • R 8 is selected from hydrogen or deuterium
  • the compound for use in the method is a compound of formulae XVII-A or XVII-B:
  • each A is independently hydrogen or deuterium
  • R 1 is selected from —NH 2 , —NHD, or —ND 2 ;
  • R 2 is selected from hydrogen or deuterium
  • R 3 and R 4 are independently selected from —CH 3 , —CH 2 D, —CHD 2 , or —CD 3 ;
  • R 5 and R 8 are each independently selected from hydrogen or deuterium
  • R 1 , R 2 , R 3 , R 4 , R 5 , or R 8 is or contains deuterium.
  • the compound for use in the method is a compound of formula XVIII-A or XVIII-B:
  • R 1 is selected from —NH 2 , —NHD, or —ND 2 ;
  • R 2 is selected from hydrogen or deuterium
  • R 3 and R 4 are independently selected from —CH 3 , —CH 2 D, —CHD 2 , or —CD 3 ;
  • R 5 , R 6 , R 7 , and R 8 are each independently selected from hydrogen or deuterium;
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , or R 8 is or contains deuterium.
  • the compound for use in the method is a compound of formula XIX:
  • R 1 is selected from —NH 2 , —NHD, or —ND 2 ;
  • R 2 is selected from hydrogen or deuterium
  • R 3 and R 4 are independently selected from —CH 3 , —CH 2 D, —CHD 2 , or —CD 3 ;
  • R 5 and R 6 are each independently selected from hydrogen or deuterium
  • R 1 , R 2 , R 3 , R 4 , R 5 , or R 6 is or contains deuterium.
  • R 1 is selected from —NH 2 , —NHD, or —ND 2 .
  • R 1 is —NH 2 . In some embodiments, R 1 is —NH 2 and at least one of R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , or R 8 is or contains deuterium.
  • R 1 is —NHD. In some embodiments, R 1 is —NHD and at least one of R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , or R 8 is or contains deuterium.
  • R 1 is —ND 2 . In some embodiments, R 1 is —ND 2 and at least one of R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , or R 8 is or contains deuterium.
  • A is selected from hydrogen or deuterium.
  • A is hydrogen. In some embodiments, A is hydrogen and at least one of R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , or R 8 is or contains deuterium. In some embodiments, A is deuterium. In some embodiments, A is deuterium and at least one of R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , or R 8 is or contains deuterium.
  • R 2 is selected from hydrogen or deuterium.
  • R 2 is hydrogen. In some embodiments, R 2 is hydrogen and at least one of R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , or R 8 is or contains deuterium. In some embodiments, R 2 is deuterium. In some embodiments, R 2 is deuterium and at least one of R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , or R 8 is or contains deuterium.
  • R 3 is selected from —CH 3 , —CH 2 D, —CHD 2 , or —CD 3 .
  • R 3 is —CH 3 . In some embodiments, R 3 is —CH 3 and at least one of R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , or R 8 is or contains deuterium.
  • R 3 is —CH 2 D. In some embodiments, R 3 is —CH 2 D and at least one of R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , or R 8 is or contains deuterium.
  • R 3 is —CHD 2 . In some embodiments, R 3 is —CHD 2 and at least one of R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , or R 8 is or contains deuterium.
  • R 3 is —CD 3 . In some embodiments, R 3 is —CD 3 and at least one of R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , or R 8 is or contains deuterium.
  • R 4 is selected from —CH 3 , —CH 2 D, —CHD 2 , or —CD 3 .
  • R 4 is —CH 3 . In some embodiments, R 4 is —CH 3 and at least one of R 1 , R 2 , R 3 , R 5 , R 6 , R 7 , or R 8 is or contains deuterium.
  • R 4 is —CH 2 D. In some embodiments, R 4 is —CH 2 D and at least one of R 1 , R 2 , R 3 , R 5 , R 6 , R 7 , or R 8 is or contains deuterium.
  • R 4 is —CHD 2 . In some embodiments, R 4 is —CHD 2 and at least one of R 1 , R 2 , R 3 , R 5 , R 6 , R 7 , or R 8 is or contains deuterium.
  • R 4 is —CD 3 . In some embodiments, R 4 is —CD 3 and at least one of R 1 , R 2 , R 3 , R 5 , R 6 , R 7 , or R 8 is or contains deuterium.
  • R 5 is selected from hydrogen or deuterium.
  • R 5 is hydrogen. In some embodiments, R 5 is hydrogen and at least one of R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , or R 8 is or contains deuterium. In some embodiments, R 5 is deuterium. In some embodiments, R 5 is deuterium and at least one of R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , or R 8 is or contains deuterium.
  • R 6 is selected from hydrogen or deuterium.
  • R 6 is hydrogen. In some embodiments, R 6 is hydrogen and at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 7 , or R 8 is or contains deuterium. In some embodiments, R 6 is deuterium. In some embodiments, R 6 is deuterium and at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 7 , or R 8 is or contains deuterium.
  • R 7 is selected from hydrogen or deuterium.
  • R 7 is hydrogen. In some embodiments, R 7 is hydrogen and at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , or R 8 is or contains deuterium. In some embodiments, R 7 is deuterium. In some embodiments, R 7 is deuterium and at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , or R 8 is or contains deuterium.
  • R 8 is selected from hydrogen or deuterium.
  • R 8 is hydrogen. In some embodiments, R 8 is hydrogen and at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , or R 7 is or contains deuterium. In some embodiments, R 8 is deuterium. In some embodiments, R 8 is deuterium and at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , or R 7 is or contains deuterium.
  • the compound for use in the method is a compound of formulae X, X-A, XI-A, XI-B, XII-A, XII-B, XII-C, XIII, or XIV, or a pharmaceutically acceptable salt thereof, wherein each of R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 is as defined above and described herein, and wherein each of R 1 and R 2 is as defined in an entry set forth in Table 4a, below.
  • the compound for use in the method is a compound of formulae X, X-A, XI-A, XI-B, XII-A, XII-B, XII-C, XIII, or XIV, or a pharmaceutically acceptable salt thereof, wherein each of R 1 , R 2 , R 5 , R 6 , R 7 , and R 8 is as defined above and described herein, and wherein each of R 3 and R 4 is as defined in an entry set forth in Table 4b, below.
  • the compound for use in the method is a compound of formulae X, X-A, XI-A, XI-B, XII-A, XII-B, XII-C, XIII, or XIV, or a pharmaceutically acceptable salt thereof, wherein each of R 1 , R 2 , R 3 , and R 4 is as defined above and described herein, and wherein each of R 5 , R 6 , R 7 , and R 8 is as defined in an entry set forth in Table 4c, below.
  • the compound for use in the method is a compound of formulae X, X-A, XI-A, XI-B, XII-A, XII-B, XII-C, XIII, or XIV, or a pharmaceutically acceptable salt thereof, wherein each of R 1 and R 2 is as defined in an entry set forth in Table 4a, above, each of R 3 and R 4 is as defined in an entry set forth in Table 4b, above, and each of R 5 , R 6 , R 7 , and R 8 , is as defined in an entry set forth in Table 4c, above.
  • the compound for use in the method is a compound selected from those recited in any of Table 4a, Table 4b, or Table 4c, or a pharmaceutically acceptable salt thereof.
  • the compound for use in the method is a compound of formula X selected from these depicted in Table 5, below.
  • the compound for use in the method is a compound depicted in Table 5, above, or a pharmaceutically acceptable salt thereof.
  • the present invention provides a deuterium-enriched analogue of a compound depicted in Table 6, below, or a pharmaceutically acceptable salt thereof, in which deuterium is enriched at any available hydrogen.
  • the compound for use in the method is any compound described herein comprising one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, or thirteen deuterium atoms.
  • the compound for use in the method is any compound described above and herein in isolated form.
  • isolated means that a compound is provide in a form that is separated from other compounds that might be present in the usual environment of that compound.
  • an isolated compound is in solid form.
  • provided compounds comprise deuterium in an amount of about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75, about 80%, about 85%, about 90%, about 95%, or about 100%.
  • the term “about” means ⁇ 2%.
  • the compound for use in the method is a compound of formula XX:
  • R 1 is H, D, or halogen
  • R 2 is H, D, or halogen
  • R 3 is H, D, Br, or I
  • R 4 is H, D, or halogen
  • R 5 is H, D, or halogen
  • R a is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium or halogen atoms
  • R b is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium or halogen atoms.
  • R 1 is H, D, or halogen.
  • R 1 is H. In some embodiments, R 1 is D. In some embodiments, R 1 is halogen. In some embodiments, R 1 is Cl. In some embodiments, R 1 is Br.
  • R 2 is H, D, or halogen.
  • R 2 is H. In some embodiments, R 2 is D. In some embodiments, R 2 is halogen. In some embodiments, R 2 is Cl. In some embodiments, R 2 is Br.
  • R 3 is H, D, Br, or I.
  • R 3 is H. In some embodiments, R 3 is D. In some embodiments, R 3 is Br. In some embodiments, R 3 is I.
  • R 4 is H, D, or halogen.
  • R 4 is H. In some embodiments, R 4 is D. In some embodiments, R 4 is halogen. In some embodiments, R 4 is Cl. In some embodiments, R 4 is Br.
  • R 5 is H, D, or halogen.
  • R 5 is H. In some embodiments, R 5 is D. In some embodiments, R 5 is halogen. In some embodiments, R 5 is Cl. In some embodiments, R 5 is Br.
  • R 6 is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium or halogen atoms.
  • R a is C 1-4 aliphatic substituted with 1, 2, or 3 deuterium or halogen atoms. In some embodiments, R a is C 1-4 aliphatic. In some embodiments, R a is C 1-4 alkyl. In some embodiments, R a is methyl, ethyl, n-propyl, or isopropyl. In some embodiments, R a is methyl.
  • R b is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium or halogen atoms.
  • R 7 is C 1-4 aliphatic substituted with 1, 2, or 3 deuterium or halogen atoms.
  • R b is C 1-4 aliphatic.
  • R b is C 1-4 alkyl.
  • R b is C 1-4 ablkyl optionally substituted with 1, 2, or 3 fluorine atoms.
  • R b is methyl, ethyl, n-propyl, or isopropyl. In some embodiments, R b is methyl.
  • R a and R b are methyl or ethyl. In some embodiments, R a and R b are methyl.
  • the compound for use in the method is a compound of formula XX-a:
  • the compound for use in the method is a compound of formula XX-b:
  • the compound for use in the method is a compound of formulae XX-c, XX-d, XX-e, or XX-f:
  • the compound for use in the method is a compound of formulae XX-g, XX-h, XX-i, or XX-j:
  • the compound for use in the method is a compound of formulae XX-k or XX-l:
  • the compound for use in the method is a compound of formula I-5:
  • R 1 is H, D, or halogen
  • R 2 is H, D, or halogen
  • R 3 is H, D, Br, or I
  • R 4 is H, D, or halogen
  • R 5 is H, D, or halogen
  • R a is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium or halogen atoms
  • R b is C 1-4 aliphatic optionally substituted with 1, 2, or 3 deuterium or halogen atoms.
  • the composition for use in the method comprises a compound of formula I-5, or a pharmaceutically acceptable salt thereof, and at least one compound according to formulae XX-a, XX-b, XX-c, XX-d, XX-e, XX-f, XX-g, XX-h, XX-i, XX-j, XX-k, or XX-l; or a pharmaceutically acceptable salt thereof.
  • composition for use in the method comprises a compound of formula I-5:
  • the composition for use in the method comprises a compound of formula I-5, or a pharmaceutically acceptable salt thereof, and one additional compound selected from XX-1, XX-2, XX-3, XX-4, or XX-5; or a pharmaceutically acceptable salt thereof.
  • the composition for use in the method comprises a compound of formula I-5, or a pharmaceutically acceptable salt thereof, and two additional compounds selected from XX-1, XX-2, XX-3, XX-4, or XX-5; or a pharmaceutically acceptable salt thereof.
  • the composition for use in the method comprises a compound of formula I-5, or a pharmaceutically acceptable salt thereof, and three additional compounds selected from XX-1, XX-2, XX-3, XX-4, or XX-5; or a pharmaceutically acceptable salt thereof.
  • the composition for use in the method comprises a compound of formula I-5, or a pharmaceutically acceptable salt thereof, and four additional compounds selected from XX-1, XX-2, XX-3, XX-4, or XX-5; or a pharmaceutically acceptable salt thereof.
  • the composition for use in the method comprises a compound of formula I-5, or a pharmaceutically acceptable salt thereof, and one additional compound selected from XX-2, XX-3, or XX-4; or a pharmaceutically acceptable salt thereof.
  • the composition for use in the method comprises a compound of formula I-5, or a pharmaceutically acceptable salt thereof, and two additional compounds selected from XX-2, XX-3, or XX-4; or a pharmaceutically acceptable salt thereof.
  • the composition comprises XX-2, XX-3, and XX-4; or a pharmaceutically acceptable salt thereof.
  • the composition for use in the method comprises a compound of formula I-5, or a pharmaceutically acceptable salt thereof, and XX-1; or a pharmaceutically acceptable salt thereof.
  • the composition for use in the method comprises a compound of formula I-5, or a pharmaceutically acceptable salt thereof, and XX-2; or a pharmaceutically acceptable salt thereof.
  • the composition for use in the method comprises a compound of formula I-5, or a pharmaceutically acceptable salt thereof, and XX-3; or a pharmaceutically acceptable salt thereof.
  • the composition for use in the method comprises a compound of formula I-5, or a pharmaceutically acceptable salt thereof, and XX-4; or a pharmaceutically acceptable salt thereof.
  • the composition for use in the method comprises a compound of formula I-5, or a pharmaceutically acceptable salt thereof, and XX-5; or a pharmaceutically acceptable salt thereof.
  • the compound for use in the method is a compound of formula XX selected from those depicted in Table 7, below.
  • the compound for use in the method is a compound depicted in Table 7, above, or a pharmaceutically acceptable salt thereof.
  • the compound for use in the method is any compound described above and herein in isolated form.
  • isolated means that a compound is provided in a form that is separated from other components that might be present in the usual environment of that compound.
  • an isolated compound is in solid form.
  • an isolated compound is at least about 50% pure as determined by a suitable HPLC method.
  • an isolated compound is at least about 60%, 70%, 80%, 90%, 95%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 99.95%, 99.99%, or 99.999% as determined by a suitable HPLC method.
  • the compound for use in the method is any compound described above and herein, or a pharmaceutically acceptable salt thereof.
  • the composition for use in the method contains a compound of any one of formulae XX, XX-a, XX-b, XX-c, XX-d, XX-e, XX-f, XX-g, XX-h, XX-i, XX-j, XX-k, or XX-l, or a pharmaceutically acceptable salt thereof, in an amount of at least about 97, 97.5, 98, 98.5, 99.0, 99.5, 99.8, 99.9, 99.95, or 99.999 weight percent where the percentages are based on the free base of said compound and the total weight of the composition.
  • the composition contains no more than about 2.0 area percent HPLC of total organic impurities or, in other embodiments, no more than about 1.5, 1.25, 1, 0.75, 0.5, 0.25, 0.2, 0.1, 0.01, 0.005, or 0.001 area percent HPLC total organic impurities relative to the total area of the HPLC chromatogram.
  • a composition for use in the method comprises a compound of formula I-5 or a pharmaceutically acceptable salt thereof, at least one compound of formulae XX, XX-a, XX-b, XX-c, XX-d, XX-e, XX-f, XX-g, XX-h, XX-i, XX-j, XX-k, or XX-l, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
  • the composition contains the compound of formula I-5 or pharmaceutically acceptable salt thereof in an amount of about 1 weight percent to about 99 weight percent, where the percentages are based on the free base of said compound and on the total weight of the composition.
  • the composition contains no more than about 2.0 area percent HPLC of total organic impurities or, in other embodiments, no more than about 1.5, 1.25, 1, 0.75, 0.5, 0.25, 0.2, 0.1, 0.01, 0.005, or 0.001 area percent HPLC total organic impurities relative to the total area of the HPLC chromatogram.
  • the composition for use in the method comprises a compound of formula I-5 or pharmaceutically acceptable salt thereof and a compound of formulae XX, XX-a, XX-b, XX-c, XX-d, XX-e, XX-f, XX-g, XX-h, XX-i, XX-j, XX-k, or XX-l, or pharmaceutically acceptable salt thereof, wherein the compound of formula I-5 or pharmaceutically acceptable salt thereof comprises about 98% and the compound of formulae XX, XX-a, XX-b, XX-c, XX-d, XX-e, XX-f, XX-g, XX-h, XX-i, XX-j, XX-k, or XX-l, or pharmaceutically acceptable salt thereof comprises about 2% of the total weight of the compounds or pharmaceutically acceptable salts thereof taken together or of the total HPLC peak area of the compounds
  • the composition for use in the method comprises a compound of formula I-5 or pharmaceutically acceptable salt thereof and a compound of formulae XX, XX-a, XX-b, XX-c, XX-d, XX-e, XX-f, XX-g, XX-h, XX-i, XX-j, XX-k, or XX-l, or pharmaceutically acceptable salt thereof, wherein the compound of formula I-5 or pharmaceutically acceptable salt thereof comprises about 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 99.95%, 99.99%, or 99.999%, and the compound of formulae XX, XX-a, XX-b, XX-c, XX-d, XX-e, XX-f, XX-g, XXX-h, XX-i, XX-j, XX-k, or XX-l, or pharmaceutically acceptable salt thereof
  • the compound of formulae XX, XX-a, XX-b, XX-c, XX-d, XX-e, XX-f, XX-g, XX-h, XX-i, XX-j, XX-k, or XX-l, or pharmaceutically acceptable salt thereof comprises about 100 ppm, 50 ppm, 10 ppm, 1 ppm, 500 ppb, 100 ppb, or 10 ppb of the total weight of the compounds or pharmaceutically acceptable salts thereof taken together.
  • the composition for use in the method comprises a compound of formula I-5 or pharmaceutically acceptable salt thereof and a compound of formulae XX, XX-a, XX-b, XX-c, XX-d, XX-e, XX-f, XX-g, XX-h, XX-i, XX-j, XX-k, or XX-l, or pharmaceutically acceptable salt thereof, wherein the compound of formula I-5 or pharmaceutically acceptable salt thereof comprises about 99%-99.9999%, 99.5-99.9999%, 99.6-99.9999%, 99.7-99.9999%, 99.8-99.9999%, 99.9-99.9999%, 99.95-99.9999%, 99.99-99.9999%, or 99.999-99.9999%, and the compound of formulae XX, XX-a, XX-b, XX-c, XX-d, XX-e, XX-f, XX-g, XX-h, XX-i
  • the compound of formula I-5 or pharmaceutically acceptable salt thereof and the compound of formula XX, XX-a, XX-b, XX-c, XX-d, XX-e, XX-f, XX-g, XX-h, XX-i, XX-j, XX-k, or XX-l, or pharmaceutically acceptable salt thereof are present in a ratio of about 98:2, 99:1, 99.5:0.5, 99.6:0.4, 99.7:0.3, 99.8:0.2, 99.9:0.1, 99.95:0.05, 99.99:0.01, or 99.999:0.001.
  • the compound of any of formulae XX, XX-a, XX-b, XX-c, XX-d, XX-e, XX-f, XX-g, XX-h, XX-i, XX-j, XX-k, or XX-l, or pharmaceutically acceptable salt thereof comprises about 0.01-0.20 area percent of the HPLC chromatogram relative to the compound of formula I-5 or pharmaceutically acceptable salt thereof.
  • the compound of formulae XX, XX-a, XX-b, XX-c, XX-d, XX-e, XX-f, XX-g, XX-h, XX-i, XX-j, XX-k, or XX-l, or pharmaceutically acceptable salt thereof comprises about 0.02-0.18, 0.03-0.16, 0.05-0.15, 0.075-0.13, 0.09-0.1, 0.1-0.2, or 0.15-0.2 area percent of the HPLC chromatogram relative to the compound of formula I-5 or pharmaceutically acceptable salt thereof.
  • the foregoing area percentages of the HPLC chromatogram are measured relative to the total area of the HPLC chromatogram.
  • the present invention provides any compound described above and herein in isolated form.
  • isolated means that a compound is provided in a form that is separated from other components that might be present in that compound's usual environment.
  • an isolated compound is in solid form.
  • an isolated compound is at least about 50% pure as determined by a suitable HPLC method.
  • an isolated compound is at least about 60%, 70%, 80%, 90%, 95%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 99.95%, 99.99%, or 99.999% as determined by a suitable HPLC method.
  • the compounds of the disclosure are used to treat inflammatory disorders.
  • the compound is administered in a therapeutically effective amount to a subject to treat a systemic inflammatory disorder.
  • the systemic inflammatory disorder is non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), inflammatory bowl disease (IBD), Crohn's disease, ulcerative colitis (UC), psoriasis, IBS (irritable bowel syndrome or spastic colon), ankylosing spondylitis, osteoporosis, rheumatoid arthritis (RA), psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, pulmonary arterial hypertension, pyridoxine-dependent epilepsy, atopic dermatitis, rosacea, multiple sclerosis (MS), systemic lupus erythematosus (SLE), lupus nephritis, sepsis, e
  • NAFLD non-alcoholic
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is used to treat a systemic disease, disorder, or condition.
  • the systemic disease, disorder, or condition is light chain deposition disease, IgA nephropathy, end-stage renal disease, gout, pseudogout, diabetic nephrophathy, diabetic neuropathy, traumatic brain injury, noise-induced hearing loss, Alzheimer's Disease, Parkinson's Disease, Huntington Malase, amyotrophic lateral sclerosis, primary biliary cirrhosis, primary sclerosing cholangitis, uterine leiomyoma, sarcoidosis, or chronic kidney disease.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat non-alcoholic fatty liver disease (NAFLD).
  • NAFLD non-alcoholic fatty liver disease
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat non-alcoholic steatohepatitis (NASH).
  • NASH non-alcoholic steatohepatitis
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat inflammatory bowl disease (IBD).
  • IBD inflammatory bowl disease
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat Crohn's disease.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat ulcerative colitis (UC).
  • UC ulcerative colitis
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat psoriasis.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat IBS (irritable bowel syndrome) or spastic colon.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat ankylosing spondylitis.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat osteoporosis.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat rheumatoid arthritis (RA).
  • RA rheumatoid arthritis
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat psoriatic arthritis.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat atherosclerosis.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat pulmonary arterial hypertension.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat pyridoxine-dependent epilepsy.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat atopic dermatitis.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat rosacea.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat multiple sclerosis (MS).
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat systemic lupus erythematosus (SLE).
  • SLE systemic lupus erythematosus
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat lupus nephritis.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat sepsis.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat eosinophilic esophagitis.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat chronic kidney disease (CKD).
  • CKD chronic kidney disease
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat fibrotic renal disease.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat chronic eosinophilic pneumonia.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat extrinsic allergic alveolitis.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat pre-eclampsia.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat endometriosis.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat polycystic ovary syndrome (PCOS).
  • PCOS polycystic ovary syndrome
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat reduced female fertility.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat reduced sperm viability and motility.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat cyclophosphamide-induced hemorrhagic cystitis.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount for treatment and/or prevention of light chain deposition disease.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount for treatment and/or prevention of IgA nephropathy.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount for treatment and/or prevention of end-stage renal disease.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount for treatment and/or prevention of gout.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount for treatment and/or prevention of pseudogout.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount for treatment and/or prevention of diabetic nephrophathy.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount for treatment and/or prevention of diabetic neurophathy.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount for treatment and/or prevention of traumatic brain injury.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount for treatment and/or prevention of noise-induced hearing loss.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount for treatment and/or prevention of Alzheimer's disease.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount for treatment and/or prevention of Parkinson's disease.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount for treatment and/or prevention of Huntington's disease.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount for treatment and/or prevention of amyotrophic lateral sclerosis.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount for treatment and/or prevention of primary biliary cirrhosis.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount for treatment and/or prevention of primary sclerosing cholangitis.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount for treatment and/or prevention of uterine leiomyoma.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount for treatment and/or prevention of sarcoidosis.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount for treatment and/or prevention of chronic kidney disease.
  • the inflammatory disorder is an ocular inflammatory disorder.
  • the ocular inflammatory disorder is diabetic macular edema (DME), atopic keratoconjunctivitis (AKC), vernal keratoconjunctivitis (VKC), age-related macular degeneration (AMD), dry eye disease (DED), allergic conjunctivitis (AC), dry eye disease with allergic conjunctivitis, noninfectious anterior uveitis, posterior uveitis, pan-uveitis, post-surgical ocular pain and inflammation.
  • DME diabetic macular edema
  • ATC atopic keratoconjunctivitis
  • VKC vernal keratoconjunctivitis
  • AMD age-related macular degeneration
  • DED dry eye disease
  • AC allergic conjunctivitis
  • the compound of the disclosure is administered in an effective amount for the prevention of corneal fibrosis after radial keratotomy, prevention of corneal fibrosis after trauma, or prevention of corneal fibrosis after infection.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat diabetic macular edema (DME).
  • DME diabetic macular edema
  • the diabetic macular edema for treatment is non-clinically significant macular edema (Non-CSME).
  • the diabetic macular edema for treatment is clinically significant macular edema (CSME).
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat uveitis, including pan-uveitis, anterior uveitis, posterior uveitis, and non-infectious uveitis, which are ocular disorders that can be secondary to a primary underlying disorder.
  • uveitis including pan-uveitis, anterior uveitis, posterior uveitis, and non-infectious uveitis, which are ocular disorders that can be secondary to a primary underlying disorder.
  • Some of the disorders with which uveitis is sometimes associated are Behçet's syndrome, ankylosing spondylitis, Lyme disease, sarcoidosis, and psoriasis.
  • Uveitis is an inflammation of the iris, ciliary body, and choroid.
  • a standard course of therapy for uveitis is a topical corticosteroid, and in some instances, a dilator such a cyclopentolate, or an immunomodulatory agent.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat atopic keratoconjunctivitis (AKC) or vernal keratoconjunctivitis (VKC).
  • AZA anterior keratoconjunctivitis
  • VKC vernal keratoconjunctivitis
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat age-related macular degeneration (AMD).
  • AMD age-related macular degeneration
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat dry eye disease (DED).
  • DED dry eye disease
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat allergic conjunctivitis (AC).
  • AC allergic conjunctivitis
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat DED with AC.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount to treat post-surgical ocular pain and inflammation.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount for prevention of corneal fibrosis after radial keratotomy.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount for prevention of corneal fibrosis after trauma.
  • a compound of the disclosure, or a pharmaceutically acceptable salt thereof is administered in an effective amount for prevention of corneal fibrosis after infection.
  • the compound for treating each of the inflammatory diseases or conditions above is a compound of formulae I to XX or subformulae thereof as described above, including any one of the exemplary compounds of Table 1a, Table 1b, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, or the other tables above.
  • a method of the inflammatory disorder comprises administering to a subject in need thereof a therapeutically effective amount of compound I-22, I-5 or 1-6 of Table 1a or Table 1b, such as compound I-22.
  • the compound above is used in combination with a second therapeutic agent.
  • the compounds of the disclosure can be administered with one or more of a second therapeutic agent, sequentially or concurrently, either by the same route or by different routes of administration. When administered sequentially, the time between administrations is selected to benefit, among others, the therapeutic efficacy and/or safety of the combination treatment.
  • the compound of the disclosure can be administered first followed by a second therapeutic agent, or alternatively, the second therapeutic agent administered first followed by the compound of the disclosure.
  • the compound of the disclosure can be administered for the same duration as the second therapeutic agent, or alternatively, for a longer or shorter duration as the second therapeutic compound.
  • the compounds of the disclosure can be administered separately at the same time as the second therapeutic agent, by the same or different routes, or administered in a single composition by the same route.
  • the compound of the disclosure is prepared as a first pharmaceutical composition
  • the second therapeutic agent prepared as a second pharmaceutical composition, where the first pharmaceutical composition and the second pharmaceutical composition are administered simultaneously, sequentially, or separately.
  • the amount and frequency of administration of the second therapeutic agent can used standard dosages and standard administration frequencies used for the particular therapeutic agent. See, e.g., Physicians' Desk Reference, 70th Ed., PDR Network, 2015; incorporated herein by reference.
  • the second therapeutic agent is a leukotriene inhibitor, non-steroidal anti-inflammatory drug (NSAID), steroid, tyrosine kinase inhibitor, receptor kinase inhibitor, modulator of nuclear receptor family of transcription factor, HSP90 inhibitor, adenosine receptor (A 2A ) agonist, disease modifying antirheumatic drugs (DMARDS), phosphodiesterase (PDE) inhibitor, neutrophil elastase inhibitor, modulator of Axl kinase, or combinations thereof.
  • NSAID non-steroidal anti-inflammatory drug
  • steroid steroid
  • tyrosine kinase inhibitor inhibitor
  • receptor kinase inhibitor modulator of nuclear receptor family of transcription factor
  • HSP90 inhibitor adenosine receptor (A 2A ) agonist
  • DARDS disease modifying antirheumatic drugs
  • PDE phosphodiesterase
  • neutrophil elastase inhibitor modulator of Axl kinase
  • the second therapeutic agent is a leukotriene inhibitor.
  • the leukotriene inhibitor is montelukast, zafirlukast, pranlukast, zileuton, or combinations thereof.
  • the second therapeutic agent is a an NSAID.
  • the NSAID is acetylsalicylic acid, diflunisal, salsalate, ibuprofen, dexibuprofen, naioxen, fenoprofen, ketoprofen, dexketoprofen, flurbiprofen, oxaprozin, loxoprofen, indomethacin, tolmetin, sulindac, etodolac, ketorolac, diclofenac, aceclofenac, nabumetone, piroxicam, meloxicam, tenoxicam, droxicam, lornoxicam, phenylbutazone, mefenamic acid, meclofenamic acid, flufenamic acid, tolfenamic acid, celecoxib or combinations thereof.
  • the second therapeutic agent is a steroid.
  • the steroid is prednisone, prednisolone, methylprednisone, triacmcinolone, betamethasone, dexamethasone, and prodrugs thereof.
  • the second therapeutic agent is a tyrosine kinase inhibitor.
  • the tyrosine kinase inhibitor is an inhibitor of the following kinases, including, among others, JAK, Syk, JNK/SAPK, MAPK, PI-3K, or Ripk2.
  • the tyrosine kinase inhibitor is ruxolitinib, tofacitinib, oclactinib, filgotinib, ganotinib, lestaurtinib, momelotinib, pacritinib, upadacitinib, peficitinib, fedratinib, bentamapimod, D-JNKI-1 (XG-102, AM-111), ponatinib, WEHI-345, OD36, GSK583, idelalisib, copanlisib, taselisib, duvelisib, alpelisib, umbralisib, dactolisib, CUDC-907, entospletinib, fostamatinib, or combinations thereof.
  • the second therapeutic agent is a receptor kinase inhibitor, including among others, and inhibitor of EGFR or HER2.
  • the receptor kinase inhibitor is gefitinib, erlotinib, neratinib, lapatinib, cetuximab, panitumumab, vandetanib, necitumumab, osimertinib, trastuzumab, neratinib, lapatinib, pertuzumab, or combinations thereof.
  • the second therapeutic agent is a modulator of nuclear receptor family of transcription factors, including, among others, and inhibitor of PPAR, RXR, FXR, or LXR.
  • the inhibitor is pioglitazone, bexarotene, obeticholic acid, ursodeoxycholic acid, fexaramine, hypocholamide, or combinations thereof.
  • the second therapeutic agent is an HSP90 inhibitor.
  • the HSP90 inhibitor is ganetespib, 17-AAG (17-allylaminogeldanamycin, NSC330507), 17-DMAG (17-dimethylaminoethylamino-17-demethoxy-geldanamycin, NSC707545), IPI-504, CNF1010, CNF2024, CNF1010, or combinations thereof.
  • the second therapeutic agent is an adenosine receptor 2A (A 2A ) agonist.
  • a 2A adenosine receptor 2A
  • the adenosine receptor agonist is, among others, disclosed in U.S. Pat. No. 9,067,963, which is incorporated herein by reference.
  • the adenosine receptor agonist is LNC-3050, LNC-3015, LNC-3047, LNC-3052, or combinations thereof.
  • the second therapeutic agent is selected from disease modifying antirheumatic drugs (DMARDS).
  • DMARDS is, among others, tocilizumab, certolizumab, etanercept, adalimumab, anakinra, abatacept, infliximab, rituximab, golimumab, uteskinumab, or combinations thereof.
  • the second therapeutic agent is a phosphodiesterase (PDE) inhibitor.
  • PDE phosphodiesterase
  • the phosphodiesterase inhibitor is apremilast, crisaborole, piclimilast, drotaverine, ibudulast, roflumilast, sildenafil, tadalafil, vardenafil, or combinations thereof.
  • the second therapeutic agent is a neutrophil elastase inhibitor.
  • the neutrophil elastase inhibitor is, among others, sivelestat.
  • the second therapeutic agent is a modulator of Axl kinase.
  • the modulator of Axl kinase is bemcentinib (BGB324 or R428), TP-0903, LY2801653, amuvatinib (MP-470), bosutinib (SKI-606), MGCD 265, ASP2215, cabozantinib (XL184), foretinib (GSK1363089/XL880), and SGI-7079.
  • the modulator of Axl kinase is a monoclonal antibody targeting AXL (e.g., YW327.6S2) or an AXL decoy receptor (e.g., GL2I.T), or glesatinib, merestinib, or a dual Flt3-Axl inhibitor such as gilteritinib.
  • AXL e.g., YW327.6S2
  • AXL decoy receptor e.g., GL2I.T
  • glesatinib, merestinib glesatinib, merestinib
  • a dual Flt3-Axl inhibitor such as gilteritinib.
  • the compounds and compositions, according to the method of the present disclosure are administered using any amount and any route of administration and any duration of treatment effective for treating or lessening the severity of a disorder provided above.
  • the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the disorder, the particular agent, its mode of administration, and the like.
  • the compounds are preferably formulated in dosage unit form for ease of administration and uniformity of dosage.
  • dosage unit form or “unit dosage form” as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions described herein can be decided by the attending physician within the scope of sound medical judgment.
  • the specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts.
  • compositions of the compounds can be administered to humans and other animals orally, rectally, intrathecally, subcutaneously, intravenously, intranasally, parenterally, intracisternally, intravaginally, intraperitoneally, intravitreally, topically (as by powders, ointments, or drops), buccally, as an oral or nasal spray, or the like, depending on the severity of the condition being treated.
  • the compounds described herein are administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
  • the compounds are administered systemically, such as by oral or parenteral administration.
  • Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • the oral compositions can also include adjuvants such as, for example, water or other solvents, solubil
  • sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid are used in the preparation of injectables.
  • Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • the rate of compound release can be controlled.
  • biodegradable polymers include poly(orthoesters) and poly(anhydrides).
  • Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
  • Subcutaneous depot formulations are also prepared with hyaluronidase.
  • compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds described herein with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and gly
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the active compounds can also be in micro-encapsulated form with one or more excipients as noted above.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
  • the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch.
  • Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
  • the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
  • buffering agents include polymeric substances and waxes.
  • Dosage forms for topical or transdermal administration of a compound of the present disclosure include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
  • the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
  • Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the scope of this disclosure.
  • the embodiments herein contemplate the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body.
  • Such dosage forms can be made by dissolving or dispensing the compound in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
  • Eye drops typically comprise an effective amount of at least one compound described herein and a carrier capable of being safely applied to an eye.
  • the eye drops are in the form of an isotonic solution, and the pH of the solution is adjusted so that there is no irritation of the eye.
  • the epithelial barrier interferes with penetration of molecules into the eye.
  • most currently used ophthalmic drugs are supplemented with some form of penetration enhancer.
  • penetration enhancers work by loosening the tight junctions of the most superior epithelial cells (Burstein, 1985, Trans Ophthalmol Soc U K 104(Pt 4):402-9; Ashton et al., 1991, J Pharmacol Exp Ther. 259(2):719-24; Green et al., 1971, Am J Ophthalmol. 72(5):897-905).
  • the most commonly used penetration enhancer is benzalkonium chloride (Tang et al., 1994, J Pharm Sci. 83(1):85-90; Burstein et al, 1980, Invest Ophthalmol Vis Sci. 19(3):308-13), which also works as preservative against microbial contamination. It is typically added to a final concentration of 0.01-0.05%.
  • the compounds for use in the method can be formulated with a cyclodextrin, for example as described in U.S. patent publication no. US 2012/0302601, incorporated herein by reference.
  • the cyclodextrin for use in the pharmaceutical compositions can be selected from ⁇ -cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin, derivatives thereof, and combinations thereof.
  • the cyclodextrin for use in the methods is selected from ⁇ -cyclodextrin, ⁇ -cyclodextrin, derivatives thereof, and combinations thereof.
  • the compounds can be formulated with a cyclodextrin or derivative thereof selected from carboxyalkyl cyclodextrin, hydroxyalkyl cyclodextrin, sulfoalkylether cyclodextrin, and an alkyl cyclodextrin.
  • the alkyl group in the cyclodextrin is methyl, ethyl, propyl, butyl, or pentyl.
  • the cyclodextrin is ⁇ -cyclodextrin or a derivative thereof.
  • the ⁇ -cyclodextrin or derivative thereof is selected from carboxyalkyl- ⁇ -cyclodextrin, hydroxyalkyl- ⁇ -cyclodextrin, sulfoalkylether- ⁇ -cyclodextrin, alkyl- ⁇ -cyclodextrin, and combinations thereof.
  • the alkyl group in the ⁇ -cyclodextrin derivative is methyl, ethyl, propyl, butyl, or pentyl.
  • the cyclodextrin is ⁇ -cyclodextrin or a derivative thereof.
  • the ⁇ -cyclodextrin or derivative thereof is selected from carboxyalkyl- ⁇ -cyclodextrin, hydroxyalkyl- ⁇ -cyclodextrin, sulfoalkylether- ⁇ -cyclodextrin, alkyl- ⁇ -cyclodextrin, and combinations thereof.
  • the alkyl group in the ⁇ -cyclodextrin derivative is methyl, ethyl, propyl, butyl, or pentyl.
  • the ⁇ -cyclodextrin or a derivative thereof is hydroxyalkyl- ⁇ -cyclodextrin or sulfoalkylether- ⁇ -cyclodextrin. In some embodiments, the hydroxyalkyl- ⁇ -cyclodextrin is hydroxypropyl- ⁇ -cyclodextrin. In some embodiments, the sulfoalkylether- ⁇ -cyclodextrin is sulfobutylether- ⁇ -cyclodextrin. In some embodiments, ⁇ -cyclodextrin or a derivative thereof is alkyl- ⁇ -cyclodextrin, in particular methyl- ⁇ -cyclodextrin. In some embodiments using methyl- ⁇ -cyclodextrin, the ⁇ -cyclodextrin is randomly methylated ⁇ -cyclodextrin.
  • the cyclodextrin is ⁇ -cyclodextrin or a derivative thereof.
  • the ⁇ -cyclodextrin or derivative thereof is selected from carboxyalkyl- ⁇ -cyclodextrin, hydroxyalkyl- ⁇ -cyclodextrin, sulfoalkylether- ⁇ -cyclodextrin, and alkyl- ⁇ -cyclodextrin.
  • the alkyl group in the ⁇ -cyclodextrin derivative is methyl, ethyl, propyl, butyl, or pentyl.
  • the ⁇ -cyclodextrin or derivative thereof is hydroxyalkyl- ⁇ -cyclodextrin or sulfoalkylether- ⁇ -cyclodextrin. In some embodiments, the hydroxyalkyl- ⁇ -cyclodextrin is hydroxypropyl- ⁇ -cyclodextrin.
  • the cyclodextrin can be present at about 0.1 w/v to about 30% w/v, about 0.1 w/v to about 20% w/v, about 0.5% w/v to about 10% w/v, or about 1% w/v to about 5% w/v.
  • the cyclodextrin is present at about 0.1% w/v, about 0.2% w/v, about 0.5% w/v, about 1% w/v, about 2% w/v, about 3% w/v, about 4% w/v, about 5% w/v, about 6% w/v, about 7% w/v, about 8% w/v, about 9% w/v, about 10% w/v, about 12% w/v, about 14% w/v, about 16% w/v, about 18% w/v, about 20% w/v, about 25% w/v, or about 30% w/v or more.
  • the compound can be present at a concentration of about 0.05% w/v to about 10% w/v, about 0.1% w/v to about 5% w/v, about 0.2% w/v to about 4% w/v, about 0.3% to about 3% w/v, about 0.4% w/v to about 2% w/v, or about 0.5% w/v to about 1.5% w/v.
  • the compound can be present at a concentration at about least about 0.05% w/v, about 0.1% w/v, about 0.2% w/v, about 0.3% w/v, about 0.4% w/v, about 0.5% w/v, about 0.6% w/v, about 0.7% w/v, about 0.8% w/v, about 0.9% w/v, about 1% w/v, about 1.5% w/v, about 2% w/v, about 3% w/v, about 4% w/v, about 5% w/v, about 6% w/v, about 7% w/v, about 8% w/v, about 9% w/v, or about 10% w/v.
  • the concentrations are for a formulation with a cyclodextrin, such as ⁇ -cyclodextrin.
  • the amount administered topically can be about 20 to about 100 ⁇ L per dose, about 30 to 80 ⁇ L per dose or about 40 to 60 ⁇ L per dose of a defined concentration of the compound effective for treating the disorder.
  • compound I-22, I-5 or 1-6 of Table 1a or Table 1b is formulated with a ⁇ -cyclodextrin, such as hydroxypropyl- ⁇ -cyclodextrin or sulfobutylether- ⁇ -cyclodextrin.
  • the compound is formulated as an ophthalmic solution such as those described in US provisional patent application serial no. U.S. 62/736,417, the entire contents of which are hereby incorporated by reference.
  • the compound is I-5.
  • Diabetic macular edema is a common cause of vision loss.
  • Hyperglycemia leads to carbonyl stress in the retina, resulting in accumulation of toxic aldehydes such as methylglyoxal, 4-hydroxy-trans-2-nonenal, and malondialdehyde, which induce inflammatory changes in the eye, including the development of DME.
  • Type 1 diabetes was induced in male brown Norway rats by intraperitoneal administration of streptozotocin (STZ; 55 mg/kg). Forty days after STZ administration, animals were assessed for the presence of diabetes by testing blood glucose levels.
  • STZ streptozotocin
  • Compound I-22 was supplied as a preformulated sterile solution at 5 mg/mL.
  • the vehicle was 25% hydroxypropyl- ⁇ -cyclodextrin solution (333 mOsm/kg) in a sodium phosphate buffer, pH 7.2.
  • Animals with diabetes were assigned to groups of ten, to receive either vehicle (HP ⁇ CD) or compound I-22.
  • STZ streptozotocin
  • Vehicle 3.5 ⁇ L
  • Compound I-22 17.5 ⁇ g per eye; 3.5 ⁇ L
  • Clinical observations (daily), body weights (weekly), qualitative food consumption, and blood glucose levels (weekly) were assessed.
  • ERG electroretinography
  • OCT optical coherence tomography
  • FFA fundus fluorescein angiography
  • Type 1 diabetes was induced by intraperitoneal administration of 55 mg/kg STZ after an overnight fast.
  • the STZ dosing solution (27.5 mg/mL) was prepared immediately prior to injection by dissolving STZ (Sigma-Aldrich Corp, St. Louis, Mo., Catalog S0130) in a citrate solution (see below) followed by filtration of the STZ solution using a 0.2 ⁇ m syringe filter (Pall Life Sciences, Ann Arbor, Mich., Catalog PN4192).
  • the STZ dosing solution was used for injection within approximately 30 minutes after reconstitution.
  • the citrate solution (0.01 M) used for reconstitution of STZ was made by mixing 1.9 g citric acid (Sigma-Aldrich Corp, St. Louis, Mo., Catalog C0759) with 1 L 0.9% Sodium Chloride for Injection (Hospira NDC0409-7983-02, Lot 62-034-JT), adjusting the pH to 4.5 with sodium hydroxide (Sigma-Aldrich Corp, St. Louis, Mo., Catalog S2770 for 1 N NaOH) followed by filtration of the STZ solution using a 0.2 ⁇ m syringe filter. This citrate solution was stored at room temperature and used for reconstituting STZ within two weeks of preparation.
  • the rats were weighed prior to dosing, weekly thereafter, and prior to necropsy.
  • Non-fasting blood glucose levels were determined prior to STZ administration, weekly thereafter and at necropsy, by a glucometer (AlphaTrak Blood Glucose Monitoring System, Abbott Laboratories, North Chicago, Ill.).
  • Electroretinography was performed on Days 55, 62 and 69. After an overnight dark adaption, both eyes were dilated with 1% tropicamide. Animals were anesthetized by isoflurane prior to the procedure. ERG responses to light stimuli (8.0 cd ⁇ s/m 2 ) were recorded by RETevet (LKC Technologies, Inc.). Implicit times and amplitudes of a-waves and b-waves were reported. There was a deviation from the protocol in which ERG was not performed prior to Test Article administration ( ⁇ Day 40). The deviation had no impact on the conclusion of the study. Baseline ERG measurements are not required to determine efficacy of the Test Article. A Day-62 ERG assessment was added to the study.
  • OCT optical coherence tomography
  • FFA fundus fluorescein angiography
  • Retinas of both eyes in each animal were scanned by OCT (Envisu R-Class, Leica/Bioptogen). Thickness of retinal mid-layers, approximately including the outer plexiform layer (OPL), the outer nuclear layer (ONL) and the photoreceptor inner segment (IS), were measured using Bioptigen InVivoVue Reader software. For each eye, four (4) digital calipers were placed randomly on a cross-section image between OPL and IS, away from optic nerve; and measurements were exported to Microsoft Excel files. An average thickness of each retina was calculated from the four (4) measurements, using Microsoft Excel.
  • ⁇ 1.5 mL/kg fluorescein (AK-FLUOR® fluorescein injection, USP, 10%, NDC 17478253-10) was injected intraperitoneally to visualize the retinal vasculature.
  • Retinal angiograms were obtained from both eyes of each animal (Micron IV, Phoenix Phoenix Research Labs) and the images were manually scored for retinal vasculature leakage on a scale of 0 to 4 (0-normal, I-slight, 2-mild, 3-moderate, 4-severe).
  • STZ injected rats showed elevated blood glucose levels and reduced body weight (and body weight gain) from one week post-STZ administration until the end of study, compared to the non-diabetic control rats (Group 1).
  • rats in the vehicle-treated diabetic group (Group 2) exhibited delayed ERG a-waves and b-waves, and thickened retinal mid-layers by OCT at 8, 9 and 10 weeks post-STZ injection.
  • Increased vascular leakage (FFA) was observed at 8 and 9 weeks post-STZ injection in Group 2 as well. No statistically significant differences were observed between the Test Article-treated Group 3 and the Vehicle-treated Group 2 for these parameters (body weights, glucose levels, ERG, OCT or FFA).
  • a further analysis of the change in retinal thickness based on scoring of microscopically visible changes also showed a reduction in retinal thickness in diabetic rats treated with compound I-22 compared to the vehicle treated rats.
  • Statistical analysis was performed by a non-parametric Dunn's multiple comparison followed by the Kruskal-Wallis test. Treatment with compound I-22 resulted in a statically significant decrease in retinal thickness.
  • Diabetic retinopathy was successfully induced in rats in this 10-week study.
  • Compound I-22 (5 mg/mL) was administered intravitreally into each eye (25 ⁇ g/eye), or topically to both eyes at 1, 3, 7, 10, and 17 hours post-LPS injection, within one hour of LPS administration.
  • Balanced salt solution (BSS) served as a vehicle control. Retinal exams were performed prior to study start and six and 24 hours following LPS administration and scored using a Combined Draize and McDonald Shadduck scoring system, based on assessments of: retinal vasculopathy and retinal hemorrhage, exudate, and detachment.
  • Parameters evaluated during the study included changes in the anterior and posterior segments of the eye.
  • Endotoxin-induced uveitis was created by a single injection of lipopolysaccharide (LPS; 100 ⁇ L) into one hind footpad.
  • LPS lipopolysaccharide
  • BSS balanced salt solution
  • test article compound I-22
  • BSS balanced salt solution
  • two drops 5 ⁇ L each, separated by approximately two minutes, for a total of 10 ⁇ L/eye/dose
  • IVT intravitreal injection
  • Ophthalmic examinations were performed on both eyes of each animal approximately six and 24 hours following LPS administration, using slit-lamp biomicroscopy and a surgical microscope or via indirect ophthalmoscopy. Pupils were dilated with 1% Tropicamide Ophthalmic Solution before ophthalmic examinations.
  • rats that had received Compound I-22 topical had a significantly lower (p ⁇ 0.05) overall ophthalmic examination score than rats that had received control topically.
  • the overall scores for rat that had received Compound I-22 topical were significantly lower (p ⁇ 0.05) than rats that had received control topically.
  • Ocular exam scores were significantly improved, compared to vehicle, at 6 hours and 24 hours after topical (TO) administration of Compound I-5 or Compound I-22.
  • Total ocular inflammation, anterior chamber inflammation and retina-choroid inflammation scores were all lower in the Compound I-5- or Compound I-22-treated groups.
  • ocular exam scores were also significantly improved vs. vehicle.
  • Total ocular inflammation, anterior chamber inflammation, and retina-choroid inflammation for intravitreal administration were all lower in the Compound I-5- and Compound I-22-treated groups compared to vehicles.
  • Example 3 A Multi-Center, Phase 2b, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of I-5 Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects with Dry Eye Disease
  • I-5 was formulated as an ophthalmic solution as described in the specification.
  • a subject's participation was estimated to be approximately 14 weeks (98 days).
  • I-5 Ophthalmic Solution at concentrations of 0.1%, 0.25%, or vehicle ophthalmic solution was administered QID by bilateral topical ocular dosing. Subjects were randomized to one of three treatment groups (1:1:1) to receive study drug after the Post-CAE® assessments at Visit 2.
  • the study sample size of 100 per group was selected based on prior Phase 2 and 3 clinical trial results using the DED Hybrid CAE study design with other development programs and the effect size seen in Phase 2a with I-5 on change from baseline after four weeks of treatment. This sample size was deemed sufficient to assess the effect size on the DED sign and symptom endpoints with I-5 vs vehicle, to confirm the endpoint selection and sample size needed for Phase 3 studies with I-5.
  • phase 2b data are shown in FIGS. 1 through 8 and Table above.
  • Ocular Discomfort Scale ⁇ ⁇ ⁇ OD & 4-Symptom Overall Ocular (0-5) ⁇ ⁇ ⁇ C ⁇ A Questionnaire: Discomfort Burning (0-5) ⁇ N/A B N/A Dryness (0-5) ⁇ ⁇ ⁇ ⁇ C A Grittiness (0-5) ⁇ ⁇ ⁇ C Stinging (0-5) ⁇ ⁇ B C C A Ocular Surface Disease (0-100) ⁇ ⁇ N/A Index (OSDI) SANDE Questionnaire Severity (0-100 mm) ⁇ ⁇ N/A ⁇ B Frequency (0-100 mm) ⁇ ⁇ ⁇ Sign Measures Usamine Green Staining: Total Score (0-20; ⁇ 5x) ⁇ ⁇ ⁇ ⁇ (all five regions) Corneal Sum Score (0-12; ⁇ 3x) ⁇ ⁇ ⁇ ⁇ C (Inferior, Superior, and Central
  • DSS dextran sulfate sodium
  • UC acute ulcerative colitis
  • mice have been shown to develop acute colitis with signs of diarrhea, gross rectal bleeding, and body weight loss within six to ten days after ingesting 3% to 10% DSS (Okayasu, 1990). Gross and histopathologic changes resulting from this treatment resemble those occurring in human ulcerative colitis, a subset of inflammatory bowel disease (Okayasu, 1990; MacDermott, 1992; Cooper, 1993). Compounds that are effective in the treatment of human IBD have activity in this model and it is being used to investigate potential new therapies (Axelsson, 1998; Egger, 1999; Miceli, 1999).
  • mice Female Swiss Webster mice, aged six to eight weeks, were used in the study. The mice weighed approximately 20 to 27 grams (mean 23 g) at enrollment on Study Day ⁇ 3.
  • Dextran sulfate sodium (DSS; Spectrum, Cat #DE136, Lot #2DC0020) was stored at room temperature until added to appropriate volume of sterile filtered water (VetOne, Lot #B1712033) to prepare a 3% DSS solution.
  • test articles were: Compound I-5, Compound I-22, and Compound I-6.
  • Test articles for oral (PO) dosing were supplied for the main study were prepared in methylcellulose vehicle (MC: Sigma, Lot #SLBM2910V) at 10 mL/kg.
  • Compound I-6 for IP dosing at 10 mL/kg was prepared in sulfobutylether- ⁇ -cyclodextrin (SBECD) vehicle (Captisol®) by dissolving 20% w/v Captisol® into a solution of sterile saline with sodium phosphate, dibasic, anhydrous and sodium phosphate, monobasic, monohydrate. NaOH was added to adjust the pH to 7.3.
  • SBECD sulfobutylether- ⁇ -cyclodextrin
  • Cyclosporine A (CsA: Teva) was prepared in Kolliphor EL (Sigma)/1% carboxymethylcellulose for PO dosing at 10 mL/kg.
  • mice in Groups 8, 9, and 10 were dosed BID by the oral (PO) route with Compound I-5 (200 mg/kg), Compound I-22 (200 mg/kg), or Compound I-6 (200 mg/kg), respectively.
  • Groups 2 through 11 were started on 3% DSS in drinking water.
  • DSS water was replaced with normal drinking water for the remainder of the study.
  • mice in Groups 3, 5, 6, and 7 were dosed PO, BID with PO vehicle (MC), Compound I-5 (200 mg/kg), I-22 (200 mg/kg), or I-6 (200 mg/kg), respectively, and mice in Groups 2 and 11 were dosed QD by the intraperitoneal (IP) route with IP vehicle [SBECD (Captisol®)] or I-6 (100 mg/kg), respectively.
  • IP intraperitoneal
  • SBECD Captisol®
  • I-6 100 mg/kg
  • Positive control mice were dosed PO, QD on Days 0 through 6 with cyclosporine A (CsA, 75 mg/kg). Group 1 animals served as naive controls. On Study Day 7, the mice were euthanized for necropsy and tissue collection.
  • Efficacy was evaluated based on animal body weight measurements, colon lengths and weights, colon weight-length ratio, colon content scores, disease activity index (DAI) scores (percent body weight loss, stool consistency, occult/gross blood, and summed scores), and histopathology of colons (full, proximal, and distal). All animals in the main study survived to the scheduled termination.
  • DAI disease activity index
  • mice from each group were bled to exsanguination and euthanized by cervical dislocation for tissue collection.
  • Whole blood was collected via cardiac blood draw and processed for plasma (K2EDTA, >150 ⁇ L/mouse), which was stored at ⁇ 80° C.
  • the entire colon from each animal was harvested, inspected visually, and measured for length, and weighed. The colon contents were assessed for clinical evidence of blood or blood-tinged fluid, and scored using the following criteria:
  • proximal and distal tissues are submitted individually for histopathology. For each region, pieces were cut and embedded in paraffin. Sections were cut and stained with hematoxylin & eosin (H&E). Each piece was evaluated individually, and values were averaged separately for the various regions.
  • H&E hematoxylin & eosin
  • Submucosal edema was quantitated by measuring the distance from the muscularis mucosa to the internal border of the outer muscle layer in a non-tangential area thought to most represent the severity of this change.
  • the extent of macrophage, lymphocyte and polymorphonuclear leukocyte cell (PMN) infiltrate was assigned severity scores according to the following criteria:
  • the loss of surface epithelium was scored based on the approximate percent of the mucosa that was affected as follows. This may have been associated with mucosal hemorrhage (reflective of the bleeding seen clinically and at necropsy):
  • Mucosal thickness was measured in a non-tangential area of the section that best represents the overall mucosal thickness. This parameter was indicative of gland elongation and mucosal hyperplasia. A hyperplasia score was derived from the measurement as follows:
  • Inflammatory cell infiltrates in the colonic mucosa were evaluated for approximate percent of neutrophils in the total infiltrate, rounded to 0, 10, 25, 50, or 75 percent. This value was then multiplied by the inflammation score to determine the neutrophil score.
  • GALT definite mucosal lymphoid aggregates
  • Clinical data were entered into Microsoft Excel, and arithmetic means and standard errors were calculated. Groups were compared to vehicle controls using a one-way analysis of variance (ANOVA) with a Dunnett's post-hoc analysis or a Student's two-tailed t-test for measured data (parametric) or a Kruskal-Wallis test with a Dunn's post hoc analysis or Mann-Whitney U test for scored data (non-parametric). Naive animals were compared to vehicle controls using a Student's two-tailed t-test for model validation. Statistical analysis was performed using Prism 7.0d software (GraphPad). Unless indicated statistical analyses were performed on raw (untransformed) data only. Statistical tests make certain assumptions regarding normality and homogeneity of variance, and further analysis may be required if testing resulted in violations of these assumptions. P values were rounded to three decimal places. Significance for all tests was set at p ⁇ 0.050.
  • % Change B/A ⁇ 100
  • A Mean Normal ⁇ Mean Disease Control
  • B Mean Treated ⁇ Mean Disease Control
  • mice had disease-induced body weight loss, with a maximum decrease of 9.1% on Day 7 (mean decrease of 1.97 g).
  • IP vehicle control mice (Group 2) had disease-induced body weight loss, with a maximum decrease of 11.8% on Day 7 (mean decrease of 2.46 g).
  • Body weight loss was significantly inhibited in mice treated IP with 100 mg/kg Compound I-6 (Group 11; Days 0 through 6) compared to IP vehicle (SBECD) control mice (Group 2).
  • Body weights of mice treated PO with Compound I-5, Compound I-22, or Compound I-6 (Groups 5, 6, 7, 8, 9, and 10) did not differ significantly from PO vehicle control animals.
  • Body weight loss in mice treated PO with CsA (Group 4) was significantly less than in IP vehicle (SBECD) control mice ( FIG. 11 ).
  • DAI Disease activity index
  • DAI scores of stool consistency, occult/gross blood in stool and summed scores expressed as area under the curve (AUC) were significantly lower following IP treatment with Compound I-6 (Group 11), compared to IP vehicle control mice (Group 2).
  • Body weight loss in CsA-treated mice (Group 4) was significantly less than in IP vehicle control mice (Group 2) on Days 2 and 4 and in PO vehicle control mice (Group 3) on Day 2.
  • Occult/gross blood in stool scores were significantly lower on Days 4 and 6 in CsA-treated mice (Group 4) compared to IP vehicle control animals (Group 2), and summed scores in CsA-treated mice were significantly lower on Day 6 than in either the PO or IP vehicle controls.
  • DAI scores AUC for stool consistency and occult/gross blood in stool were significantly lower following treatment with CsA (Group 4) compared to PO and IP vehicle controls (Groups 3 and 2, respectively), and DAI scores AUC for body weight loss in CsA-treated mice were significantly increased as compared to IP vehicle controls.
  • Mean colon lengths were significantly increased in PO vehicle control mice (Group 3) compared to IP vehicle control mice (Group 2).
  • Colon lengths were significantly (41%) increased, in the direction of normal, in mice treated PO with 200 mg/kg Compound I-22 (Group 6; Days 0 through 6) compared to PO vehicle control mice (Group 3).
  • Colon lengths were significantly (56%) increased, in the direction of normal, in mice treated IP with 100 mg/kg Compound I-6 (Group 11; Days 0 through 6) compared to IP vehicle control mice (Group 2).
  • Mice treated with CsA had significantly increased colon lengths compared to IP vehicle control mice (61%) and PO vehicle control mice (51%).
  • Mean colon weight-to-length ratios were significantly increased in IP vehicle control mice (Group 2) as compared to PO vehicle control mice (Group 3). Colon weight-to-length ratios were significantly (35%) reduced, in the direction of normal, in mice treated IP with 100 mg/kg Compound I-6 (Group 11); Days 0 through 6) compared to IP vehicle control mice (Group 2).
  • Mice treated with CsA (Group 4) had significantly reduced colon weight-to-length ratios compared to IP vehicle control mice (65%) and PO vehicle control mice (45%).
  • IP vehicle control mice had significantly increased distal colon edema, inflammation, gland loss, erosion, summed scores, PMN percentages, and neutrophil scores, and significantly increased full colon PMN percentages and neutrophil scores compared to PO vehicle control mice ( FIGS. 17 through 24 ).
  • mice treated PO with 200 mg/kg Compound I-22 had significantly reduced full colon edema (62% reduction), proximal colon edema (43%), distal colon edema (78%), distal colon hyperplasia (86%), and distal colon mucosal thickness (66%) compared to PO vehicle control mice (Group 3).
  • PMN percentages in the proximal colon were significantly increased in mice treated PO with 200 mg/kg Compound I-22 (Days 0 through 6) as compared to PO vehicle control mice ( FIGS. 17 through 24 ).
  • mice treated PO with 200 mg/kg Compound I-6 had significantly reduced full colon edema (44% reduction), proximal colon edema (48%), and proximal colon inflammation (36%) compared to PO vehicle control mice ( FIGS. 17 through 24 ).
  • mice treated PO with 200 mg/kg Compound I-5 had significantly reduced proximal colon edema (63% reduction) and proximal colon erosion (73%) compared to PO vehicle control mice ( FIGS. 17 through 24 ).
  • mice treated PO with 200 mg/kg Compound I-22 had significantly reduced full colon edema (48% reduction), proximal colon edema (60%), and proximal colon mucosal thickness (58%) compared to PO vehicle control mice ( FIGS. 17 through 24 ).
  • mice treated PO with 200 mg/kg Compound I-6 had significantly reduced full colon edema (58% reduction), proximal colon edema (41%), and proximal colon erosion (75%) compared to PO vehicle control mice ( FIGS. 17 through 24 ).
  • mice treated IP with 100 mg/kg Compound I-6 had significantly reduced edema (53%), inflammation (56%), gland loss (82%), erosion (91%), summed scores (68%) PMN percentages (53%), neutrophil scores (73%), and lymphoid aggregate counts (113%) in the full colon compared to IP vehicle control mice.
  • inflammation 32%
  • gland loss 57%
  • summed scores 36%
  • lymphoid aggregate counts 107%
  • all histopathology parameters were significantly reduced (45 to 116%) by IP treatment with 100 mg/kg Compound I-6 (Days 0 through 6) compared to IP vehicle control mice ( FIGS. 17 through 24 ).
  • mice treated with CsA had significantly reduced edema (57%), inflammation (41%), gland loss (55%), hyperplasia (77%), summed scores (51%) PMN percentages (48%), neutrophil scores (50%), mucosal thickness (73%), and lymphoid aggregate counts (104%) in the full colon compared to IP vehicle control mice.
  • Full colon edema (41%), hyperplasia (74%), mucosal thickness (70%), and lymphoid aggregate counts (106%) were significantly reduced by CsA treatment compared to PO vehicle controls.
  • all histopathology parameters except edema and PMN percentages were significantly (4 to 95%) reduced by CsA treatment compared to PO and IP control mice.
  • CsA treatment resulted in significantly reduced edema (72%), inflammation (43%), gland loss (55%), hyperplasia (76%), summed scores (54%) PMN percentages (58%), neutrophil scores (60%), mucosal thickness (61%), and lymphoid aggregate counts (116%) compared to IP vehicle controls and significantly reduced edema (52%) and hyperplasia (66%) compared to PO vehicle controls ( FIGS. 17 through 24 ).
  • results of treatment with CsA were as expected, in that treatment resulted in significant improvement to DAI scores, colon lengths, colon weight-length ratios, colon content scores, and colon hi stopathology.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
US16/157,069 2017-10-10 2018-10-10 Treatment of inflammatory disorders Active US11040039B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US16/157,069 US11040039B2 (en) 2017-10-10 2018-10-10 Treatment of inflammatory disorders
US17/328,772 US11583529B2 (en) 2017-10-10 2021-05-24 Treatment of inflammatory disorders
US18/092,758 US20230248727A1 (en) 2017-10-10 2023-01-03 Treatment of inflammatory disorders
US18/202,694 US20230293527A1 (en) 2017-10-10 2023-05-26 Treatment of inflammatory disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762570389P 2017-10-10 2017-10-10
US201862644263P 2018-03-16 2018-03-16
US16/157,069 US11040039B2 (en) 2017-10-10 2018-10-10 Treatment of inflammatory disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/328,772 Continuation US11583529B2 (en) 2017-10-10 2021-05-24 Treatment of inflammatory disorders

Publications (2)

Publication Number Publication Date
US20190105322A1 US20190105322A1 (en) 2019-04-11
US11040039B2 true US11040039B2 (en) 2021-06-22

Family

ID=65992347

Family Applications (4)

Application Number Title Priority Date Filing Date
US16/157,069 Active US11040039B2 (en) 2017-10-10 2018-10-10 Treatment of inflammatory disorders
US17/328,772 Active US11583529B2 (en) 2017-10-10 2021-05-24 Treatment of inflammatory disorders
US18/092,758 Pending US20230248727A1 (en) 2017-10-10 2023-01-03 Treatment of inflammatory disorders
US18/202,694 Pending US20230293527A1 (en) 2017-10-10 2023-05-26 Treatment of inflammatory disorders

Family Applications After (3)

Application Number Title Priority Date Filing Date
US17/328,772 Active US11583529B2 (en) 2017-10-10 2021-05-24 Treatment of inflammatory disorders
US18/092,758 Pending US20230248727A1 (en) 2017-10-10 2023-01-03 Treatment of inflammatory disorders
US18/202,694 Pending US20230293527A1 (en) 2017-10-10 2023-05-26 Treatment of inflammatory disorders

Country Status (9)

Country Link
US (4) US11040039B2 (fr)
EP (1) EP3694500A4 (fr)
JP (2) JP7311162B2 (fr)
CN (1) CN111356451A (fr)
AU (1) AU2018348174A1 (fr)
CA (1) CA3077362A1 (fr)
IL (1) IL273693A (fr)
MX (1) MX2020003425A (fr)
WO (1) WO2019075136A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11312692B1 (en) 2018-08-06 2022-04-26 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US11459300B2 (en) 2015-08-21 2022-10-04 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
US11583529B2 (en) * 2017-10-10 2023-02-21 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
US11701331B2 (en) 2013-01-23 2023-07-18 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US11724987B2 (en) 2005-05-26 2023-08-15 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
US11786518B2 (en) 2019-03-26 2023-10-17 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
US11932617B2 (en) 2018-12-18 2024-03-19 Zhuhai United Laboratories Co., Ltd. Compound for use in retinal diseases
US12006298B2 (en) 2019-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017264697A1 (en) 2016-05-09 2018-11-22 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
WO2020068986A1 (fr) 2018-09-25 2020-04-02 Aldeyra Therapeutics, Inc. Formulations pour le traitement de la maladie de l'œil sec
WO2021211625A1 (fr) * 2020-04-13 2021-10-21 Aldeyra Therapeutics, Inc. Composés de quinoléine pour le traitement de maladies, de troubles ou d'affections du poumon, du foie et du rein
EP4142717A4 (fr) * 2020-04-28 2024-05-29 Kymera Therapeutics Inc Inhibiteurs d'irak et leurs utilisations
EP4149470A4 (fr) * 2020-05-13 2024-04-24 Aldeyra Therapeutics Inc Formulations pharmaceutiques et leurs utilisations
WO2021254456A1 (fr) * 2020-06-17 2021-12-23 南京明德新药研发有限公司 Forme cristalline de 2-méthyl-2-propanol et composé aryle amino-substitué
WO2021254453A1 (fr) * 2020-06-17 2021-12-23 南京明德新药研发有限公司 Composé aminopyridine
CN116406263A (zh) * 2020-09-28 2023-07-07 珠海联邦制药股份有限公司 吡啶苯基类化合物的晶型及其制备方法
US20240092744A1 (en) * 2020-12-29 2024-03-21 The National Institutes of Pharmaceutical R&D Co., Ltd. Tricyclic compound, and preparation method therefor and medical use thereof
WO2022232110A1 (fr) * 2021-04-26 2022-11-03 Jem Therapeutics Pbc Méthode de traitement de maladies d'autophagie par administration de dexibuprofène et utilisation de dexibuprofène pour la préparation d'un médicament associé

Citations (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU50906A1 (ru) 1935-12-20 1936-11-30 А.И. Бурляев Веретено дл пр дильных машин
US2086186A (en) 1933-10-10 1937-07-06 Us Rubber Co Treatment of rubber
US3912748A (en) 1972-05-18 1975-10-14 Lilly Industries Ltd Benzoxazole derivatives
EP0186367A2 (fr) 1984-12-10 1986-07-02 Warner-Lambert Company Composés acides de l'indole et leur utilisation comme antiallergiques
US4668626A (en) 1984-10-12 1987-05-26 Director Of National Food Research Institute, Ministry Of Agriculture, Forestry And Fisheries Method for the preparation of branched cyclodextrins
EP0245054A1 (fr) 1986-05-06 1987-11-11 Ici Americas Inc. Quinoléinecarboxamides
US4956351A (en) 1987-07-01 1990-09-11 Janssen Pharmaceutica N.V. Frame-543 Antiviral pharmaceutical compositions containing cyclodextrins
US5024998A (en) 1987-12-30 1991-06-18 University Of Florida Pharmaceutical formulations for parenteral use
EP0483881A1 (fr) 1990-11-02 1992-05-06 Merrell Pharmaceuticals Inc. Dérivés amido-3-indolyl
US5364637A (en) 1990-10-22 1994-11-15 Bausch & Lomb Incorporated Method and composition for cleaning contact lenses with cyclodextrins
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5419898A (en) 1992-12-25 1995-05-30 Senju Pharmacuetical Co., Ltd. Antiallergic composition for ophthalmic or nasal use
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5493027A (en) 1993-01-22 1996-02-20 Board Of Regents, The University Of Texas System Anticonvulsive agents and uses thereof
WO1996022992A1 (fr) 1995-01-27 1996-08-01 Abbott Laboratories Antagonistes alpha-1-adrenergiques d'hexahydrobenzeisoindol tricyclique substitue
US5576311A (en) 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
WO1998005645A1 (fr) 1996-08-01 1998-02-12 Dow Agrosciences Llc Derives de quinoleine 4-substituee dotes d'une activite fongicide
US5767109A (en) 1993-10-20 1998-06-16 Sanchez; Robert A. Complexing urushiols
GB2327672A (en) 1997-07-23 1999-02-03 Merck & Co Inc 4-(1,2,3,4-Tetrahydro-1,8-naphthyridin-7-yl)butanoyl-glycyl-3(S)-quinolin-3-yl-beta-alanine
WO1999046237A1 (fr) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulateurs de proteine-tyrosine-phosphatases
US5998488A (en) 1994-12-26 1999-12-07 Lion Corporation Ophthalmic composition
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US6191127B1 (en) 1997-05-02 2001-02-20 Schering Aktiengesellschaft Substituted heterocycles and their use in medicaments
WO2001041757A1 (fr) 1999-12-10 2001-06-14 Senju Pharmaceutical Co., Ltd. Composition pharmaceutique contenant de la cyclodextrine
JP2002003364A (ja) 2000-06-23 2002-01-09 Lion Corp 点眼剤、眼科用組成物及び吸着抑制方法
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US6492520B1 (en) * 1996-08-06 2002-12-10 Pfizer Inc Substituted pyrido-or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6515010B1 (en) 1999-11-15 2003-02-04 Smithkline Beecham Corporation Carvedilol methanesulfonate
US6525056B2 (en) * 1997-09-02 2003-02-25 Bristol-Myers Squibb Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (CRH) antagonists, useful for treating cns and stress-related disorders
US6569879B2 (en) 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
US20040132636A1 (en) 2002-12-13 2004-07-08 Dooley David James Pharmaceutical uses for alpha2delta ligands
WO2004082622A2 (fr) 2003-03-14 2004-09-30 University Of Washington Substituts de retinoides et agonistes d'ospine et methodes d'utilisation correspondantes
US20040198828A1 (en) 2003-01-17 2004-10-07 Abelson Mark B. Combinational use of long-acting and short-acting anti-histamines for ocular allergies
WO2004091630A1 (fr) 2003-04-18 2004-10-28 Advanced Medicine Research Institute Remedes a des affections, a usage ophtalmique
US20040235892A1 (en) 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
US20050020603A1 (en) 2003-05-22 2005-01-27 Yujia Dai Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2005035506A1 (fr) 2003-10-15 2005-04-21 Ube Industries, Ltd. Nouveau derive d'indazole
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
WO2005040151A1 (fr) 2003-10-27 2005-05-06 Astellas Pharma Inc. Derives de pyrazine et utilisation pharmaceutique de ce derive
WO2005051328A2 (fr) 2003-11-20 2005-06-09 Othera Pharmaceuticals, Inc. Amelioration de la degenerescence maculaire et d'autres maladies ophtalmiques
WO2005079774A2 (fr) 2004-02-17 2005-09-01 President And Fellows Of Harvard College Gestion de troubles ophtalmologiques, notamment la degenerescence maculaire
US20050197292A1 (en) 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
WO2006000421A2 (fr) 2004-06-24 2006-01-05 Wacker-Chemie Gmbh Agent et produit alimentaire agissant contre l'ige
WO2006002473A1 (fr) 2004-07-02 2006-01-12 Adelaide Research & Innovation Pty Ltd Procédé de controle de dommages causés par des aldéhydes alpha, béta-insaturés
JP3736916B2 (ja) 1996-02-19 2006-01-18 株式会社サンコンタクトレンズ 含水性ソフトコンタクトレンズの消毒用組成物とその用途
US20060014786A1 (en) 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
WO2006049968A1 (fr) 2004-10-28 2006-05-11 Merck & Co., Inc. Potentialisateurs de pyrimidine et quinoline des recepteurs metabotropiques du glutamate
US20060111318A1 (en) 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
WO2006077821A1 (fr) 2005-01-19 2006-07-27 Dainippon Sumitomo Pharma Co., Ltd. Dérivé de sulfone aromatique en tant que régulateur de récepteur de l'aldostérone
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US20060183909A1 (en) 2001-07-20 2006-08-17 Martine Schmitt Compositions derived from quinoline and quinoxaline, preparation and use thereof
US20060189608A1 (en) 2005-02-23 2006-08-24 Alcon, Inc. Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US20060257488A1 (en) 2005-05-10 2006-11-16 Cytophil, Inc. Injectable hydrogels and methods of making and using same
WO2006127945A1 (fr) 2005-05-26 2006-11-30 Neuron Systems Compositions et methodes de traitement de maladies retiniennes
WO2007118276A1 (fr) 2006-04-14 2007-10-25 Prana Biotechnology Ltd Procédé de traitement de la dégénérescence maculaire liée a l'âge (amd)
WO2008014602A1 (fr) 2006-07-25 2008-02-07 Envivo Pharmaceuticals, Inc. Dérivés de quinoline
US20080108818A1 (en) 2006-08-14 2008-05-08 Xiaoming Chen Maleate, tosylate, fumarate and oxalate salts of 5-(1-(S)-amino-2-hydroxyethyl)-N-[(2,4-difluorophenyl)-methy]-2-[8-methoxy-2-(triflouromethy)-5-quinoline]-4-oxazolecarboxamide and preparation process therefore
US20080241256A1 (en) 2007-03-30 2008-10-02 Liisa Kuhn Targeted active agent delivery system based on calcium phosphate nanoparticles
WO2009045479A1 (fr) 2007-10-05 2009-04-09 Acucela Inc. Composés d'alcoxy pour le traitement de maladies
US20090118503A1 (en) 2007-06-20 2009-05-07 Kevin Sprott Faah inhibitors
US7531564B2 (en) 2001-12-05 2009-05-12 Wyeth Substituted benzoxazoles as estrogenic agents
WO2009102418A1 (fr) 2008-02-11 2009-08-20 University Of Washington Procédés pour le traitement et la prévention d'un dysfonctionnement rétinien lié à l'âge
WO2010048332A2 (fr) 2008-10-22 2010-04-29 Acucela, Inc. Composés de traitement de maladies et troubles ophtalmiques
JP4466875B2 (ja) 2006-04-05 2010-05-26 ライオン株式会社 ソフトコンタクトレンズ用点眼剤
US20100240624A1 (en) 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic Formulations of Ketotifen and Methods of Use
WO2010133672A1 (fr) 2009-05-20 2010-11-25 Clanotech Ab Dérivés d'acide quinoléine-3-carboxylique et leur utilisation médicale
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
US20100331315A1 (en) 2009-06-18 2010-12-30 Mustapha Haddach Rhodanines and related heterocycles as kinase inhibitors
WO2011008202A1 (fr) 2009-07-15 2011-01-20 Vanderbilt University Piégeurs d’isokétal et réduction des troubles impliquant une lésion oxydative
US20110071091A1 (en) 2009-09-23 2011-03-24 Chowhan Masood A Injectable aqueous ophthalmic composition and method of use therefor
US20110105450A1 (en) 2009-06-05 2011-05-05 Aciex Therapeutics, Inc. Ophthalmic formulations of fluticasone and methods of use
WO2011071995A2 (fr) 2009-12-08 2011-06-16 Case Western Reserve University Composés et procédés de traitement de troubles oculaires
WO2011072141A1 (fr) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions et procédés pour le traitement de la dégénérescence maculaire
WO2011078204A1 (fr) 2009-12-24 2011-06-30 浜理薬品工業株式会社 Agent prophylactique ou thérapeutique destiné à une hyperlipémie et agent anti-fatigue
US8158609B1 (en) 2006-11-02 2012-04-17 Novartis Ag Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
US20120108585A1 (en) 2008-08-12 2012-05-03 Sirtris Pharmaceuticals, Inc. Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators
WO2012097173A2 (fr) 2011-01-12 2012-07-19 Ventirx Pharmaceuticals, Inc. Benzoazépines substituées utilisables comme modulateurs des récepteurs de type toll
WO2012105887A1 (fr) 2011-01-31 2012-08-09 Tim Bowden Principe actif destiné à atténuer des troubles médicaux indésirables
US20120295967A1 (en) 2011-05-19 2012-11-22 Gamache Daniel A High concentration olopatadine ophthalmic composition
US8435965B2 (en) 2005-12-27 2013-05-07 Lion Corporation Composition for soft contact lens and adsorption suppressing method
JP5194218B2 (ja) 2006-06-05 2013-05-08 株式会社メニコンネクト 含水性コンタクトレンズの保存方法ならびに該保存方法により保存された含水性コンタクトレンズ
US20130165419A1 (en) 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
US20130190500A1 (en) 2011-12-12 2013-07-25 Neuron Systems, Inc. Process to prepare 6-chloro-3-amino-2-(2-hydroxypropyl)-1-azanaphthalene
US8575221B2 (en) 2010-03-17 2013-11-05 Concert Pharmaceuticals, Inc. Derivatives of dimethylcurcumin
US20140038918A1 (en) 2011-01-20 2014-02-06 Cornell University Treatments for retinal disorders
WO2014100425A1 (fr) 2012-12-20 2014-06-26 Aldexa Therapeutics, Inc. Péri-carbinols
WO2014116836A2 (fr) 2013-01-23 2014-07-31 Aldexa Therapeutics, Inc. Maladies liées à un aldéhyde toxique et traitement
WO2014116593A1 (fr) 2013-01-25 2014-07-31 Aldexa Therapeutics, Inc. Nouveaux pièges dans le traitement de la dégénérescence maculaire
US20140235722A1 (en) 2008-11-11 2014-08-21 Novartis Ag Organic Compounds
WO2015002893A1 (fr) 2013-07-02 2015-01-08 The Trustees Of Columbia University In The City Of New York Élimination de lipides bioactifs de structures membranaires au moyen de cyclodextrines
US9067963B2 (en) 2012-08-01 2015-06-30 Lewis and Clark Pharmaceuticals, LLC N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists
US20150258120A1 (en) 2012-11-08 2015-09-17 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
WO2015187942A1 (fr) 2014-06-04 2015-12-10 Case Western Reserve University Compositions et méthodes de traitement de la rétinopathie diabétique
US20160009698A1 (en) 2013-02-27 2016-01-14 Almirall S.A. SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH β2 ADRENERGIC RECEPTOR AGONIST AND M3 MUSCARINIC RECEPTOR ANTAGONIST ACTIVITIES
US20160030449A1 (en) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
US20160052930A1 (en) 2014-08-21 2016-02-25 Pfizer Inc. Aminopyrimidinyl compounds
US20160136231A1 (en) 2011-10-13 2016-05-19 Rogne Bioscience, Inc. Topical formulations of chemerin c15 peptides for the treatment of dermatological conditions
US20160151381A1 (en) 2010-09-01 2016-06-02 Arena Pharmaceuticals, Inc. Salts of lorcaserin with optically active acids
WO2016085939A2 (fr) 2014-11-24 2016-06-02 Case Western Reserve University Composés et méthodes de traitement de troubles oculaires
US9375408B2 (en) 2014-09-02 2016-06-28 Bhupinder Singh Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment
WO2016165626A1 (fr) 2015-04-15 2016-10-20 Beigene, Ltd. Sels de maléate d'un inhibiteur de kinase b-raf, formes cristallines, procédés de préparation, et leurs utilisations
WO2017035082A1 (fr) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Conjugués d'aldéhyde et leurs utilisations
WO2017035077A1 (fr) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Composés deutérés et leurs utilisations
US20170095449A1 (en) 2010-02-26 2017-04-06 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US20170143627A1 (en) 2014-06-25 2017-05-25 Synergia Bio Sciences Private Limited A pharmaceutical oil-in-water nano-emulsion
WO2017147617A1 (fr) 2016-02-28 2017-08-31 Aldeyra Therapeutics, Inc. Traitement des pathologies oculaires allergiques avec des cyclodextrines
WO2017196881A1 (fr) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Polythérapie de troubles et de maladies inflammatoires oculaires
WO2017214201A1 (fr) 2016-06-06 2017-12-14 Thesan Pharmaceuticals, Inc. Formulations de 3-pyrrolidines substituées, compositions contenant celles-ci et leurs utilisations
US20180050989A1 (en) 2016-08-22 2018-02-22 Aldeyra Therapeutics, Inc. Aldehyde trapping compounds and uses thereof
WO2018039197A1 (fr) 2016-08-22 2018-03-01 Aldeyra Therapeutics, Inc. Composés de piégeage d'aldéhydes et leurs procédés d'utilisation
WO2018064354A1 (fr) 2016-09-28 2018-04-05 Medicon Pharmaceuticals, Inc. Compositions et méthodes de traitement de troubles ophtalmologiques
WO2018067860A1 (fr) 2016-10-05 2018-04-12 Mitobridge, Inc. Formes cristallines et salines de composés agonistes de ppar
US20180235980A1 (en) 2013-01-23 2018-08-23 Semnur Pharmaceuticals, Inc. Pharmaceutical formulation
US10058095B2 (en) 2013-03-15 2018-08-28 Deuteria Agrochemicals, Llc Deuterium-enriched aldehydes
US20180265474A1 (en) 2017-03-16 2018-09-20 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US20190105322A1 (en) 2017-10-10 2019-04-11 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
WO2020018498A1 (fr) 2018-07-16 2020-01-23 Aldeyra Therapeutics, Inc. Formulations de cyclodextrine
US20200038392A1 (en) 2018-08-03 2020-02-06 Aldeyra Therapeutics, Inc. Topical compositions and methods of preparation and use
WO2020033344A1 (fr) 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Composés polymorphes et leurs utilisations
WO2020072621A1 (fr) 2018-10-02 2020-04-09 Aldeyra Therapeutics, Inc. Solutions pour lentilles de contact et kits
US20200121591A1 (en) 2018-09-25 2020-04-23 Aldeyra Therapeutics, Inc. Formulations for treatment of dry eye disease
WO2020118045A1 (fr) 2018-12-05 2020-06-11 Aldeyra Therapeutics, Inc. Formulations injectables
WO2020198064A1 (fr) 2019-03-26 2020-10-01 Aldeyra Therapeutics, Inc. Formulations ophtalmiques et leurs utilisations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005132834A (ja) 2003-10-09 2005-05-26 Kyowa Hakko Kogyo Co Ltd キノリン誘導体
FR2875409B1 (fr) 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
US20070297981A1 (en) 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
US20070203216A1 (en) * 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases
MX2009002166A (es) 2006-08-31 2009-03-12 Eurand Inc Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos.
TW201628622A (zh) 2014-11-17 2016-08-16 製藥公司 Tlr抑制劑與布魯頓氏(bruton's)酪胺酸激酶抑制劑之組合
WO2020223685A1 (fr) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Composés polymorphes et leurs utilisations
US20220089542A1 (en) 2019-05-02 2022-03-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
US20230131929A1 (en) 2020-03-24 2023-04-27 Aldeyra Therapeutics, Inc. Quinoline compounds for treating respiratory disorders and viral infections
WO2021211625A1 (fr) 2020-04-13 2021-10-21 Aldeyra Therapeutics, Inc. Composés de quinoléine pour le traitement de maladies, de troubles ou d'affections du poumon, du foie et du rein
EP4149470A4 (fr) 2020-05-13 2024-04-24 Aldeyra Therapeutics Inc Formulations pharmaceutiques et leurs utilisations
JP2023529840A (ja) 2020-06-04 2023-07-12 アルデイラ セラピューティクス， インコーポレイテッド ドライアイ疾患バイオマーカーおよび処置するための該バイオマーカーの使用
US20220211691A1 (en) 2021-01-07 2022-07-07 Aldeyra Therapeutics, Inc. Treatment of dry eye disease
WO2022150580A1 (fr) 2021-01-07 2022-07-14 Aldeyra Therapeutics, Inc. Traitement du syndrome de l'œil sec

Patent Citations (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2086186A (en) 1933-10-10 1937-07-06 Us Rubber Co Treatment of rubber
SU50906A1 (ru) 1935-12-20 1936-11-30 А.И. Бурляев Веретено дл пр дильных машин
US3912748A (en) 1972-05-18 1975-10-14 Lilly Industries Ltd Benzoxazole derivatives
US4668626A (en) 1984-10-12 1987-05-26 Director Of National Food Research Institute, Ministry Of Agriculture, Forestry And Fisheries Method for the preparation of branched cyclodextrins
EP0186367A2 (fr) 1984-12-10 1986-07-02 Warner-Lambert Company Composés acides de l'indole et leur utilisation comme antiallergiques
EP0245054A1 (fr) 1986-05-06 1987-11-11 Ici Americas Inc. Quinoléinecarboxamides
US4956351A (en) 1987-07-01 1990-09-11 Janssen Pharmaceutica N.V. Frame-543 Antiviral pharmaceutical compositions containing cyclodextrins
US5024998A (en) 1987-12-30 1991-06-18 University Of Florida Pharmaceutical formulations for parenteral use
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5364637A (en) 1990-10-22 1994-11-15 Bausch & Lomb Incorporated Method and composition for cleaning contact lenses with cyclodextrins
EP0483881A1 (fr) 1990-11-02 1992-05-06 Merrell Pharmaceuticals Inc. Dérivés amido-3-indolyl
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5419898A (en) 1992-12-25 1995-05-30 Senju Pharmacuetical Co., Ltd. Antiallergic composition for ophthalmic or nasal use
US5493027A (en) 1993-01-22 1996-02-20 Board Of Regents, The University Of Texas System Anticonvulsive agents and uses thereof
US5767109A (en) 1993-10-20 1998-06-16 Sanchez; Robert A. Complexing urushiols
US5576311A (en) 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
US5998488A (en) 1994-12-26 1999-12-07 Lion Corporation Ophthalmic composition
WO1996022992A1 (fr) 1995-01-27 1996-08-01 Abbott Laboratories Antagonistes alpha-1-adrenergiques d'hexahydrobenzeisoindol tricyclique substitue
JP3736916B2 (ja) 1996-02-19 2006-01-18 株式会社サンコンタクトレンズ 含水性ソフトコンタクトレンズの消毒用組成物とその用途
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
WO1998005645A1 (fr) 1996-08-01 1998-02-12 Dow Agrosciences Llc Derives de quinoleine 4-substituee dotes d'une activite fongicide
US6492520B1 (en) * 1996-08-06 2002-12-10 Pfizer Inc Substituted pyrido-or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
US6191127B1 (en) 1997-05-02 2001-02-20 Schering Aktiengesellschaft Substituted heterocycles and their use in medicaments
GB2327672A (en) 1997-07-23 1999-02-03 Merck & Co Inc 4-(1,2,3,4-Tetrahydro-1,8-naphthyridin-7-yl)butanoyl-glycyl-3(S)-quinolin-3-yl-beta-alanine
US6525056B2 (en) * 1997-09-02 2003-02-25 Bristol-Myers Squibb Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (CRH) antagonists, useful for treating cns and stress-related disorders
WO1999046237A1 (fr) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulateurs de proteine-tyrosine-phosphatases
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6515010B1 (en) 1999-11-15 2003-02-04 Smithkline Beecham Corporation Carvedilol methanesulfonate
WO2001041757A1 (fr) 1999-12-10 2001-06-14 Senju Pharmaceutical Co., Ltd. Composition pharmaceutique contenant de la cyclodextrine
US6569879B2 (en) 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
JP2002003364A (ja) 2000-06-23 2002-01-09 Lion Corp 点眼剤、眼科用組成物及び吸着抑制方法
US20060183909A1 (en) 2001-07-20 2006-08-17 Martine Schmitt Compositions derived from quinoline and quinoxaline, preparation and use thereof
US7531564B2 (en) 2001-12-05 2009-05-12 Wyeth Substituted benzoxazoles as estrogenic agents
US20060014786A1 (en) 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
US20040132636A1 (en) 2002-12-13 2004-07-08 Dooley David James Pharmaceutical uses for alpha2delta ligands
US20040198828A1 (en) 2003-01-17 2004-10-07 Abelson Mark B. Combinational use of long-acting and short-acting anti-histamines for ocular allergies
WO2004082622A2 (fr) 2003-03-14 2004-09-30 University Of Washington Substituts de retinoides et agonistes d'ospine et methodes d'utilisation correspondantes
EP1621199A1 (fr) 2003-04-18 2006-02-01 Advanced Medicine Research Institute Remedes a des affections, a usage ophtalmique
US20060111318A1 (en) 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
EP2301549A1 (fr) 2003-04-18 2011-03-30 Advanced Medicine Research Institute Remèdes à des affections, à usage ophtalmique
WO2004091630A1 (fr) 2003-04-18 2004-10-28 Advanced Medicine Research Institute Remedes a des affections, a usage ophtalmique
US20050020603A1 (en) 2003-05-22 2005-01-27 Yujia Dai Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US20040235892A1 (en) 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US20070129404A1 (en) 2003-10-15 2007-06-07 Masahiko Hagihara Novel indazole derivatives
WO2005035506A1 (fr) 2003-10-15 2005-04-21 Ube Industries, Ltd. Nouveau derive d'indazole
WO2005040151A1 (fr) 2003-10-27 2005-05-06 Astellas Pharma Inc. Derives de pyrazine et utilisation pharmaceutique de ce derive
US20050130906A1 (en) 2003-11-20 2005-06-16 Matier William L. Amelioration of macular degeneration and other ophthalmic diseases
WO2005051328A2 (fr) 2003-11-20 2005-06-09 Othera Pharmaceuticals, Inc. Amelioration de la degenerescence maculaire et d'autres maladies ophtalmiques
US20050197292A1 (en) 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
WO2005079774A2 (fr) 2004-02-17 2005-09-01 President And Fellows Of Harvard College Gestion de troubles ophtalmologiques, notamment la degenerescence maculaire
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
JP2007532648A (ja) 2004-04-15 2007-11-15 アラーガン、インコーポレイテッド 眼の後部へのドラッグデリバリー
WO2005105067A2 (fr) 2004-04-15 2005-11-10 Allergan, Inc. Administration de medicaments au fond de l'oeil
WO2006000421A2 (fr) 2004-06-24 2006-01-05 Wacker-Chemie Gmbh Agent et produit alimentaire agissant contre l'ige
WO2006002473A1 (fr) 2004-07-02 2006-01-12 Adelaide Research & Innovation Pty Ltd Procédé de controle de dommages causés par des aldéhydes alpha, béta-insaturés
WO2006049968A1 (fr) 2004-10-28 2006-05-11 Merck & Co., Inc. Potentialisateurs de pyrimidine et quinoline des recepteurs metabotropiques du glutamate
US20100160304A1 (en) 2005-01-19 2010-06-24 Dainippon Sumitomo Pharma Co., Ltd Aromatic sulfone compound as aldosterone receptor modulator
WO2006077821A1 (fr) 2005-01-19 2006-07-27 Dainippon Sumitomo Pharma Co., Ltd. Dérivé de sulfone aromatique en tant que régulateur de récepteur de l'aldostérone
US20060189608A1 (en) 2005-02-23 2006-08-24 Alcon, Inc. Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US20060257488A1 (en) 2005-05-10 2006-11-16 Cytophil, Inc. Injectable hydrogels and methods of making and using same
US20090182009A1 (en) 2005-05-26 2009-07-16 Neuron Systems, Inc. Compositions and methods of treating retinal disease
US8940764B2 (en) 2005-05-26 2015-01-27 Aldexa Therapeutics, Inc. Compositions and methods of treating retinal disease
US20190210971A1 (en) 2005-05-26 2019-07-11 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
JP2008542291A (ja) 2005-05-26 2008-11-27 ニューロン システムズ 網膜疾患を処置するための組成物および方法
US10202348B2 (en) 2005-05-26 2019-02-12 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
US20180194733A1 (en) 2005-05-26 2018-07-12 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
WO2006127945A1 (fr) 2005-05-26 2006-11-30 Neuron Systems Compositions et methodes de traitement de maladies retiniennes
US7973025B2 (en) 2005-05-26 2011-07-05 Neuron Systems, Inc. Compositions and methods of treating retinal disease
US9896419B2 (en) 2005-05-26 2018-02-20 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
US9650342B2 (en) 2005-05-26 2017-05-16 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
EP1888548B1 (fr) 2005-05-26 2012-08-22 Neuron Systems, Inc Dérivé de quinoline pour le traitement de maladies rétiniennes
US20070135481A1 (en) 2005-05-26 2007-06-14 Thomas Jordan Compositions and methods of treating retinal disease
US9364471B2 (en) 2005-05-26 2016-06-14 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
US9265759B2 (en) 2005-05-26 2016-02-23 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
US20110263645A1 (en) 2005-05-26 2011-10-27 Neuron Systems, Inc. Compositions and Methods of Treating Retinal Disease
US20150209345A1 (en) 2005-05-26 2015-07-30 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
US20150209333A1 (en) 2005-05-26 2015-07-30 Aldexa Therapeutics, Inc. Compositions and methods of treating retinal disease
US8940721B2 (en) 2005-05-26 2015-01-27 Aldexa Therapeutics, Inc. Compositions and methods of treating retinal disease
US8435965B2 (en) 2005-12-27 2013-05-07 Lion Corporation Composition for soft contact lens and adsorption suppressing method
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
JP4466875B2 (ja) 2006-04-05 2010-05-26 ライオン株式会社 ソフトコンタクトレンズ用点眼剤
WO2007118276A1 (fr) 2006-04-14 2007-10-25 Prana Biotechnology Ltd Procédé de traitement de la dégénérescence maculaire liée a l'âge (amd)
JP5194218B2 (ja) 2006-06-05 2013-05-08 株式会社メニコンネクト 含水性コンタクトレンズの保存方法ならびに該保存方法により保存された含水性コンタクトレンズ
WO2008014602A1 (fr) 2006-07-25 2008-02-07 Envivo Pharmaceuticals, Inc. Dérivés de quinoline
US20080108818A1 (en) 2006-08-14 2008-05-08 Xiaoming Chen Maleate, tosylate, fumarate and oxalate salts of 5-(1-(S)-amino-2-hydroxyethyl)-N-[(2,4-difluorophenyl)-methy]-2-[8-methoxy-2-(triflouromethy)-5-quinoline]-4-oxazolecarboxamide and preparation process therefore
US8158609B1 (en) 2006-11-02 2012-04-17 Novartis Ag Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
US20080241256A1 (en) 2007-03-30 2008-10-02 Liisa Kuhn Targeted active agent delivery system based on calcium phosphate nanoparticles
US20090118503A1 (en) 2007-06-20 2009-05-07 Kevin Sprott Faah inhibitors
US7982071B2 (en) 2007-10-05 2011-07-19 Acucela Inc. Alkoxy compounds for disease treatment
WO2009045479A1 (fr) 2007-10-05 2009-04-09 Acucela Inc. Composés d'alcoxy pour le traitement de maladies
WO2009102418A1 (fr) 2008-02-11 2009-08-20 University Of Washington Procédés pour le traitement et la prévention d'un dysfonctionnement rétinien lié à l'âge
US20120108585A1 (en) 2008-08-12 2012-05-03 Sirtris Pharmaceuticals, Inc. Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators
JP2012506449A (ja) 2008-10-22 2012-03-15 アキュセラ インコーポレイテッド 眼の疾患及び障害を治療する化合物
WO2010048332A2 (fr) 2008-10-22 2010-04-29 Acucela, Inc. Composés de traitement de maladies et troubles ophtalmiques
US20140235722A1 (en) 2008-11-11 2014-08-21 Novartis Ag Organic Compounds
US20100240624A1 (en) 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic Formulations of Ketotifen and Methods of Use
WO2010133672A1 (fr) 2009-05-20 2010-11-25 Clanotech Ab Dérivés d'acide quinoléine-3-carboxylique et leur utilisation médicale
US20110105450A1 (en) 2009-06-05 2011-05-05 Aciex Therapeutics, Inc. Ophthalmic formulations of fluticasone and methods of use
US20100331315A1 (en) 2009-06-18 2010-12-30 Mustapha Haddach Rhodanines and related heterocycles as kinase inhibitors
WO2011008202A1 (fr) 2009-07-15 2011-01-20 Vanderbilt University Piégeurs d’isokétal et réduction des troubles impliquant une lésion oxydative
US20110071091A1 (en) 2009-09-23 2011-03-24 Chowhan Masood A Injectable aqueous ophthalmic composition and method of use therefor
WO2011071995A2 (fr) 2009-12-08 2011-06-16 Case Western Reserve University Composés et procédés de traitement de troubles oculaires
US20140235604A1 (en) 2009-12-08 2014-08-21 Case Western Reserve University Compounds and methods of treating ocular disorders
US8722669B2 (en) 2009-12-08 2014-05-13 Case Western Reserve University Compounds and methods of treating ocular disorders
US20180092882A1 (en) 2009-12-11 2018-04-05 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
US9814701B2 (en) 2009-12-11 2017-11-14 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
WO2011072141A1 (fr) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions et procédés pour le traitement de la dégénérescence maculaire
US20120302601A1 (en) 2009-12-11 2012-11-29 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
WO2011078204A1 (fr) 2009-12-24 2011-06-30 浜理薬品工業株式会社 Agent prophylactique ou thérapeutique destiné à une hyperlipémie et agent anti-fatigue
US20170095449A1 (en) 2010-02-26 2017-04-06 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US8575221B2 (en) 2010-03-17 2013-11-05 Concert Pharmaceuticals, Inc. Derivatives of dimethylcurcumin
US20160151381A1 (en) 2010-09-01 2016-06-02 Arena Pharmaceuticals, Inc. Salts of lorcaserin with optically active acids
WO2012097173A2 (fr) 2011-01-12 2012-07-19 Ventirx Pharmaceuticals, Inc. Benzoazépines substituées utilisables comme modulateurs des récepteurs de type toll
US20140038918A1 (en) 2011-01-20 2014-02-06 Cornell University Treatments for retinal disorders
WO2012105887A1 (fr) 2011-01-31 2012-08-09 Tim Bowden Principe actif destiné à atténuer des troubles médicaux indésirables
US20120295967A1 (en) 2011-05-19 2012-11-22 Gamache Daniel A High concentration olopatadine ophthalmic composition
US8791154B2 (en) 2011-05-19 2014-07-29 Alcon Research, Ltd. High concentration olopatadine ophthalmic composition
US20160136231A1 (en) 2011-10-13 2016-05-19 Rogne Bioscience, Inc. Topical formulations of chemerin c15 peptides for the treatment of dermatological conditions
US20130190500A1 (en) 2011-12-12 2013-07-25 Neuron Systems, Inc. Process to prepare 6-chloro-3-amino-2-(2-hydroxypropyl)-1-azanaphthalene
US20130165419A1 (en) 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
US9067963B2 (en) 2012-08-01 2015-06-30 Lewis and Clark Pharmaceuticals, LLC N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists
US20150258120A1 (en) 2012-11-08 2015-09-17 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
US9604997B2 (en) 2012-12-20 2017-03-28 Aldeyra Therapeutics, Inc. Peri-carbinols
US20150344432A1 (en) 2012-12-20 2015-12-03 Aldexa Therapeutics, Inc. Peri-carbinols
WO2014100425A1 (fr) 2012-12-20 2014-06-26 Aldexa Therapeutics, Inc. Péri-carbinols
US10588874B2 (en) 2013-01-23 2020-03-17 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US20150335632A1 (en) 2013-01-23 2015-11-26 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US10543181B2 (en) 2013-01-23 2020-01-28 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US20190247334A1 (en) 2013-01-23 2019-08-15 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US9687481B2 (en) 2013-01-23 2017-06-27 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US20190231715A1 (en) 2013-01-23 2019-08-01 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
WO2014116836A2 (fr) 2013-01-23 2014-07-31 Aldexa Therapeutics, Inc. Maladies liées à un aldéhyde toxique et traitement
US10213395B2 (en) 2013-01-23 2019-02-26 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US20180235980A1 (en) 2013-01-23 2018-08-23 Semnur Pharmaceuticals, Inc. Pharmaceutical formulation
US20170239196A1 (en) 2013-01-23 2017-08-24 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US20190125729A1 (en) 2013-01-25 2019-05-02 Aldeyra Therapeutics, Inc. Novel traps in the treatment of macular degeneration
US10111862B2 (en) 2013-01-25 2018-10-30 Aldeyra Therapeutics, Inc. Traps in the treatment of macular degeneration
US20150344447A1 (en) 2013-01-25 2015-12-03 Aldeyra Therapeutics, Inc. Novel traps in the treatment of macular degeneration
WO2014116593A1 (fr) 2013-01-25 2014-07-31 Aldexa Therapeutics, Inc. Nouveaux pièges dans le traitement de la dégénérescence maculaire
US20160009698A1 (en) 2013-02-27 2016-01-14 Almirall S.A. SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH β2 ADRENERGIC RECEPTOR AGONIST AND M3 MUSCARINIC RECEPTOR ANTAGONIST ACTIVITIES
US10058095B2 (en) 2013-03-15 2018-08-28 Deuteria Agrochemicals, Llc Deuterium-enriched aldehydes
WO2015002893A1 (fr) 2013-07-02 2015-01-08 The Trustees Of Columbia University In The City Of New York Élimination de lipides bioactifs de structures membranaires au moyen de cyclodextrines
WO2015187942A1 (fr) 2014-06-04 2015-12-10 Case Western Reserve University Compositions et méthodes de traitement de la rétinopathie diabétique
US20170143627A1 (en) 2014-06-25 2017-05-25 Synergia Bio Sciences Private Limited A pharmaceutical oil-in-water nano-emulsion
US20160030449A1 (en) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
US20160052930A1 (en) 2014-08-21 2016-02-25 Pfizer Inc. Aminopyrimidinyl compounds
US20170029354A1 (en) 2014-09-02 2017-02-02 Bhupinder Singh Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment
US9375408B2 (en) 2014-09-02 2016-06-28 Bhupinder Singh Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment
WO2016085939A2 (fr) 2014-11-24 2016-06-02 Case Western Reserve University Composés et méthodes de traitement de troubles oculaires
WO2016165626A1 (fr) 2015-04-15 2016-10-20 Beigene, Ltd. Sels de maléate d'un inhibiteur de kinase b-raf, formes cristallines, procédés de préparation, et leurs utilisations
US20180250306A1 (en) 2015-08-21 2018-09-06 Aldeyra Therapeutics, Inc. Aldehyde conjugates and uses thereof
US10550085B2 (en) 2015-08-21 2020-02-04 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
US20200199075A1 (en) 2015-08-21 2020-06-25 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
US20200246345A1 (en) 2015-08-21 2020-08-06 Aldeyra Therapeutics, Inc. Aldehyde conjugates and uses thereof
WO2017035077A1 (fr) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Composés deutérés et leurs utilisations
US20180354905A1 (en) 2015-08-21 2018-12-13 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
WO2017035082A1 (fr) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Conjugués d'aldéhyde et leurs utilisations
US10426790B2 (en) 2016-02-28 2019-10-01 Aldeyra Therapeutics, Inc. Treatment of allergic eye conditions with cyclodextrins
US20170266220A1 (en) 2016-02-28 2017-09-21 Aldeyra Therapeutics, Inc. Treatment of allergic eye conditions with cyclodextrins
WO2017147617A1 (fr) 2016-02-28 2017-08-31 Aldeyra Therapeutics, Inc. Traitement des pathologies oculaires allergiques avec des cyclodextrines
WO2017196881A1 (fr) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Polythérapie de troubles et de maladies inflammatoires oculaires
US20190183878A1 (en) 2016-05-09 2019-06-20 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
WO2017214201A1 (fr) 2016-06-06 2017-12-14 Thesan Pharmaceuticals, Inc. Formulations de 3-pyrrolidines substituées, compositions contenant celles-ci et leurs utilisations
WO2018039197A1 (fr) 2016-08-22 2018-03-01 Aldeyra Therapeutics, Inc. Composés de piégeage d'aldéhydes et leurs procédés d'utilisation
US20180050989A1 (en) 2016-08-22 2018-02-22 Aldeyra Therapeutics, Inc. Aldehyde trapping compounds and uses thereof
US20200062712A1 (en) 2016-08-22 2020-02-27 Aldeyra Therapeutics, Inc. Aldehyde trapping compounds and uses thereof
WO2018039192A1 (fr) 2016-08-22 2018-03-01 Aldeyra Therapeutics, Inc. Composés de piégeage d'aldéhydes et leurs utilisations
WO2018064354A1 (fr) 2016-09-28 2018-04-05 Medicon Pharmaceuticals, Inc. Compositions et méthodes de traitement de troubles ophtalmologiques
WO2018067860A1 (fr) 2016-10-05 2018-04-12 Mitobridge, Inc. Formes cristallines et salines de composés agonistes de ppar
US10414732B2 (en) 2017-03-16 2019-09-17 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2018170476A1 (fr) 2017-03-16 2018-09-20 Aldeyra Therapeutics, Inc. Composés polymorphes et leurs utilisations
US20180265474A1 (en) 2017-03-16 2018-09-20 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US20190105322A1 (en) 2017-10-10 2019-04-11 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
WO2020018498A1 (fr) 2018-07-16 2020-01-23 Aldeyra Therapeutics, Inc. Formulations de cyclodextrine
US20200038392A1 (en) 2018-08-03 2020-02-06 Aldeyra Therapeutics, Inc. Topical compositions and methods of preparation and use
WO2020033344A1 (fr) 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Composés polymorphes et leurs utilisations
US20200121591A1 (en) 2018-09-25 2020-04-23 Aldeyra Therapeutics, Inc. Formulations for treatment of dry eye disease
WO2020072621A1 (fr) 2018-10-02 2020-04-09 Aldeyra Therapeutics, Inc. Solutions pour lentilles de contact et kits
WO2020118045A1 (fr) 2018-12-05 2020-06-11 Aldeyra Therapeutics, Inc. Formulations injectables
WO2020198064A1 (fr) 2019-03-26 2020-10-01 Aldeyra Therapeutics, Inc. Formulations ophtalmiques et leurs utilisations

Non-Patent Citations (497)

* Cited by examiner, † Cited by third party
Title
Abelson et al., "Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity," American Journal of Ophthalmology, 125(6):797-804 (1998).
Abelson et al., "Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis," Archives of Ophthalmology, 108(1):84-88 (1990).
Abelson et al., "Conjunctival allergen challenge: models in the investigation of ocular allergy," Current Allergy and Asthma Reports, 3(4):363-368 (2003).
Abelson et al., "The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate," J Ocul Pharmacol Ther, 14(6):533-42 (Dec. 1998).
Abramovitz, M. et al., "The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs," Biochem. Biophys. Acta., 1483(2):285-293 (2000).
Ackerman et al., "Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management," Ther. Adv. Chronic Dis., 2016; 7(1):52-67.
Acland et al., "Gene Therapy Restores Vision in a Canine Model of Childhood Blindness," Nature Genetics, 28(1):92-95 (2001).
Aharony, D. et al., "Pharmacological characterization of cloned human NK-2 (neurokinin A) receptor expressed in a baculovirus/Sf-21 insect cell system," Molecular Pharmacology, 44(2):356-363 (1993).
Akturk, S. et al., "Nitric oxide and malondialdehyde levels in plasma and tissue of psoriasis patients," Journal of the European Academy of Dermatology and Venereology, 26(7):833-837 (2012).
Albano et al., "Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis," Gut 54:987-93 (2005).
Al-Bari, "Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases," J Antimicrob Chemother. 2015;70(6):1608-21.
Aldeyra Press Release Phase II Allergic Conjunctivitis, Feb. 29, 2016 (3 pages).
Aldeyra Press Release—Aldeyra Therapeutics Abstract Accepted at 2015 American Academy of Allergy Asthma & Immunology Annual Meeting, Dec. 16, 2014 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Abstract Accepted for Presentation at the 2015 Multinational Association of Supportive Care in Cancer—International Society of Oral Oncology (MASCCISOO) Annual Meeting, Apr. 23, 2015 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Abstracts Accepted for Presentation at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology, Feb. 2, 2015 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Announces Agreement with Johnson & Johnson Innovation to Advance Novel Immune-Modulating Drugs for Systemic Inflammatory Diseases, Feb. 27, 2018 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Announces Clinical Development Update for Phase 3 Programs, Jan. 25, 2017 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Announces Collaboration With the National Organization for Rare Disorders to Enhance Awareness for Sjogren-Larsson Syndrome Patients, Dec. 4, 2014 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Announces Development Programs at 2018 Research Day, Jun. 26, 2018 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 2b Clinical Trial, Feb. 22, 2017 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 2b Clinical Trial, Feb. 7, 2017 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical Trial, Apr. 24, 2018 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical Trial, May 1, 2018 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase IIa Clinical Trial, Sep. 29, 2015 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2a Clinical Trial, Jun. 6, 2017 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2b Clinical Trial, Jan. 30, 2018 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase 3 Clinical Trial, Apr. 27, 2017 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase II Clinical Trial, Apr. 16, 2015 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Announces First Patient Enrolled in Sjogren-Larsson Syndrome Phase II Clinical Trial, Mar. 24, 2015 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Announces Last Patient Dosed in Dry Eye Disease Phase 2a Clinical Trial, Jul. 18, 2017 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Announces Last Patient Dosed in Dry Eye Disease Phase 2b Clinical Trial, Jul. 12, 2018 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Announces Last Patient Dosed in Phase II Trial of NS2 in Patients with Allergic Conjunctivitis, Dec. 16, 2015 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Announces Last Patient Dosed in the ALLEVIATE Phase 3 Clinical Trial, Dec. 20, 2018 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Announces Positive Mesothelioma Investigator-Sponsored Clinical Trial Results Presented at the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer, Sep. 25, 2018 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Announces Positive Results from Phase 2b Dry Eye Disease Clinical Trial, Sep. 26, 2018 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Announces Positive Top-Line Results from the Phase 3 ALLEVIATE Trial in Patients with Allergic Conjunctivitis, Mar. 26, 2019 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Announces Presentation of Novel Data on the Efficacy of ADX-102 in a Model of Succinic Semialdehyde Dehydrogenase Activity at the 2017 American Society of Human Genetics Annual Meeting, Oct. 5, 2017 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Announces Presentation of Phase 2 Allergic Conjunctivitis Results at the 2016 American College of Allergy, Asthma and Immunology Annual Scientific Meeting, Nov. 7, 2016 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Announces Presentation of Results on the Efficacy of ADX-102 in Noninfectious Anterior Uveitis at the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting, Oct. 25, 2017 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Announces Results from Allergic Conjunctivitis Phase 2b Clinical Trial and Plans for Phase 3 Clinical Testing, Jun. 14, 2017 (3 pages).
Aldeyra Press Release—Aldeyra Therapeutics Announces Third Quarter 2017 Financial Results, Nov. 9, 2017 (4 pages).
Aldeyra Press Release—Aldeyra Therapeutics' Data on Lead Candidate NS2 to be Presented at Society for Investigative Dermatology 2014 Annual Meeting, May 8, 2014 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Opens Enrollment in Noninfectious Anterior Uveitis Phase II Clinical Trial, Mar. 26, 2015 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Opens Enrollment in Sjogren-Larsson Syndrome Clinical Trial and Finalizes Noninfectious Anterior Uveitis Clinical Trial Protocol, Mar. 17, 2015 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Presents Evidence for Aldehyde Sequestration as a Potential Therapeutic Approach in Succinic Semialdehyde Dehydrogenase Deficiency at the American Society of Human Genetics 2017 Annual Meeting, Oct. 24, 2017 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data at the Association for Research in Vision and Ophthalmology 2017 Annual Meeting, May 17, 2017 (3 pages).
Aldeyra Press Release—Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data to the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting, Nov. 29, 2017 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Provides Update on Late-Stage Clinical Trials at 2016 Research and Development Day, Sep. 26, 2016 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Provides Update on NS2 Clinical Program, Mar. 2, 2015 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Provides Update on Ophthalmic Programs at 2019 Research & Development Day, Feb. 28, 2019 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Results from Allergic Conjunctivitis Phase 2b Clinical Trial, Jun. 13, 2017 (1 page).
Aldeyra Press Release—Aldeyra Therapeutics Schedules Conference Call to Present Results of a Randomized, Double-Blind, Vehicle-Controlled Clinical Trial in Sjogren-Larsson Syndrome, Aug. 8, 2016 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Results from Dry Eye Disease Phase 2a Clinical Trial, Sep. 11, 2017 (1 page).
Aldeyra Press Release—Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Results from Dry Eye Disease Phase 2a Clinical Trial, Sep. 12, 2017 (3 pages).
Aldeyra Press Release—Aldeyra Therapeutics Selected for Podium Presentation of Phase 2a Dry Eye Disease Results at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Feb. 21, 2018 (3 pages).
Aldeyra Press Release—Aldeyra Therapeutics Submits FDA IND Filing for Noninfectious Anterior Uveitis, Dec. 18, 2014 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics Submits IND Filing to FDA for Clinical Testing of NS2 in Patients With Sjogren-Larsson Syndrome, Jan. 5, 2015 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics to Host 2019 Research & Development Day, Feb. 12, 2019 (1 page).
Aldeyra Press Release—Aldeyra Therapeutics to Present at the 2016 SSADH Symposium, Mar. 24, 2016 (1 page).
Aldeyra Press Release—Aldeyra Therapeutics to Present Novel Data on a Potential Treatment for Sjogren-Larsson Syndrome at the 2015 Society for Inherited Metabolic Disorders Annual Meeting, Jan. 29, 2015 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics to Present Novel Data on a Potential Treatment for Succinic Semi-Aldehyde Dehydrogenase Deficiency at the 2015 American Society of Human Genetics (ASHG) Annual Meeting, Sep. 9, 2015 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics, Inc. Announces Last Patient Dosed in Allergic Conjunctivitis Phase 2b Clinical Trial, Apr. 18, 2017 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics, Inc. Announces Last Patient Dosed in Phase II Clinical Trial of Topical Dermatologic NS2 in Patients With Sjögren-Larsson Syndrome Jun. 7, 2016 (2 pages).
Aldeyra Press Release—Aldeyra Therapeutics, Inc. Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-102 in Sjögren-Larsson Syndrome, Apr. 20, 2017 (2 pages).
Aldeyra Press Release—Positive Results From Phase II Clinical Trial in Subjects With Noninfectious Anterior Uveitis, May 9, 2016 (4 pages).
Aldeyra Therapeutics Announces First Patient Enrolled in Sjögren-Larsson Syndrome Pivotal Phase 3 Clinical Trial, Jul. 24, 2018 (2 pages).
Aldini et al., "Lipoxidation-Derived Reactive Carbonyl Species as Potential Drug Targets in Preventing Protein Carbonylation and Related Cellular Dysfunction," ChemMedChem, 1(10):1045-1058 (2006).
Aldini et al., "The carbonyl scavenger carnosine ameliorates dyslipidaemia and renal function in Zucker obese rats," The Journal of Cellular and Molecular Medicine, 15(6):1339-1354 (2011).
Al-Essa et al., "Clinical, fluorine-18 labeled 2-fluoro-2-deoxyglucose positron emission tomography (FDG PET), MRI of the brain and biochemical observations in a patient with 4-hydroxybutyric aciduria; a progressive neurometabolic disease," Brain Dev., 22(2):127-31 (2000).
Al-Hasani, H. et al., "Phosphoryl exchange is involved in the mechanism of the insulin receptor kinase," FEBS Lett., 349:17-22 (1994).
Amara et al., "Autoantibodies to malondialdehyde-modified epitope in connective tissue disease and vasculitides," Clinical and Experimental Immunology, 101(2):233-238 (1995).
Ao et al., "Methyl-β-Cyclodextrin Impairs the Monocyte-Adhering Ability of Endothelial Cells by Down-Regulating Adhesion Molecules and Caveolae and Reorganizing the Actin Cytoskeleton," Biol Pharm Bull, 39(6):1029-1034 (2016).
Apparsundaram, S. et al., "Molecular cloning of a human, hemicholinium-3-sensitive choline transporter," Biochem. Biophys. Res. Commun., 276(3):862-867 (2000).
Ardati, A. et al., "Interaction of [3H] orphanin FQ and 125I-Tyr14-orphanin FQ with the orphanin FQ receptor: kinetics and modulation by cations and guanine nucleotides," Mol. Pharmacol., 51:816-824 (1997).
Ashton et al., "Location of penetration and metabolic barriers to levobunolol in the corneal epithelium of the pigmented rabbit," The Journal of Pharmacology and Experimental Therapeutics, 259(2):719-724 (1991).
Atkinson et al., "Triazaphenanthrenes. Part VI.* Further Observations on the Widman-Stoermer and Brosche Reactions," J. Chem. Soc. (C) pp. 2053-2060 (1966).
Augustin et al., "Oxidative reactions in the tear fluid of patients suffering from dry eyes," Graefe's Archive for Clinical and Experimental Ophthalmology, 233(11):694-698 (1995).
Axelsson et al., "Experimental colitis induced by dextran sulphate sodium in mice: beneficial effects of sulphasalazine and olsalazine," Aliment Pharmacol Ther, 12:925-934 (1998).
Bachman, G.B. et al., "Quinoline derivatives from 3-nitro-4-hydroxyquinoline," Am. Chem. Soc., 69:365-371 (1947).
Bacsi et al., "Effect of pollen-mediated oxidative stress on immediate hypersensitivity reactions and late-phase inflammation in allergic conjunctivitis," J. Allergy Clin. Immunol., 2005; 116(4):836-843.
Badii, "Allergic Conjunctivitis," https://www.healthline.com/health/allergic-conjunctivitis, Apr. 28, 2016 (12 pages) [retrieved on Nov. 22, 2019].
Balci et al., "Effects of computer monitor-emitted radiation on oxidant/antioxidant balance in cornea and lens from rats," Molec Vis, 15:2521-2525 (2009).
Balci et al., "Investigation of oxidative stress in pterygium tissue," Molecular Vision, 17:443-447 (Feb. 2011).
Ballard, S.A. et al., "Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes," J. Urol., 159(6):2164-2171 (1998).
Baltatzis et al., "Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders," Ophthalmology, 110(5):1061-5 (May 2003).
Bardwell, A.J. et al., "Docking sites on mitogen-activated protein kinase (MAPK) kinases, MAPK phosphatases and the Elk-1 transcription factor compete for MAPK binding and are crucial for enzymic activity," Biochem. J., 370:1077-1085 (2003).
Baron, B.M. et al., "[3H]MDL 105,519, a high-affinity radioligand for the N-methyl-D-aspartate receptor-associated glycine recognition site," J. Pharmacol. Exp. Ther., 279:62-68 (1996).
Bartoli et al., "Malondialdehyde in Exhaled Breath Condensate as a Marker of Oxidative Stress in Different Pulmonary Diseases," Mediators of Inflammation, vol. 2011, Article ID 891752 (2011) (7 pages).
Batista et al., "Age-dependent changes in rat lacrimal gland anti-oxidant and vesicular related protein expression profiles," Molecular Vision, 18:194-202 (2012).
Batista et al., "Short-term treatment with bisphenol-A leads to metabolic abnormalities in adult male mice," PLOS One, vol. 7, No. 3, (2012).
Baum et al, "Omega 3 fatty acid inhibition of inflammatory cytokine-mediated Connexin43 regulation in the heart," Front. Physiol. 3:272 doi: 10.3389/fphys.2012.00272. eCollection 2012 (2012).
Baz et al., "Plasma reactive oxygen species activity and antioxidant potential levels in rosacea patients: correlation with seropositivity to Helicobacter pylori," International Journal of Dermatology, 43(7):494-497 (2004).
Berge et al., "Pharmaceutical salts," The Journal of Pharmaceuticals Sciences, 66(1):1-19 (1977).
Berkhout, T.A. et al., "Cloning, in vitro expression, and functional characterization of a novel human CC chemokine of the monocyte chemotactic protein (MCP) family (MCP-4) that binds and signals through the CC chemokine receptor 2B," , J. Biol. Chem., 272:16404-16413 (1997).
Bermudez et al., "Thermosensitive poloxamer-based injectables as controlled drug release platforms for veterinary use: Development and in-vitro evaluation," Intl Res J Pharmacy Pharmacol, 1(6):109-118 (Sep. 2011).
Bernstein et al., "Mechanism of Action of Aromatic Amines that Short-Circuit the Visual Cycle," Biochemistry, 25(11):3370-3377 (1986).
Bernstein et al., "Retinal Toxicity Associated with Occupational Exposure to the Fish Anesthetic MS-222," Am J Ophthalmol, 124(6):843-844 (1997).
Bernstein et al., "Short-Circuiting the Visual Cycle with Retinotoxic Aromatic Amines," Proc Natl Acad Sci USA, 83(6):1632-1635 (1986).
Bernstein et al., The Specific Inhibition of 11-cis-retinyl Palmitate Formation in the Frog Eye by Diaminophenoxypentane, an Inhibitor of Rhodopsin Regeneration, Vision Research, 25(6):741-748 (1985).
Bickett, D.A. et al., "A high throughput fluorogenic substrate for interstitial collagenase (MMP-1) and gelatinase (MMP-9)," Anal. Biochem., 212:58-64 (1993).
Bignon, E. et al., "SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies," J. Pharmacol. Exp. Ther. 289:742-751 (1999).
Boldogh et al., "ROS generated by pollen NADPH oxidase provide a signal that augments antigen-induced allergic airway inflammation," J. Clin. Invest., 2005; 115(8):2169-2179.
Bousquet et al., "How to Design and Evaluate Randomized Controlled Trials in Immunotherapy for Allergic Rhinitis: An ARIA-GA2 LEN Statement," Allergy, 66(6):765-774 (2011).
Boyer et al., "Lipofuscin and N-Retinylidene-N-Retinylethanolamine (A2E) Accumulate in Retinal Pigment Epithelium in Absence of Light Exposure," J Biol Chem, 287(26):22276-22286 (Jun. 2012).
Bozkir et al., "Effect of hydroxypropyl-beta-cyclodextrin on the solubility, stability and in-vitro release of ciprofloxacin for ocular drug delivery," Acta Poloniae Pharmaceutica, 69(4):719-24 (2012).
Bragagni et al., "Cyclodextrin complexation highly enhances efficacy of arylsulfonylureido benzenesulfonamide carbonic anhydrase inhibitors as a topical antiglaucoma agents," Bioorganic & Medicinal Chemistry, 23(18):6223-6227) (2015).
Brenneman et al., "Cannabidiol Provides Protection from Ethanol and Ammonium toxicity in a Hippocampal Model of Hepatic Encephalopathy," 24th Annual Symposium of the International Cannabinoid Research Society, Baveno, Italy, Jun. 28-Jun. 3, 2014 (p. 73).
Brenneman et al., "Small Molecule Anticonvulsant Agents with Potent In Vitro Neuroprotection," Journal of Molecular Neuroscience, 47(2):368-379 (2012).
Brewitt et al., "Dry Eye Disease—The Scale of the Problem," Survey of Ophthalmol, 45(Suppl 2): S199-S2 (Mar. 2001).
Brockhaus, M. et al., "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies," Proc. Natl. Acad. Sci. U.S.A., 87:3127-3131 (1990).
Brown, G.B., "3H-batrachotoxinin-A benxoate binding to voltage-sensitive sodium channels: inhibition by the channel blockers tetrodotoxin and saxitoxin," J. Neurosci., 6:2064-2070 (1986).
Brozek et al., "Grading quality of evidence and strength of recommendations in clinical practice guidelines: Part 2 of 3. The GRADE approach to grading quality of evidence about diagonstic tests and strategies," Allergy, 64(8):1109-1116 (2009).
Bryant, H.U. et al., "A novel class of 5-HT2A receptor antagonists: aryl ammoguanidines," Life Sci., 59(15):1259-1268 (1996).
Bucciantini et al., "Inherent Toxicity of Aggregates Implies a Common Mechanism for Protein Misfolding Diseases," Nature, 416(6880):507-511 (2002).
Buchan, K.W. et al., "Characterization of three non-peptide endothelin receptor ligands using human cloned ETA and ETB receptors," Brit. J. Pharmacol., 112:1251-1257 (1994).
Buddi et al., "Evidence of oxidative stress in human corneal diseases," The Journal of Histochemistry and Cytochemistry: official journal of the Histochemistry Society, 50(3):341-351 (2002).
Bundgaard et al., "Glycolamide esters as biolabile prodrugs of carboxylic acid agents: Synthesis, Stability, bioconversion, and physicochemical properties," Journal of Pharmaceutical Sciences, 77(4):285-298 (1988).
Bundgaard, "Mean to enhance penetration: (1) Prodrugs as a means to improve the delivery of peptide drugs," Advanced Drug Delivery Review, 8(1):1-38 (1992).
Burcham et al., "Aldehyde-Sequestering Drugs: Tools for Studying Protein Damage by Lipid Peroxidation Products," Toxicology, 181-182:229-236 (2002).
Burstein, "Preservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneas," Investigative Ophthalmology and Visual Science, 19(3):308-313 (1980).
Burstein, "The effects of topical drugs and preservatives on the tears and corneal epithelium in dry eye," Transactions of the Ophthalmological Societies of the United Kingdom, 104:402-409 (1985).
Canonica et al., "Recommendations for standardization of clinical with Allergen Specific Immunotherapy for repsiratory allergy. A statement of a World Allergy Organization (WAO) taskforce," Allergy, 62(3):317-324 (2007).
Canonica et al., "Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009," Allergy, 64(Suppl 91:1-59 (2009).
Casanaro et al., "A convenient solvent system for cellulose dissolution and derivatization: Mechanistic aspects of the acylation of the biopolymer in tetraallylammonium fluoride/dimethyl sulfoxide," Carbohydrate Polymers, 8(3):1395-1402 (2011).
Casanaro et al., "Efficacy of vigabatrin intervention in a mild phenotypic expression of succinic semialdehyde dehydrogenase deficiency," JIMD Rep. 2:119-23 (2011).
Cejkova et al., "The role of conjunctival epithelial cell xanthine oxidoreductase/xanthine oxidase in oxidative reactions on the ocular surface of dry eye patients with Sjögren's syndrome," Histol Histopathol 22(9):997-1003 (Sep. 2007).
Cesura et al., "Characterization of the binding of [3H]Ro 41-1049 to the active site of human monoamine oxidase-A," Mol. Pharmacol., 37:358-366 (1990).
Chapple et al., "Unfolding Retinal Dystrophies: a Role for Molecular Chaperones?" Trends Mol Med, 7(9):414-421 (2001).
Chen et al., "Methazolamide Calcium Phosphate Nanoparticles in an Ocular Delivery System," Pharm Soc Japan, 130(3):419-24 (2010).
Cheng et al., "A synthetic peptide derived from p34cdc2 is a specific and efficient substrate of src-family tyrosine kinases," J. Biol. Chem., 267:9248-9256 (1992).
Chiarpotto et al., "Role of 4-hydroxy-2,3-nonenal in the pathogenesis of fibrosis," Biofactors, 24(1-4):229-36 (2005).
Chicchi et al., "Alterations in receptor activation and divalent cation activation of agonist binding by deletion of intracellular domains of the glucagon receptor," J. Biol. Chem., 272:7765-7769 (1997).
Choi et al., "Expression of Lipid Peroxidation Markers in the Tear Film and Ocular Surface of Patients with Non-Sjogren Syndrome: Potential Biomarkers for Dry Eye Disease," Curr Eye Res, 41(9):1143-11 (2016).
Choi et al., "The human serotonin 5-HT2B receptor: pharmacological link between 5-HT2 and 5-HT1D receptors," FEBS Lett., 352:393-399 (1994).
Ciolino et al., "Effect of alcaftadine 0.25% on ocular itch associated with seasonal or perennial allergic conjunctivitis: a pooled analysis of two multicenter randomized clinical trials," Clin Ophthalmol, 9:765-72 (May 2015).
Clark et al., "Inhibition of dexamethasone-induced cytoskeletal changes in cultured human trabecular meshwork cells by tetrahydrocortisol," Invest. Ophtalmol Vis. Sci., 37:805-813 (1996).
Clinical Trials Results for Outcome Measures of Ocular Itching and Ocular Tearing (1 page) (2016).
Clinical Trials Results of Treatment with Aldehyde Trapping Compound NS2 (1 page) (2015).
Clinical Trials Results of Treatment with NS2 Topical Formulation (1 page) (2015).
ClinicalTrials.gov identifier NCT02402309, "A Study of Topical NS2 Cream to Treat Ichthyosis in Sjogren-Larsson Syndrome (SLS)," https://clinicaltrials.gov/ct2/show/NCT02402309 (3 pages) (2015).
ClinicalTrials.gov identifier NCT02406209, "A Safety and Efficacy Study of NS2 in Patients with Anterior Uveitis," https://clinicaltrials.gov/ct2/show/NCT02406209 (4 pages) (2015).
ClinicalTrials.gov identifier NCT02578914, "A Safety and Activity Study of NS2 in Subjects with Allergic Conjunctivitis," https://clinicaltrials.gov/ct2/show/NCT02578914 (6 pages) (2015).
ClinicalTrials.gov identifier NCT03162783, "A Randomized, Double Masked, Clinical Study of Subjects with Dry Eye Syndrome," (7 pages) (2017).
Conover et al., "Thiazole Analogs of Pyridoxine," Journal of the American Chemical Society, 72(11):5221-5225 (1950).
Cooper et al., "Clinicopathologic study of dextran sulfate sodium experimental murine colitis," Lab Invest, 69(2):238-49 (Aug. 1993).
Couvineau et al., "Molecular identification and structural requirement of vasoactive intestinal peptide (VIP) receptors in the human colon adenocarcinoma cell line, HT-29," Biochem. J., 231:139-143 (1985).
Cullen et al, "Administration of the small molecule aldehyde trap NS2 in a hamster model of radiation-induced oral mucositis," ISOO 2015 Annual Meeting Abstract, Support Care Cancer, 23 (Suppl 1):S107 (Jun. 2015).
Cullen et al, "The small molecule aldehyde trap NS2 exhibits potent anti-inflammatory activity in three murine models of inflammation," AAAAI Annual Meeting Abstract, 1 page (Feb. 2015).
Davies, "Biopharmaceutical considerations in topical ocular drug delivery," Clin Exp Pharmacol Physiol, 27(7):558-62 (Jul. 2000).
De Jong, "Age-Related Macular Degeneration," N Engl J Med, 355(14):1474-1485 (2006).
Del Valle, "Cyclodextrins and their uses: a review," Process Biochemistry, 39(9):1033-1046 (2004).
Demir et al., "Oxidative stress of intracameral lidocaine and levobupivacaine on ocular tissues," Br J Ophthalmol, 94(8):1083-7 (Aug. 2010).
Demir et al., "The protective effect of alpha-lipoic acid against oxidative damage in rabbit conjunctiva and cornea exposed to ultraviolet radiation," Ophthalmologica, 219(1):49-53 (Jan.-Feb. 2005).
Dente et al., "Modified phage peptide libraries as a tool to study specificity of phosphorylation and recognition of tyrosine containing peptides," J. Mol. Biol., 269:694-703 (1997).
Devedjian et al., "Further characterization of human alpha 2-adrenoceptor subtypes: [3H]RX821002 binding and definition of additional selective drugs," Eur. J. Pharmacol., 252:43-49 (1994).
Devillier et al., "The allergen challenge chamber: A valuable tool for optimizing the clinical development of pollen immunotherapy," Allergy, 2011; 66(2):163-9.
Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services, Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, V2.0, 33 pages. (Nov. 2014).
Dolmotova et al, "Cardiomyocyte ATP release through pannexin 1 aids in early fibroblast activation," Am. J. Physiol Heart Circ Physiol 303(10):H1208-1218 (2012).
Dorje et al., "Antagonist binding profiles of five cloned human muscarinic receptor subtypes," J. Pharmacol. Exp. Ther., 256:727-733 (1991).
Dowling, "Neural and Photochemical Mechanisms of Visual Adaptation in the Rat," Journal of General Physiology, 46(6):1287-1291 (1963).
Drysdale et al., "Complex Promoter and Coding Region Beta 2-adrenergic Receptor Haplotypes Alter Receptor Expression and Predict in vivo Responsiveness," Proc Natl Acad Sci USA, 97(19):10483-10488 (2000).
Egger, et al., "Keratinocyte growth factor ameliorates dextran sodium sulfate colitis in mice," Dig Dis Sci, 44(4): 836-44 (Apr. 1999).
Ellman et al., "A new and rapid colorimetric determination of acetylcholinesterase activity", Biochem. Pharmacol., 7: 88-95 (1961).
Erdos et al, "Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones," FASEB J. 3:145 (1989).
Ermolieff et al., "Proteolytic activation of recombinant pro-memapsin 2 (pro-beta-secretase) studied with new fluorogenic substrates," Biochemistry, 39:12450-12456 (2000).
Escalera et al., "Succinic semialdehyde dehydrogenase deficiency: decrease in 4-OH-butyric acid levels with low doses of vigabatrin," An Pediatr (Barc). 72(2):128-32 (2010).
Esterbauer et al., "Chemistry and Biochemistry of 4-Hydroxynonenal, Malonaldehyde and Related Aldehydes," Free Radic Biol Med, 11:81-128 (1991).
European Supplementary Partial Search Report issued by the European Patent Office for European Patent Application No. 13865015.5 dated Mar. 31, 2016 (9 pages).
European Supplementary Partial Search Report issued by the European Patent Office for European Patent Application No. 14743711.5 dated Jul. 20, 2016 (14 pages).
Everest-Todd, "Topical Application of Cyclodextrin Ethers in the Control of Pain," Proceedings of the Eighth International Symposium on Cyclodextrins, pp. 495-498 (1998).
FDA, "BAM R59: Phosphate-Buffered Saline (PBS), pH 7.4," Jan. 2001, retrieved online at <http://www.fda.gov/Food/FoodScienceR.esearch/LaboratoxyMethods/ucm062268.htm> on Apr. 18, 2015 (1 page).
Feighner et al., "Receptor for motilin identified in the human gastrointestinal system," Science, 284:2184-2188 (1999).
Fernandes et al., "Characterization of angiotensin-converting enzymes 1 and 2 in the soleus and plantaris muscles of rats," Braz J Med Biol Res., 43:837-842 (2010).
Ferry et al., "Binding of prostaglandins to human PPARγ: Tool assessment and new natural ligands," Eur. J. Pharmacol., 417:77-89 (2001).
Feve et al., "Transcriptional down-regulation by insulin of the beta 3-adrenergic receptor expression in 3T3-F442A adipocytes: a mechanism for repressing the cAMP signaling pathway," Proc Natl Acad Sci USA. 91:5677 (1994).
Fiske et al., "The Colormetric Determination of Phosphorus," J. Biol. Chem., 66:375-400 (1925).
Fitzmaurice et al., "Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease," Proc. Natl Acad Sci U.S.A, 110(2):636-641 (2013).
Ford et al., "Pharmacological pleiotropism of the human recombinant alpha1 A-adrenoceptor: implications for alpha1-adrenoceptor classification," Brit. J. Pharmacol., 121:1127-1135 (1997).
Fowler et al., "Coloured Complexes of all-trans-retinal with Benzocaine and Other Local Anesthetics," J Photochem Photobiol B, 8(2):183-188 (1991).
Frantz et al., "The Activation State of p38 Mitogen-Activated Protein Kinase Determines the Efficiency of ATP Competition for Pyridinylimidazole Inhibitor Binding," Biochemistry, 37:13846-13853 (1998).
Friesen et al., "Optimization of a Tertiary Alcohol Series of Phosphodiesterase-4 (PDE4) Inhibitors: Structure-Activity Relationship Related to PDE4 Inhibition and Human Ether-a-go-go Related Gene Potassium Channel Binding Affinity," J. Med. Chem., 46(12):2413-2426 (2003).
Fuchs et al., "Functional characterization of three mutations of the endothelin B receptor gene in patients with Hirschsprung's disease: evidence for selective loss of Gi coupling," Mol. Med., 7:115-124 (2001).
Fukunaga et al., "Single nucleotide polymorphism of human platelet-activating factor receptor impairs G-protein activation," J. Biol. Chem., 276:43025-43030 (2001).
Full 1H NMR assignment for RAL-NS2 in CDCIJ, submitted to Japanese Patent Office Mar. 1, 2012.
Ganapathy et al., "Molecular and ligand-binding characterization of the sigma-receptor in the Jurkat human T lymphocyte cell line," JPET, 289:251-260 (1999).
Gasper et al., "2-Hydroxypropyl-beta-cyclodextrin (HPβCD) reduces age-related lipofuscin accumulation through a cholesterol-associated pathway," Scientific Reports, 7(2197):1-7 (2017).
Gibson et al., "Stable isotope dilution analysis of 4-hydroxybutyric acid: an accurate method for quantification in physiological fluids and the prenatal diagnosis of 4-hydroxybutyric aciduria," Biomed Environ Mass Spectrom., 19(2):89-93 (1990).
Gibson et al., "Stable-isotope dilution analysis of D- and L-2-hydroxyglutaric acid: application to the detection and prenatal diagnosis of D- and L-2-hydroxyglutaric acidemias," Pediatr Res., 34(3):277-80 (1993).
Gibson et al., "The Aldehyde Trap NS2 Mitigates Dense Haze in a Rabbit Model of Photorefractive Keratectomy" ARVO Annual Meeting Abstract, 1 page (Jun. 2015).
Godard et al., "Sur les orthoamino formyl quinoleines, nouveaux synthons hetercycliques," J Heterocyclic Chem, 17(3):465-473 (1980).
Goldstein et al., "A Phase 2 Exploratory Study of a Novel Interleukin-1 Receptor Inhibitor (EBI-005) in the Treatment of Moderate-to-Severe Allergic Conjunctivitis," Eye Contact Lens, 41(3):145-55 (May 2015).
Gomez, "Dimethyltin(IV) 2,6-disubstituted pyridine complexes," J. Organometallic Chemistry, 672(2):115-122 (2003).
Good, "Measuring field loss in children administered vigabatrin: a problem in search of a solution," J AAPOS. 15(5):411-2 (2011).
Gopalakrishnan et al., "Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor," J. Pharmacol. Exp. Ther., 276:289-297 (1996).
Gould et al., "[3H]nitrendipine-labeled calcium channels discriminate inorganic calcium agonists and antagonists," Proc. Natl. Acad. Sci. U.S.A., 79:3656-3660 (1982).
Grandy et al., "Cloning of the cDNA and gene for a human D2 dopamine receptor," Proc. Natl. Acad. Sci. U.S.A., 86:9762-9766 (1989).
Green et al., "Characterization of [(3)H]-CGP54626A binding to heterodimeric GABA(B) receptors stably expressed in mammalian cells," Brit. J. Pharmacol., 131:1766-1774 (2000).
Green et al., "Influence of Various Agents on Corneal Permeability," American Journal of Ophthalmology, 72(5):897-905 (1971).
Grob et al., "Die Synthese von 5-Oxy-benz(cd)indolin and dessen Umpagerung in 5-Keto-1,3,4,5-tetrahydro-benz(cd)indol," Helvetica Chimica Acta, Verlag Helvetica Chimica Acta, CH, 33(6):1796-1808 (1950) [Machine Translation].
Grob et al., "Die Synthese von 5-Oxy-benz(cd)indolin and dessen Umpagerung in 5-Keto-1,3,4,5-tetrahydro-benz(cd)indol," Helvetica Chimica Acta, Verlag Helvetica Chimica Acta, CH, 33(6):1796-1808 (1950).
Gromachevskaya et al., "4H-3,1-benzoxazines. 2. Synthesis of 2,4-substituted 1,2-dihydro-4H-3,1-benzoxazines," Chemistry of Heterocyclic Compounds, 24(6):692-697 (Jun. 1988).
Grotto et al., "Importance of the lipid peroxidation biomarkers and methodological aspects for malondialdehyde quantification," Quim Nova, 32(1):169-174 (2009).
Halilovic et al., "ADX-103, a Novel Small Molecule Aldehyde Sequestering Agent, Decreases Retinal Edema and Inflammation in a Rat Model of Diabetic Macular Edema," ARVO Annual Meeting Abstract, 2 pages (Jul. 2018).
Hampson et al., "Cannabidiol and (−)Delta9-tetrahydrocannabinol are neuroprotective antioxidants," Proc. Nat. Acad. Sci 95:8268-8273 (1998).
Hassan et al., "Oxidative stress in systemic lupus erythematosus and rheumatoid arthritis patients: relationship to disease manifestations and activity," International Journal of Rheumatic Diseases, 14(1):325-331 (2011).
Herbort et al., "Endotoxin-induced uveitis in the rat," Graefe's Arch Clin Exp Ophthalmol, 226:553-8 (1988).
Hessen et al., "Dry Eye: an Inflammatory Ocular Disease," J Ophthalmic Vis Res, 9(2):240-250 (2014).
Heuillet et al., "Characterization of a Human NK1 Techykinin Receptor in the Astrocytoma Cell Line U 373 MG ," J. Neurochem., 60:868-876 (1993).
Highlights of Prescribing Information, Bridion® (sugammadex) Injection, for intravenous use, Initial U.S. Approval: 2015, Last Revised Dec. 2015 (19 pages).
Hogema et al., "Pharmacologic rescue of lethal seizures in mice deficient in succinate semialdehyde dehydrogenase," Nat Genet. 29:212-16 (2001).
Hom et al., "Allergic conjunctivitis and dry eye syndrome," Ann Allergy Asthma Immunol, 108(3):163-6 (Mar. 2012).
Hope et al., "Characterization of a human 5-hydroxytryptamine3 receptor type A (h5-HT3R-AS) subunit stably expressed in HEK 293 cells," Brit. J. Pharmacol., 118:1237-1245 (1996).
Horner et al., "Analogs of 3-Amino-7-chloro-1,2,4-benzotriazine 1-Oxide as Antimalarial Agents," J. Med. Chem., 11(5):946-949 (1968).
Hoyer et al., "Characterization of the 5-HT1B recognition site in rat brain: binding studies with (−)[125I]iodocyanopindolol," Eur. J. Pharmacol., 118:1-12 (1985).
Huang et al., "Characterization of Calcium Phosphate Nanoparticles Based on a PEGylated Chelator for Gene Delivery," ACS Appl Mater Interfaces, 9:10435-10445 (Mar. 2017).
Huang et al., "Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting," Assay Drug Dev Technol., 8(6):727-42 (2010).
Huang et al., "Novel peptide inhibitors of angiotensin-converting enzyme 2," J. Biol. Chem., 278:15532-15540 (2003).
Hubbard, "Geometrical Isomerization of Vitamin A, Retinene and Retinene Oxime," Journal of the American Chemical Society, 78(18):4662-4667 (1956).
Hugues et al., "Preparation of a pure monoiodo derivative of the bee venom neurotoxin apamin and its binding properties to rat brain synaptosomes," J. Biol. Chem., 257:2762-2769 (1982).
Hurd et al., "Reaction of Propiolactone with Aniline Derivatives," Journal of the American Chemical Society, 74(23):5889-5893 (1952).
Inoue et al., "Filter-binding assay procedure for thyroid hormone receptors," Anal Biochem. 134(1):176 (1983).
International Preliminary Report on Patentability issued by the European Patent Office as International Searching Authority for International Application PCT/US2006/020320 dated Nov. 30, 2007 (8 pages).
International Preliminary Report on Patentability issued by the Korean Intellectual Property Office as International Searching Authority for International Applicati0n No. PCT/US2013/076592 dated Jun. 23, 2015 (6 pages).
International Preliminary Report on Patentability issued by the Korean Intellectual Property Office as International Searching Authority for International Application No. PCT/US2014/012356 dated Jul. 28, 2015 (7 pages).
International Preliminary Report on Patentability issued by the United States Patent and Trademark Office as International Searching Authority for International Application No. PCT/US2014/012762 dated Jul. 28, 2015 (8 pages).
International Preliminary Report on Patentability issued in PCT/US2016/048054 dated Feb. 27, 2018 (5 pages).
International Preliminary Report on Patentability issued in PCT/US2016/048064 dated Feb. 27, 2018 (6 pages).
International Search Report and Written Opinion issued by the European Patent Office as International Searching Authority for International Patent Application No. PCT/US2019/044929 dated Nov. 20, 2019 (15 pages).
International Search Report and Written Opinion issued by the Korean Intellectual Property Office as International Searching Authority for International Application No. PCT/US2013/076592 dated Apr. 30, 2014 (10 pages).
International Search Report and Written Opinion issued by the Korean Intellectual Property Office as International Searching Authority for International Application No. PCT/US2014/012356 dated May 30, 2014 (11 pages).
International Search Report and Written Opinion issued by the United States Patent and Trademark Office as International Searching Authority for International Application No. PCT/US2010/059719 dated Feb. 8, 2011 (7 pages).
International Search Report and Written Opinion issued by the United States Patent and Trademark Office as International Searching Authority for International Application No. PCT/US2014/012762 dated Jul. 18, 2014 (11 pages).
International Search Report and Written Opinion issued by the United States Patent and Trademark Office as International Searching Authority for International Application No. PCT/US2017/047945 dated Oct. 20, 2017 (9 pages).
International Search Report and Written Opinion issued by the United States Patent and Trademark Office as International Searching Authority for International Patent Application No. PCT/US2017/020020 dated May 24, 2017 (12 pages).
International Search Report and Written Opinion issued by the United States Patent and Trademark Office as International Searching Authority for International Patent Application No. PCT/US2018/055310 dated Jan. 29, 2019 (9 pages).
International Search Report and Written Opinion issued by the United States Patent and Trademark Office as International Searching Authority for International Patent Application No. PCT/US2019/041942 dated Sep. 30, 2019 (18 pages).
International Search Report and Written Opinion issued by the United States Patent and Trademark Office as International Searching Authority for International Patent Application No. PCT/US2019/045206 dated Oct. 17, 2019 (13 pages).
International Search Report and Written Opinion issued by the United States Patent and Trademark Office as International Searching Authority for International Patent Application No. PCT/US2019/054263, dated Jan. 6, 2020 (13 pages).
International Search Report and Written Opinion issued by the United States Patent and Trademark Office as International Searching Authority for International Patent Application No. PCT/US2019/064669, dated Feb. 27, 2020 (12 pages).
International Search Report and Written Opinion issued by the United States Patent and Trademark Office as International Searching Authority for International Patent Application No. PCT/US2019/169097, dated Dec. 10, 2019 (11 pages).
International Search Report and Written Opinion issued by the United States Patent and Trademark Office as International Searching Authority for International Patent Application No. PCT/US2020/024022, dated Jun. 17, 2020 (11 pages).
International Search Report and Written Opinion issued by the United States Patent and Trademark Office as International Searching Authority for International Patent Application No. PCT/US2020/031138, dated Jul. 13, 2020 (7 pages).
International Search Report and Written Opinion issued by the United States Patent and Trademark Office as International Searching Authority for International Patent Application No. PCT/US2020/031219, dated Aug. 31, 2020 (14 pages).
International Search Report and Written Opinion issued in PCT/US2006/020320, dated Sep. 26, 2006 (10 pages).
International Search Report and Written Opinion issued in PCT/US2016/048054 dated Nov. 4, 2016 (7 pages).
International Search Report and Written Opinion issued in PCT/US2016/048064 dated Nov. 15, 2016 (8 pages).
International Search Report and Written Opinion issued in PCT/US2017/031808 dated Aug. 11, 2017.
International Search Report and Written Opinion issued in PCT/US2017/047958 dated Oct. 31, 2017.
International Search Report and Written Opinion issued in PCT/US2018/023000 dated Jun. 1, 2018 (8 pages).
Iriyama et al., "A2E, a pigment of the lipofuscin of retinal pigment epithelial cells, is an endogenous ligand for retinoic acid receptor," J Biol Chem., 283(18):11947-53 (2008) Epub Mar. 6, 2008.
Ishida et al., "Stabilization of calmodulin-dependent protein kinase II through the autoinhibitory domain," J Biol. Chem., 270:2163-2170 (1995).
Ito et al., "A Medium-Term Rat Liver Bioassay for Rapid in vivo Detection of Carcinogenic Potential of Chemicals," Cancer Science, 94(1):3-8 (2003).
Itokawa et al., "Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling," Mol. Cancer Ther., 1:295-302 (2002).
Jacobs et al., "Responses to ragweed pollen in a pollen challenge chamber versus seasonal exposure identify allergic rhinoconjunctivitis endotypes," J. Allergy Clin. Immunol., 2012; 130(1):122-7.
Jafari et al., "Evaluation of plasma, erythrocytes, and bronchoalveolar lavage fluid antioxidant defense system in sulfur mustard-injured patients," Clin Toxicol (Phila)., 48(3):184-92 (2010).
Janowski et al., "Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta," Proc. Natl. Acad. Sci. USA, 96:266-271 (1999).
Jarrett et al., "Mitochondrial DNA damage and impaired base excision repair during epileptogenesis," Neurobiology of Disease, 30(1):130-138 (2008).
Jellinger et al., "American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipemia and Prevention of Cardiovascular Disease," Endocr Pract, 23(Suppl 2):1-87 (Apr. 2017).
Ji et al., "Exploration of diverse hinge-binding scaffolds for selective Aurora kinase inhibitors," Bioorg. & Med. Chem. Let. 22:4528 (2012).
Johannsdottir et al., "Development of a Cyclodextrin-Based Aqueous Cyclosporin a Eye Drop Formulations," International Journal of Pharmaceutics, 493(1-2):86-95 (2015).
Johnson et al., "2-Hydroxypropy1-β-Cyclodextrin Removes All-Trans Retinol from Frog Rod Photoreceptors in a Concentration-Dependent Manner," Journal of Ocular Pharmacology and Therapeutics, 26(3):245-248 (2010).
Joseph et al., "Binding of (−)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers," Naun.-Sch. Arch. Pharm., 369:525-532 (2004).
Kam et al., "Topical Cyclodextrin Reduces Amyloid Beta and Inflammation Improving Retinal Function in Ageing Mice," Experimental Eye Research, 135:59-66 (2015).
Kamino et al., "Deficiency in mitochondrial aldehyde dehydrogenase increases the risk for late-onset Alzheimer's disease in the Japanese population," Biochemical and Biophysical Research Communications, 273(1):192-196 (2000).
Karahashi et al., "Changes of caspase activities involved in apoptosis of a macrophage-like cell line J774.1/JA-4 treated with lipopolysaccharide (LPS) and cycloheximide," Biol. Pharm. Bull., 23:140-144 (2000).
Karan et al., Lipofuscin Accumulation, Abnormal Electrophysiology, and Photoreceptor Degeneration in Mutant ELOVL4 Transgenic Mice: A Model for Macular Degeneration, Proc Natl Acad Sci USA, 102(11):4164-4169 (2005).
Katugampola et al., "[(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man," Brit. J. Pharmacol., 132:1255-1260 (2001).
Kenney et al., "The Cascade Hypothesis of Keratoconus," Contact Lens & Ant Eye, 26:139-146 (2003).
Keri, "Rosacea," Merck Manual, Professional Version, https://www.merckmanuals.com/professional/dermatologic-disorders/acne-and-related-disorders/rosacea, 7 pages (2017).
Knapp et al., "Intraocular Availability of Topically Applied Mycophenolate Mofetil in Rabbits," J. Ocul. Pharmacol. Ther., 19(2):181-192 (2003).
La Rosa et al., "Allergic conjunctivitis: a comprehensive review of the literature," Ital J Pediatr, 39:18 (2013).
Landor et al., "Allenes. Part 49, 4-Amino-2-(1-hydroxyalkyl)quinolones from Phenylhydroxylamine and Allenic Nitrites," J Chem Soc Perkin Trans 1, pp. 251-254 (1989).
Langin et al., "[3H]RX821002: a new tool for the identification of alpha 2A-adrenoceptors," Eur. J. Pharmacol., 167: 95-104 (1989).
Lankin et al., "Role of Oxidative Stress in the Genesis of Atherosclerosis and Diabetes Mellitus: A Personal Look Back on 50 Years of Research," Curr. Aging Sci. 10:18 (2017).
Le et al., "Ligand binding and functional properties of human angiotensin AT1 receptors in transiently and stably expressed CHO-K1 cells," Eur. J. Pharmacol., 513:35-45 (2005).
Lee et al., "Human recombinant soluble guanylyl cyclase: expression, purification, and regulation," Proc. Natl. Acad. Sci. USA, 97(20):10763-10768 (2000).
Lee et al., "The human brain cholecystokinin-B/gastrin receptor. Cloning and characterization," J. Biol. Chem., 268 : 8164-8169 (1993).
Leibundgut et al., "Oxidation-specific epitopes and immunological responses: Translational biotheranostic implications for atherosclerosis," Current Opinion in Pharmacology, 13(2):168-179 (2013).
Leonardi et al., "Correlation Between Conjunctival Provocation Test (CPT) and Systemic Allergometric Tests in Allergic Conjunctivitis," Eye, 4:760-764 (1990).
Leonardi, "Allergy and allergic mediators in tears," Exp. Eye Res., 2013; 117:106-17.
Leurs et al., "Pharmacological characterization of the human histamine H2 receptor stably expressed in Chinese hamster ovary cells," Brit. J. Pharmacol., 112: 847-854 (1994).
Levey et al., "A new equation to estimate glomerular filtration rate," Ann Intern Med, 150(9):604-12 (May 2009).
Levin et al., "The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation," J. Biol.Chem., 277:30429-30435 (2002).
Lewin et al., "meta- and para-isothiocyanato-t-butylbicycloorthobenzoate: irreversible ligands of the gamma-aminobutyric acid-regulated chloride ionophore," Mol. Pharmacol., 35:189-194 (1989).
Li et al., "Effect of Vitamin A Supplementation on Rhodopsin Mutants Threonine-17 -> Methionine and Proline-347 -> Serine in Transgenic Mice and in Cell Cultures," Proc Natl Acad Sci USA, 95(20):11933-11938 (1998).
Liang et al., "Ocular safety of cationic emulsion of cyclosporine in an in vitro corneal wound-healing model and an acute in vivo rabbit model," Mol Vis, 18:2195-204 (2012).
Liu et al., "Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation," J. Pharmacol. Exp. Ther., 299:121-130 (2001).
Loftsson et al., "Cyclodextrin Microparticles for Drug Delivery to the Posterior Segment of the Eye: Aqueous Dexamethasone Eye Drops," Journal of Pharmacy and Pharmacology, 59(5):629-635 (2007).
Loftsson et al., "Cyclodextrins in Eye Drop Formulations: Enhances Topical Delivery of Corticosteroids to the Eye," Acta Ophthalmologica Scandinavica, 80(2):144-150 (2002).
Lopachin et al., "Molecular mechanisms of aldehyde toxicity: a chemical perspective," Chem Res Toxicol, 27(7):1081-91 (Jul. 2014).
Lovenberg et al., "Cloning and functional expression of the human histamine H3 receptor," Mol. Pharmacol., 55:1101-1107 (1999).
Lukas, R.J., "Characterization of curaremimetic neurotoxin binding sites on membrane fractions derived from the human medulloblastoma clonal line, TE671," J. Neurochem., 46:1936-1941 (1986).
Luthin et al., "Characterization of two affinity states of adenosine A2a receptors with a new radioligand, 2-[2-(4-amino-3-[125I]iodopheny)ethylamino]adenosine," Mol. Pharmacol., 47:307-313 (1995).
MacDonald et al., "ADX-102, a novel aldehyde trap, reduces nociceptive behavior in mouse models of carrageenan and CFA induced pain," Int'l Conference on Pain Research & Management Abstract, J Pain Relief, 5 (5 Suppl):50 (Oct. 2016).
MacDonald et al., "Inhibition of fibroblast activation to the myofibroblast phenotype in neonatal rat cardiac fibroblasts using a small molecule aldehyde trap," ASCB Annual Meeting Abstract, p. 2 (Dec. 2016).
MacDonald et al., "Molecular characterization of the melanin-concentrating hormone/receptor complex: identification of critical residues involved in binding and activation," Mol. Pharmacol., 58:217-225 (2000).
MacDonald et al., "Novel Small Molecule Aldehyde Sequestering Agents Demonstrate Broad Therapeutic Potential for Ocular Inflammation," ARVO Annual Meeting Abstract, 2 pages (Jul. 2018).
MacDonald et al., "The novel aldehyde trap, ADX-102, reduces inflammation-mediated lung infilrate in a mouse model of LPS-induced acute lung injury," 13th World Congress on Inflammation Abstract, p. 192 (Jul. 2017).
Mackenzie et al., "Characterization of the human dopamine D3 receptor expressed in transfected cell lines," Eur. J. Pharmacol., 266:79-85 (1994).
Maeda et al., "Involvement of All-trans-retinal in Acute Light-induced Retinopathy of Mice," J Biol Chem, 284(22):15173-83 (May 2009).
Maeda et al., "Primary amines protect against retinal degeneration in mouse models of retinopathies," Nat Chem Biol, 8(2):170-178 (Dec. 2011).
Maguire et al., "Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1," Brit. J. Pharmacol., 131:441-446 (2000).
Mandell et al., "The Aldehyde Trap NS2 Reduces Ocular Inflammation in an Endotoxin-Induced Model in Rats," ARVO Annual Meeting Abstract, 2 pages (Jun. 2015).
Mantey et al., "Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors," J. Biol. Chem., 272:26062-26071 (1997).
Marnett, "Oxy radicals, lipid peroxidation and DNA damage," Toxicology, 181-182:219-222 (2002).
Martin et al., "Molecular cloning and functional characterization of murine cysteinyl-leukotriene 1 (CysLT(1)) receptors.," Biochem. Pharmacol., 62:1193-1200 (2001).
Matern et al.,"Seizures in a boy with succinic semialdehyde dehydrogenase deficiency treated with vigabatrin (gamma-vinyl-GABA)," J Inherit Metab Dis., 19(3):313-8 (1996).
Maurice et al., "Advances in targeting cyclic nucleotide phosphodiesterases," Nat Rev Drug Discov., 13:290-314(2014).
McCord et al., "Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein).," J. Biol. Chem., 244: 6049-6055 (1969).
McGinnity et al., "Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance." Drug Metab. Dispos., 32(11):1247-1253 (2004).
McLaurin et al., "Phase 3 Randomized Double-Masked Study of Efficacy and Safety of Once-Daily 0.77% Olopatadine Hydrochloride Ophthalmic Solution in Subjects with Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model," Clinical Science, 34(10):1245-1251 (2015).
Medline Plus. Macular Degeneration—age-related. (6 pages) (2013).
Meijer et al., "Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5," Eur. J. Biochem., 243:527-536 (1997).
Meng et al., "Cloning and pharmacological characterization of a rat kappa opiod receptor," Proc. Natl. Acad. Sci. U.S.A., 90:9954-9958 (1993).
Mialet et al., "Isolation of the serotoninergic 5-HT4(e) receptor from human heart and comparative analysis of its pharmacological profile in C6-glial and CHO cell lines," Brit. J. Pharmacol., 129:771-781 (2000).
Miceli et al., "Efficacy of keratinocyte growth factor-2 in dextran sulfate sodium-induced murine colitis," J Pharmacol Exp Ther, 290(1):464-71 (Jul. 1999).
Mishra et al., "Recent Patents and Emerging Therapeutics in the Treatment of Allergic Conjunctivitis," Recent Pat. Inflamm. Allergy Drug Discov.; 2011; 5(1):26-36.
Mittl et al., "Structure of recombinant human CPP32 in complex with the tetrapeptide acetyl-Asp-Val-Ala-Asp fluoromethyl ketone," J. Biol. Chem., 272:6539-6547 (1997).
Monaghan et el., "The distribution of [3H]kainic acid binding sites in rat CNS as determined by autoradiography," Brain Res., 252:91-100 (1982).
Monsma et al., "Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs," Mol. Pharmacol., 43:320-327 (1993).
Mulheron et al., "Human 5-HT1A receptor expressed in insect cells activates endogenous G(o)-like G protein(s)," J. Biol. Chem., 269:12954-12962 (1994).
Muller-Enoch et al., "[6.7-Dihydroxycoumarin (Aesculetin) as a substrate for catechol-o-methyltransferase (author's transl)]," Z. Naturforsch., 31:280-284 (1976).
Munro et al., "Molecular characterization of a peripheral receptor for cannabinoids," Nature, 365:61-65 (1993.
Murphy et al., "Characterization of quisqualate recognition sites in rat brain tissue using DL-[3H]alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and a filtration assay," Neurochem. Res., 12:775-781 (1987).
Na et al.,"Molecular profiling of a 6-hydroxydopamine model of Parkinson's disease," Neurochem Res, 35(5):761-72 (May 2010).
Nagai et al., Improved corneal toxicity and permeability of tranilast by the preparation of ophthalmic formulations containing its nanoparticles, J Oleo Sci, 63(2):177-86 (2014).
Nagase et al., "Design and characterization of a fluorogenic substrate selectively hydrolyzed by stromelysin 1 (matrix metalloproteinase-3)," J. Biol. Chem., 269:20952-20957 (1994).
Nakamura et al., "Involvement of Oxidative Stress on Corneal Epithelial Alterations in a Blink-Suppressed Dry Eye," Investigative Ophthalmology and Visual Science, 48(4):1552-1558 (2007).
Negre-Salvayre et al., "Advanced Lipid Peroxidation End Products in Oxidative Damage to Proteins. Potential Role in Diseases and Therapeutic Prospects for the Inhibitors," Br J Pharmacol, 153(1):6-20 (2008).
Nema et al., "Excipients and Their Use in injectable Products," PDA J Pharm Sci Technol, 51(4):166-171 (1997).
Nerurkar et al., "13-Aryl-Glutaconic Acids. II. Imides of Certain 13-aryl-Glutaconic and Glutaric Acids," J Org Chem, 24(12):2055-2056 (1959).
Niwa et al., "Protein oxidative damage in the stratum corneum: Evidence for a link between environmental oxidants and the changing prevalence and nature of atopic dermatitis in Japan," Br J Dermatol., 149:248 (2003).
Nociari et al., "Beta cyclodextrins bind, stabilize, and remove lipofuscin bisretinoids from retinal pigment epithelium," Proc Natl Acad Sci U.S.A E1402-E1408 (2014).
Noorwez et al., "Pharmacological Chaperone-mediated in Vivo Folding and Stablization of the P23H-Opsin Mutant Associated with Autosomal Dominant Retinitis Pigmentosa," J Biol Chem, 278:14442-14450 (2003).
Obourn et al., "Hormone- and DNA-binding mechanisms of the recombinant human estrogen receptor," Biochemistry 32(24):6229 (1993).
O'Brien et al., "Aldehyde Sources, Metabolism, Molecular Toxicity Mechanisms, and Possible Effects on Human Health," Crit Rev Toxicol, 35:609-662 (2005).
Organisciak et al., "Susceptibility to Retinal Light Damage in Transgenic Rats with Rhodopsin Mutations," Invest Ophthalmol Vis Sci, 44(2):486-492 (2003).
Pacholczyk et al., "Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter," Nature, 350:350-354 (1991).
Pal et al., "Sulfur mustard analog induces oxidative stress and activates signaling cascades in the skin of SKH-1 hairless mice," Free Radic Biol Med., 47(11):1640-51 (2009).
Palchaudhuri et al., "Corticotropin-releasing factor receptor type 1 from Tupaia belangeri—cloning, functional expression and tissue distribution," Eur. J. Biochem., 258:78-84 (1998).
Parish et al., "Isolation and One-Step Preparation of A2E and iso-A2E, Fluorophores from Human Retinal Pigment Epithelium," Proc Natl Acad Sci USA, 95(25):14609-14613 (1998).
Park et al., "Homogeneous proximity tyrosine kinase assays: scintillation proximity assay versus homogeneous time-resolved fluorescence," Anal. Biochem., 269:94-104 (1999).
Parracho et al., "Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children," Journal of Medical Microbiology, 54:987-991 (2005).
Patel C.Y., "Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5)," Endocrinology, 135:2814-2817 (1994).
PCT International Search Report from PCT/US2019/054263 dated Jan. 6, 2020 (13 pages).
Pearl et al., "Inherited disorders of gamma-aminobutyric acid metabolism and advances in ALDH5A1 mutation identification," Dev Med Child Neurol., 57(7):611-617 (2015).
Pellock, "Balancing clinical benefits of vigabatrin with its associated risk of vision loss," Acta Neurologica. Scandinavica. Supplementum., 124(s192):83-91 (2011).
Peralta et al., "Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors," EMBO. J., 6:3923-3929 (1987).
Petroski et al., "Selective labeling of embryonic neurons cultured on astrocyte monolayers with 5(6)-carboxyfluorescein diacetate (CFDA)," Journal of Neuroscience Methods, 52(1):23-32 (1994).
Pfaar et al., "Perspectives in allergen immunotherapy: 2017 and beyond," Allergy, 2018; 73(Suppl 104):5-23.
Pickering, D.S., "Pharmacological characterization of melatonin binding sites in Syrian hamster hypothalamus," Eur. J. Pharmacol., 175:71-77 (1990).
Pontikis et al., "Cyclodextrin alleviates neuronal storage of cholesterol in Niemann-Pick C disease without evidence of detectable blood-brain barrier permeability," Journal of Inherited Metabolic Disease, 36(3):491-498 (2013).
Pozzi et al., "Modification of Collagen IV by Glucose or Methylglyoxal Alters Distinct Mesangial Cell Function," Journal of the American Society of Nephrology, 20:2119-2125 (2009).
Pred Forte Prescribing Information, Allergan, 5 pages (2017).
Pristupa et al., "Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding.," Mol. Pharmacol., 45:125-135 (1994).
Pruneau et al., "LF 16.0335, a novel potent and selective nonpeptide antagonist of the human bradykinin B2 receptor," Brit. J. Pharmacol., 125:365-372 (1998).
PUBCHEM, 1824609-67-7, SID 333824451, Apr. 24, 2017 (6 pages).
PUBCHEM, 2-(3-Aminoquinolin-2-yl)propan-2-ol, CID 117758222, Feb. 23, 2016, modified Jun. 13, 2020 (11 pages).
Pubchem, SCHEMBL16316728, CID 117758222, Feb. 23, 2016 (13 pages).
Pufahl et al., "Development of a fluorescence-based enzyme assay of human 5-lipoxygenase," Anal. Biochem., 364:204-212 (2007).
Radu et al., "Isotretinoin treatment inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration," Novartis Foundation Symposium, 255(51-63):177-178 (2004).
Radu et al., "Treatment with Isotretinoin Inhibits Lipofuscin Accumulation in a Mouse Model of Recessive Stargardt's Macular Degeneration," Proc Natl Acad Sci USA, 100(8):4742-4747(2003).
Rajewski et al., "Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery," J Pharm Sci, 85(11):1142-69 (Nov. 1996).
Rapp et al., "The Effects of Local Anaesthetics on Retinal Function," Vision Res, 22(9):1097-1103 (1982).
Rauli et al., "Validation of Malondialdehyde and 4-Hydroxy-2-trans-Nonenal Measurement in Plasma by NICI-GC-MS1," J Biochem, 123:918-923 (1998).
Reed, "Lipid peroxidation and neurodegenerative disease," Free Radical Biology and Medicine, 51(7):1302-1319 (2011).
Rees et al., "Cloning and characterisation of the human 5-HT5A serotonin receptor," FEBS Lett., 355:242-246 (1994).
Restasis® Prescribing Information, Allergan, copyright 2016, revised 2017 (15 pages).
Reynolds et al., "(−)-[3H] desmethoxyverapamil labels multiple calcium channel modulator receptors in brain and skeletal muscle membranes: differentiation by temperature and dihydropyridines," J. Pharmacol. Exp. Ther., 237: 731-738 (1986).
Rinaldi-Carmona et al., "Characterization of two cloned human CB1 cannabinoid receptor isoforms," J. Pharmacol. Exp. Ther., 278:871-878 (1996).
Rivkees et al., "Identification of domains of the human A1 adenosine receptor that are important for binding receptor subtype-selective ligands using chimeric A1/A2a adenosine receptors," J. Biol. Chem., 270:20485-20490 (1995).
Rizzo et al., "Aldehyde Trapping Agent NS2 Blocks Formation of Fatty Aldehyde Adducts with Phosphatidylethanolamine and Suggests Potential Therapeutic Approach for Sjogren-Larsson Syndrome," Mol Genet and Metab, 114(3):362A (Mar. 2015) [Abstract Only].
Rizzo et al., "Endogenous antioxidants and radical scavengers," Advances in Experimental Medicine and Biology, 698:52-6 (2010).
Rizzo et al., "Ichthyosis in Sjögren-Larsson syndrome reflects defective barrier function due to abnormal lamellar body structure and secretion," Arch Dermatol Res, 302(6):443-451 (2010).
Rizzo et al., "Sjögren-Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency," Mol Genet Metab. 90(1):1-9 (2007).
Rizzo, "The role of fatty aldehyde dehydrogenase in epidermal structure and function" Dermato-Endocrinol, 3(2):91-99 (2011).
Rizzo, Fatty aldehyde and fatty alcohol metabolism: review and importance for epidermal structure and function, Biochim Biophys Acta, 1841(3):377-89 (Mar. 2014).
Roat, "Allergic Conjunctivitis," Merck Manual Professional Version, 3 pages (2016), Available at: https://www.merckmanuals.com/professional/eye-disorders/conjunctival-and-scleral-disorders/allergic-conjunctivitis.
Roat, "Keratoconjunctivitis Sicca," Merck Manual Professional Version, 5 pages (2016), Available at: https://www.merckmanuals.com/professional/eye-disorders/comeal-disorders/keratoconjunctivitis-sicca.
Roat, "Ocular Mucous Membrane Pemphigoid," Merck Manual Professional Version, 3 pages (2016), Available at: https://www.merckmanuals.com/professional/eye-disorders/conjunctival-and-scleral-disorders/ocular-mucous-membrane-pemphigoid.
Roat, "Scleritis," Merck Manual Professional Version, 3 pages (2016), Available at: https://www.merckmanuals.com/professional/eye-disorders/conjunctival-and-scleral-disorders/scleritis.
Roberts et al., "Basic Principles of Organic Chemistry," 2nd edition, copyright 1977 W. A. Benjamin, Inc., pp. 580-582.
Roberts et al., "Experimental Organic Chemistry—A Miniscale Approach," copyright 1994 by Saunders College Publishing, pp. 580-581 and 584-586.
Rohrer et al., "Cloning and characterization of a fourth human somatostatin receptor," Proc. Natl. Acad. Sci. U.S.A. , 90:4196-4200 (1993).
Rønborg et al., "Exposure chamber for allergen challenge. The development and validation of a new concept," Allergy, 1996; 51(2):82-8.
Sahi et al., "Hepatocytes as a tool in drug metabolism, transport and safety evaluations in drug discovery." Current Drug Discov. Technol., 7(3):188-198 (2010).
Salvatore et al., "Molecular cloning and characterization of the human A3 adenosine receptor," Proc. Natl. Acad. Sci. U.S.A., 90:10365-10369 (1993).
Samsonov et al., "Impact of Atherosclerosis- and Diabetes-Related Dicarbonyls on Vascular Endothelial Permeability: A Comparative Assessment," Oxid. Med. Cell Longev. Article 1625130 (2017).
Sanchez et al., "Allergic Conjunctivitis," J Investig Allergol Clin Immunol, 21(2):1-19 (2011).
Sandikci et al., "Lipid Peroxidation and Antioxidant Defence System in Patients with Active or Inactive Behcet's Disease," Acta Derm Venereol, 83:342-346 (2003).
Sarafian et al., "Synergistic cytotoxicity of Delta(9)-tetrahydrocannabinol and butylated hydroxyanisole," Toxicology Letters, 133(2-3):171-179 (2002).
Sarup et al., "Resolution of high and low affinity progesterone receptors from human breast carcinoma T47D cells," J. Biol. Chem., 263:5624-5633 (1988).
Sasaki et al. "Retinal drug delivery using eyedrop preparations of poly-L-lysine-modified liposomes," Eur J Pharm Biopharm, 83(3):364-9 (2013).
Satici et al., "Malondialdehyde and antioxidant enzyme levels in the aqueous humor of rabbits in endotoxin-induced uveitis," Eur J Ophthalmol, 13(9-10):779-83 (Nov.-Dec. 2003).
Sayed et al., "Metabolic Activation of R,S-1-(Tetrahydro-2-turanyI)-5-fluorouracil (Ftorafur) to 5-fluorouracil by Soluble Enzymes," Cancer Research, 43:4039-4044 (1983).
Schaumberg et al., "Epidemiology of dry eye syndrome," Lacrimal Gland, Tear Film, and Dry Eye Syndromes 3, Kluwer Academic/Plenum Publishers, pp. 989-998 (2002).
Schaumberg et al., "Prevalence of Dry Eye Disease among US Men: Estimates from the Physicians' Health Studies," Arch Ophthalmol, 127(6):763-768 (Jun. 2009).
Schaumberg et al., "Prevalence of Dry Eye Syndrome Among US Women," Am J Ophthalmol, 136(2):318-326 (Aug. 2003).
Schioth et al., "Characterization of the binding of MSH-B, HB-228, GHRP-6 and 153N-6 to the human melanocortin receptor subtypes," Neuropeptides, 31:565-571 (1997).
Schramm et al., "The Cross-linked Biopolymer Hyaluronic Acid as an Artificial Vitreous Substitute," Invest Ophthalmol Vis Sci, 53(2):613-621 (Feb. 2012).
Schwartz et al., "Measurement and estimation of GFR in children and adolescents," Clin J Am Soc Nephrol, 4(11):1832-43 (Nov. 2009).
Schwinn et al., "Molecular cloning and expression of the cDNA for a novel alpha 1-adrenergic receptor subtype," J. Biol. Chem., 265:8183-8189 (1990).
Sciuto et al., "Therapeutic Treatments of Phosgene-Induced Lung Injury," Inhal Toxicol, 16(8):565-580 (2004).
Search Report and Written Opinion issued by the Intellectual Property Office of Singapore for Singapore Patent Application No. 11201504859Y dated Aug. 1, 2016 (12 pages).
Search Report and Written Opinion issued by the Intellectual Property Office of Singapore for Singapore Patent Application No. 11201505587Y dated Jul. 12, 2016 (12 pages).
Search Report and Written Opinion issued by the Intellectual Property Office of Singapore for Singapore Patent Application No. 11201505599Y dated Sep. 26, 2016 (11 pages).
Serbecic et al., "Anti-oxidative vitamins prevent lipid-peroxidation and apoptosis in corneal endothelial cells," Cell Tissue Res, 320(3):465-75 (Jun. 2005).
Shank et al., "Ion and temperature effects on the binding of gamma-aminobutyrate to its receptors and the high-affinity transport system," J. Neurochem., 54:2007-2015 (1990).
Shen et al., "Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype," J. Biol. Chem., 268:18200-18204 (1993).
Sheppard et al., Targeting Anterior Uveitis: A Focus on Iontophoresis and Other Advanced Technologies, Sep. 1, 2018 [Retrieved Nov. 11, 2019] Retrieved from Internet URL: https://www.nyee.edu/files/NYEE/Health%20Professiona1s/Continuing%20Medical%20Education/Enduring%20CME%20Activities/158 _ supplernent.smaU_ v 1 _FINAL %20082818.pdf (8 pages).
Sherman et al., "Cellular Defenses Against Unfolded Proteins: A Cell Biologist Thinks about Neurodegenerative Diseases," Neuron, 29(1):15-32 (2001).
Shipp et al., "Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 ("enkephalinase"): direct evidence by cDNA transfection analysis," Proc Natl Acad Sci USA. 86:297 (1989).
Shoemaker et al., "[3H]diltiazem binding to calcium channel antagonists recognition sites in rat cerebral cortex," Eur. J. Pharmacol., 111:273-277 (1985).
Siegrist et al., "Radioreceptor assay for alpha-MSH using mouse B16 melanoma cells+.," J. Recep. Res., 8:323-343 (1988).
Sieving et al., "Inhibition of the Visual Cycle in vivo by 13-cis Retinoic Acid Protects from Light Damage and Provides a Mechanism for Night Blindness in Isotretinoin Therapy," Proc Natl Acad Sci USA, 98(4):1835-1840 (2001).
Sills et al., "[3H]CGP 39653: a new N-methyl-D-aspartate antagonist radioligand with low nanomolar affinity in rat brain," Eur. J. Pharmacol., 192:19-24 (1991).
Simeone et al, "Modification of the Pyridine Moiety of Non-peptidyl Indole GnRH Receptor Antagonists," Bioorganic & Medicinal Chemistry Letters, 12(22):3329-3332 (2002).
Simonin et al., "The human delta-opioid receptor: genomic organization, cDNA cloning, functional expression, and distribution in human brain," Mol. Pharmacol., 46:1015-1021 (1994).
Singh et al., "The epidemiology of ocular and nasal allergy in the United States, 1988-1994," J. Allergy Clin. Immunol., 2010; 126(4):778-783.
Smit et al., "Regulation of the human histamine H1 receptor stably expressed in Chinese hamster ovary cells," Brit. J. Pharmacol., 117:1071-1080 (1996).
Smith et al., "Basic pathogenic mechanisms operating in experimental models of acute anterior uveitis," Immunol Cell Biol, 76:497-512 (1998).
Smith et al., "Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinson's disease," Neuroscience. 144(3):1057-1066 (Feb. 2007).
Snead et al., "Gamma-hydroxybutyric acid," New England Journal of Medicine, 352(26):2721-2732 (2005).
Snell et al., "Novel structure having antagonist actions at both the glycine site of the N-Methyl-D-Aspartate receptor and neuronal voltage-sensitive sodium channels. Biochemical, electrophysiological, and behavioral characterization," J Pharmacol Exp Ther, 292(1):215-227 (2000).
Spadea et al., "Corneal wound healing after laser vision correction," Br J Ophthalmol. 2016; 100:28-33.
Spagnol et al., "Efficient synthesis of tricyclic benzobisoxazines by silica gel catalysis," J Org Chem, 2;72(5):1867-1869 (Mar. 2007).
Sparrow et al. "Phospholipid meets all-trans-retinal: the making of RPE bisretmoids," Journal of Lipid Research, 51: 247-261 (2010).
Speth et al., "Benzodiazepine receptors: temperature dependence of [3H]flunitrazepam binding," Life Sci., 24:351-358 (1979).
Stehle et al., "Molecular cloning and expression of the cDNA for a novel A2-adenosine receptor subtype," Mol. Endocrinol., 6:384-393 (1992).
Stevenson et al., "Dry eye disease: an immune-mediated ocular surface disorder," Arch Ophthalmol. 2012; 130(1): 90-100.
Struys et al., "Determination of the GABA analogue succinic semialdehyde in urine and cerebrospinal fluid by dinitrophenylhydrazine derivatization and liquid chromatography-tandem mass spectrometry: application to SSADH deficiency," J. Inherit Metab Dis., 28(6):913-20 (2005).
Struys et al., "Metabolism of gamma-hydroxybutyrate to d-2-hydroxyglutarate in mammals: further evidence for d-2-hydroxyglutarate transhydrogenase," Metabolism, 55(3):353-8 (2006).
Study showing effect of ADX-102 on Fibrotic Changes in Cardiac Fibroblasts Following Cell Stress, American Society for Cell Biology Annual Meeting, Dec. 3-7, 2016 (2 pages).
Sus et al., "Uber die Lichtreaktion der o-Chinondiazide V. Mitteilungl) Ubergange heterocyclischer 6-Ringe in heterocyclische 5-Ringe," Liebigs Ann. Chem. 583:150 (1953).
Tahara et al., "Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells," Brit. J. Pharmacol., 125:1463-1470 (1998).
Tang et al., "Effects of four penetration enhancers on corneal permeability of drugs in vitro," Journal of Pharmaceutical Sciences, 83(1):85-90 (1994).
Tatsumi et al., "Pharmacological profile of neuroleptics at human monoamine transporters," Eur. J. Pharmacol., 368 : 277-283 (1999).
Tayeh et al., "Macrophage oxidation of L-arginine to nitric oxide, nitrite, and nitrate. Tetrahydrobiopterin is required as a cofactor," J. Biol. Chem., 264:19654-19658 (1989).
Tempest-Roe et al., "Local therapies for inflammatory eye disease in translation: past, present and future," BMC Ophthalmol, 13(1):39 (Aug. 2013).
Tewari-Singh et al., "Silibinin attenuates sulfur mustard analog-induced skin injury by targeting multiple pathways connecting oxidative stress and inflammation," PLoS One 7(9):e46149 (2012).
Tian et al., "First total synthesis and determination of the absolute configuration of 1-N-methy 1-3-methylamino-[N-butanoicacid-3-(9-methy1-8-propen-7-one)-amide]-benzo[f][1,7]naphthyridine-2-one, a novel benzonaphthyridine alkaloid," Tetrahedron Letters, 53:4892-4895 (2012).
Tikly et al., "Lipid peroxidation and trace elements in systemic sclerosis," Clinical Rheumatology, 25(3):320-324 (2006).
Torkildsen et al., "Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model," Clinical Ophthalmology, 9:1703-1713 (2015).
Toth et al., "A simple, continuous fluorometric assay for HIV protease," Int. J. Pept. Protein Res., 36:544-550 (1990).
Tsugeno et al., "Regions of the molecule responsible for substrate specificity of monoamine oxidase A and B: a chimeric enzyme analysis," J. Biochem., 118 (5) 974-80 (1995).
Tsuzuki et al., "Molecular cloning and expression of the gene encoding human angiotensin II type 2 receptor.," Biochem. Biophys. Res. Commun., 200:1449-1454 (1994).
Tukozkan et al., "Measurement of Total Malondialdehyde in Plasma and tissues by High-Performance Liquid Chromatography and Thiobarbituric Acid Assay," Firat Tip Dergisi, 11(2):88-92 (2006).
Turk et al., "Serum anti-carbonic anhydrase antibodies and oxidant-antioxidant balance in patients with acute anterior uveitis," Ocul Immunol Inflamm, 22(2):127-32 (Apr. 2014).
U.S. Appl. No. 15/437,699 of Jordan et al., filed Feb. 21, 2017.
U.S. Appl. No. 15/754,065 of Brady et al., filed Feb. 21, 2018.
U.S. Appl. No. 16/168,309 of Chabala et al., filed Oct. 23, 2018.
U.S. Appl. No. 16/300,020 of Brady et al., filed Nov. 8, 2018.
U.S. Appl. No. 16/374,845 of Machatha et al., filed Apr. 4, 2019.
U.S. Appl. No. 16/530,705 of Brady et al., filed Aug. 3, 2019.
U.S. Appl. No. 16/547,930 of Buist et al., filed Aug. 22, 2019.
U.S. Appl. No. 16/582,720 of Clark et al., filed Sep. 25, 2019.
U.S. Appl. No. 16/592,572 of Brady et al., filed Oct. 3, 2019.
U.S. Appl. No. 16/720,645 of Brady et al., filed Dec. 19, 2019.
U.S. Appl. No. 16/773,654, filed Jan. 27, 2020.
U.S. Appl. No. 16/825,898, filed Mar. 20, 2020.
Ueda et al., "Evaluation of a Sulfobutyl Ether 13-Cyclodextrin as a Solubilizing/Stabilizing Agent for Several Drugs," Drug Dev Ind Pharm, 24(9):863-867(1998).
Upadhyaya et al., "The sphingolipid degradation product trans-2-hexadecenal forms adducts with DNA," Biochem Biophy Res Comm., 424(1):18-21 (2012).
Vanachayangkul et al., "Inhibition of heme peroxidases by melamine," Enzyme Research, 2012:416062 (2012).
Vignon et al., "[3H]thienyl-phencyclidine ([3H]TCP) binds to two different sites in rat brain. Localization by autoradiographic and biochemical techniques," Brain Res., 378:133-141 (1986).
Vlaskina et al., "Novel Synthesis of Substituted Benzimidazoles by Reduction of Esters of 4-Alkylamino-3,5-dinitrobenzoic Acids by Tin Chloride," Chemistry of Heterocyclic Compounds, vol. 40(4):523-524 (2004).
Vogel et al, "Thirty years beyond discovery—clinical trials in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism," J Inherit Metab Dis., 36(3):401-10 (2013).
Voziyan et al., "A Post-Amadori Inhibitor Pyridoxamine also Inhibits Chemical Modification of Proteins by Scavenging Carbonyl Intermediates for Carbohydrate and Lipid Degradation," J Biol Chem, 277(5):3397-3403 (2002).
Wagner et al., "Omega-conotoxin GVIA binding to a high-affinity receptor in brain: characterization, calcium sensitivity, and solubilization," J. Neurosci., 8:3354-3359 (1988).
Wakamatsu et al., "Evaluation of lipid oxidative stress status and inflammation in atopic ocular surface disease," Mol Vis, 16:2465-75 (Nov. 2010).
Wall et al., "Plant Antitumor Agents. 30. Synthesis and Structure Activity of Novel Camptothecin Analogs," J. Med. Chem., 36(18):2689-2700 (1993).
Walter et al., "Novel Complex N-Heterocycles via Intramolecular 1,5-Electrocyclizations: 1,2,3,4,4a,5,5a,10-Octahydropyrido-[4″,3″:2′,3′]cyclobuta[1′,2′:4,5]pyrrolo[2,3-b]pyridines," Heterocycles, 48(8):1581-1591 (1998).
Wang et al., "A facile one-pot synthesis of 2-substituted-3-aminoquinolines: Preparation of benzo [b]naphthyridine-3-carbonitriles," Tetrahedron, 60(13):2937-2942 (2004).
Wang et al., "Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment," FEBS Lett., 338:217-222 (1994).
Wang et al., "Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity," Arthritis and Rheumatism, 62(7):2064-2072 (2010).
Wang, X.K., "Pharmacological study on recombinant human GABA-A receptor complex containing alpha5 (leucine155 to valine) combined with beta3gamma2s subunits," Acta. Pharmacol. Sin., 22:521-523 (2001).
Waslidge et al., "A colorimetric method for the determination of lipoxygenase activity suitable for use in a high throughput assay format," Anal. Biochem., 231:354-358 (1995).
Webb et al., "Intralesional cytokines in chronic oxazolone-induced contact sensitivity suggest roles for tumor necrosis factor alpha and interleukin-4," J Invest Dermatol, 111(1):86-92 (Jul. 1998).
Weishaar et al., "Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents," Biochem. Pharmacol., 35:787-800 (1986).
Weng et al., "Insights into the Function of Rim Protein in Photoreceptors and Etiology of Stargardt's Disease from the Phenotype in abcr Knockout Mice," Cell, 98(1):13-23 (1999).
Westphal et al., "Reactions with Pyridinium Pyruvic Acid Esters," Pharmazie, 31(11):770-773 (1976).
Wieland et al., "Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226," J. Pharmacol. Exp. Ther., 275:143-149 (1995).
Witt-Enderby et al., "Characterization and regulation of the human MLIA melatonin receptor stably expressed in Chinese hamster ovary cells," Mol. Pharmacol., 50:166-174 (1996).
Wolkenberg et al., "Design, synthesis, and evaluation of novel 3,6- diary1-4-aminoalkoxyquinolines as selective agonists of somatostatin receptor subtype 2," J Med Chem, 54(7):2351-2358 (2011).
Wood et al., "Aldehyde Load in Ischemia-Reperfusion Brain Injury: Neuroprotection by Neutralization of reactive Aldehydes with Phenelzine," Brain Res, 1122(1):184-190 (2006).
Wood et al., "The concept of "aldehyde load" in neurodegenerative mechanisms: cytotoxicity of the polyamine degradation products hydrogen peroxide, acrolein, 3-aminopropanal, 3-acetamidiorioanal and 4-aminobutanal in a retinal ganglion cell line," Brain Research, 1145:150-156 (2007).
Wurch et al., "Sequence and functional analysis of cloned guinea pig and rat serotonin 5-HT1D receptors: common pharmacological features within the 5-HT1D receptor subfamily," J. Neurochem., 68:410-418 (1997).
Yadav et al., "Regulation of NF-κB-Induced Inflammatory Signaling by Lipid Peroxidation-Derived Aldehydes," Oxidative Med & Cell Longev, 2013, Art ID 690545, 11 pages (2013).
Yarnell, "Light Flips the Lipid Switch: Palmitoylation—the reversible attachment of palmitate to proteins—gets a new role in vision," C&EN, 82(29):22-23 (2004).
Yokomizo et al., "Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2," J. Biol. Chem., 276:12454-12459 (2001).
Yu et al., "Injectable Chemically Crosslinked Hydrogel for the Controlled Release of Bevacizumab in Vitreous: A 6-Month In Vivo Study," Transl Vis Sci Technol, 4(2,5):1-11 (2015).
Zagol-Ikapitte et al., "Characterization of scavengers of y-ketoaldehydes that do not inhibit prostaglandin biosynthesis," Chem Res Toxicol, 23(1):240-250 (2010).
Zarkovic "4-hydroxynonenal and neurodegenerative diseases," Molecular Aspects of Medicine, 24(4-5):293-303 (2003).
Zava et al., "Androgen receptor assay with [3H]methyltrienolone (R1881) in the presence of progesterone receptors," Endocrinology, 104:1007-1012 (1979).
Zhang et al., "Potent nonsteroidal progesterone receptor agonists: synthesis and SAR study of 6-aryl benzoxazines," Bioorg Med Chem Lett, 12(5):787-90 (Mar. 2002).
Zhou et al, "Cloning and expression of human and rat D1 dopamine receptors," Nature, 347:76-80 (1990).
Zhou et al., "Chemical and biological evidence for base propenals as the major source of the endogenous M1dG adduct in cellular DNA," J Biol Chem., 280(27):25377-82 (2005).
Zhou et al., "Mechanisms for the induction of HNE-MDA- and AGE-adducts, RAGE and VEGF in retinal pigment epithelial cells," Exp Eye Res., 80(4):567-80 (2005).

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11724987B2 (en) 2005-05-26 2023-08-15 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
US11701331B2 (en) 2013-01-23 2023-07-18 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US11771664B2 (en) 2013-01-23 2023-10-03 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US11459300B2 (en) 2015-08-21 2022-10-04 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
US11845722B2 (en) 2015-08-21 2023-12-19 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
US11583529B2 (en) * 2017-10-10 2023-02-21 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
US11312692B1 (en) 2018-08-06 2022-04-26 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US11932617B2 (en) 2018-12-18 2024-03-19 Zhuhai United Laboratories Co., Ltd. Compound for use in retinal diseases
US11786518B2 (en) 2019-03-26 2023-10-17 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
US12006298B2 (en) 2019-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof

Also Published As

Publication number Publication date
AU2018348174A1 (en) 2020-04-23
JP2020536896A (ja) 2020-12-17
EP3694500A4 (fr) 2021-06-30
WO2019075136A1 (fr) 2019-04-18
US20210353628A1 (en) 2021-11-18
US20230248727A1 (en) 2023-08-10
MX2020003425A (es) 2020-07-29
US20230293527A1 (en) 2023-09-21
CA3077362A1 (fr) 2019-04-18
US11583529B2 (en) 2023-02-21
EP3694500A1 (fr) 2020-08-19
JP2023115307A (ja) 2023-08-18
US20190105322A1 (en) 2019-04-11
JP7311162B2 (ja) 2023-07-19
CN111356451A (zh) 2020-06-30
IL273693A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
US11583529B2 (en) Treatment of inflammatory disorders
Farkouh et al. Systemic side effects of eye drops: a pharmacokinetic perspective
US20220184057A1 (en) Combination treatment of ocular inflammatory disorders and diseases
JP6974669B2 (ja) Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬
US11197821B2 (en) Formulations for treatment of dry eye disease
TWI578990B (zh) 眼睛過敏之治療
JP7362870B2 (ja) 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物
JP5897592B2 (ja) 葉酸−ラミプリルの組合せ：細胞保護性、神経保護性、および網膜保護性の眼科用組成物
JP2024037806A (ja) ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
US20170112936A1 (en) Pharmaceutical compositions comprising gels and methods for fabricating thereof
TWI816660B (zh) 噻托銨用於製造預防近視、治療近視及/或預防近視增長之點眼劑之用途
WO2022228546A1 (fr) Procédé et composition pharmaceutique de traitement de la myopie
Mekkes et al. Solar urticaria induced by infrared radiation
JP6908616B2 (ja) 網膜疾患の治療のためのミラベグロン
Hayashi et al. Scrotal metastases originating from colorectal carcinoma
JP7417531B2 (ja) 選択的ｓｙｋ阻害剤の使用方法および医薬組成物
Marini et al. Comparative Clinical Trial to Evaluate the Efficacy and Toxicity of Bepostastine Besilate 1, 5% Preservative-free vs Olopatadine Hydrochloride 0, 2 Bak-preserved in Patients With Allergic Conjuctivitis
Drummond et al. Subungual haemorrhage in hydroa vacciniforme
Kulthanan et al. Cutaneous reaction to oral antihistamine

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: ALDEYRA THERAPEUTICS, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MACDONALD, SUSAN;HALILOVIC, ADNA;REEL/FRAME:047520/0909

Effective date: 20181024

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE